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 Abstract  
Mycobacterial diseases are responsible for numerous deaths worldwide, the major pathogens 
being Mycobacterium tuberculosis and Mycobacterium leprae. Also, in recent years threats 
from opportunistic pathogens, such as Mycobacterium marinum and Mycobacterium kansasii 
have been on the rise. These mycobacteria possess a unique lipid-rich cell wall with an array 
of mycolic acids and species-specific antigenic glycolipids, like the lipooligosaccharides. 
Some of these solvent extractable lipids possess immunomodulatory properties and play an 
important role during infection.  
Lipooligosaccharides (LOS) are surface exposed, polar, antigenic glycolipids that are 
present in several mycobacterial species. This study used the opportunistic human pathogens 
M. marinum and M. kansasii as a model system to unravel the genes involved in the 
biosynthesis of LOSs in Mycobacterium. Using directed mutagenesis and transposon 
mutagenesis, mutant strains defective in various parts of the LOS biosynthetic pathway were 
isolated. Analysis of these strains helped in further delineating the pathway and understanding 
the role of LOSs in virulence.  
A part of this thesis focussed on studying mycolic acid processing and transport using 
Mycobacterium smegmatis as a surrogate system. Mycolic acids are the most distinctive 
components of the mycobacterial cell wall. While their biosynthesis has been studied in detail, 
processing and transport across the membrane is not well understood. This study attempted to 
explore the roles of the two putative type II mycolyltransferases MSMEG3437 and 
MSMEG5851 in mycolic acid processing. Additionally, the role of M. tuberculosis mmpL11 
gene was probed as the Mtb-mmpL11 had been reported to be involved in virulence. A null 
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mutant of the M. smegmatis homologue, Ms-mmpL11 (MSMEG0241) was generated and 
analysed for the above study. Deletion mutant strains of the two putative mycolyltransferase II 
did not show any phenotype, suggesting that their roles are redundant in vivo. Although the 
Ms-mmpL gene was found to be non-essential, it was found to be involved in transport of free 
mycolic acids.  
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1.1 Mycobacterium species 
Mycobacteria are unicellular, aerobic, non-spore forming bacteria with high G+C content in 
their DNA.  They appear as slightly curved rod shaped cells, 0.2 – 0.6m in width and 1.0 – 
2.0m in length (Alteri et al., 2007; Holt, 1994). Mycobacteria are a genus of Actinobacteria. 
They are unusual among bacteria in that they have a thick, hydrophobic, lipid rich cell wall.  A 
characteristic feature of mycobacteria is the presence of a wide diversity of unique complex 
lipids that constitute 60% of the cell wall. This lipid-rich, low permeability matrix contributes 
to the difficulty in combating mycobacterial diseases by endowing the organism with innate 
resistance to therapeutic agents and host defences.  
 
Figure 1.1. A) Colonies of M. tuberculosis on Löwenstein-Jensen agar. B) Acid-fast staining of M. 
tuberculosis, C) Scanning electron microscopy of M. tuberculosis bacilli, scale bar represents 
2m, Mag 15549X; (adapted from CDC photo publications). 
 
The cell wall core is composed of the mycolyl arabinogalactan – peptidoglycan (mAGP) 
complex (Besra et al., 1995, Brennan, 2003, McNeil et al., 1990, Dover et al., 2004). Other 
glycolipids, polysaccharides, lipoglycans intercalate with the mycolic acid layer to form the 
outer region of the cell wall (Brennan and Nikaido, 1995, Brennan and Crick, 2007). The cell 
Chapter 1  General Introduction 
3 
 
wall makes a substantial contribution to the persistence of this genus (McNeil and Brennan, 
1991, Minnikin et al., 2002). Hence, the biosynthetic pathways of cell wall components are 
potential targets for new drugs for tuberculosis.  
Most species of the genus Mycobacterium are closely related to soil bacteria, but some are 
pathogenic. These include Mycobacterium tuberculosis and Mycobacterium leprae, the 
causative agents of tuberculosis and leprosy, respectively. Some are opportunistic pathogens, 
like Mycobacterium kansasii, which causes a disseminated disease in immunocompromised 
humans, and Mycobacterium marinum; a fish pathogen also causes skin infection in 
immunocompromised humans. Based on their generation time mycobacteria are classified as 
fast growers and slow growers. M. tuberculosis is a slow grower, has a generation time of 16 - 
18 hours, while Mycobacterium smegmatis is a fast grower, and has a generation time of 3 to 4 
hours.  
Table 1.1.  Mycobacterium species, fast and slow growers.  
Slow Growing Mycobacteria Fast Growing Mycobacteria 
Mycobacterium 
tuberculosis 
Mycobacterium leprae Mycobacterium aurum Mycobacterium phlei 
Mycobacterium 
kansasii 
Mycobacterium 
africanum 
Mycobacterium 
chelonae 
Mycobacterium 
porcinum 
Mycobacterium avium Mycobacterium 
marinum  
Mycobacterium duvalii Mycobacterium pulveris 
Mycobacterium bovis Mycobacterium microti Mycobacterium 
flavescens 
Mycobacterium 
rhodesiae 
Mycobacterium 
malmoense 
Mycobacterium 
paratubercuosis  
Mycobacterium 
fortuitum 
Mycobacterium 
shinshuense 
Mycobacterium 
ulcerans 
Mycobacterium 
scrofulaceum 
Mycobacterium  
gadium 
Mycobacterium 
smegmatis 
Mycobacterium gastri Mycobacterium xenopi Mycobacterium 
komossense 
Mycobacterium vaccae 
Mycobacterium 
genavense 
Mycobacterium simiae   
Mycobacterium 
haemophilum 
Mycobacterium szulgai   
Mycobacterium 
intracellulare 
Mycobacterium 
farcinogenes 
  
Chapter 1  General Introduction 
4 
 
1.2 Tuberculosis   
Diseases caused by mycobacteria claim millions of lives globally, with M. tuberculosis, the 
causative agent of TB being responsible for more deaths each year than any other single 
pathogen. 
TB is an ancient disease and has afflicted mankind for thousands of years. Molecular 
analysis of human bone samples dating back to 600 BC, support the existence of TB in human 
populations from those days (Donoghue, 2009). DNA from the members of the M. 
tuberculosis complex has been detected in Egyptian and Peruvian mummies dating back to 
5000 BC (Crubezy et al., 1998, Salo et al., 1994). Recent findings show M. tuberculosis 
infection using PCR and lipid biomarkers in a 9000-year-old mummy from the pre-pottery 
Neolithic settlement period of the Middle East (Hershkovitz et al., 2008).  
Ancient literature has mentioned TB by different names. Hippocrates (400 BC) used the 
term ‘Phthisis’ to describe the condition associated with fever, cough and loss of appetite. The 
disease was also known as ‘Consumption’, ‘Kings’s evil’, ‘Scrofula’, ‘Pott’s disease’ and 
‘White Plague’.   
The symptoms of TB are chest pain, fever, persistent coughing associated with phlegm, 
fatigue and loss of appetite and weight. TB was regarded as a deadly and contagious disease; 
the etiological agent of the disease could not be identified for many years. There was a 
significant level of understanding about the disease and different measures were adopted to 
prevent and contain infections. The first major step towards deciphering tuberculosis was the 
discovery of the tubercle bacilli, the bacteria causing TB, by the German bacteriologist Robert 
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Koch in 1882 (Koch., 1882). The introduction of ‘Sanatoria’ in the 19th century was major 
step towards TB prevention. 
1.3 Epidemiology 
Tuberculosis remains a major public health concern despite the availability of effective 
chemotherapy. The World Health Organization (WHO) estimates that one–third of the world 
population is infected with M. tuberculosis which causes nearly 9.4 million new cases and 
kills 2 million people each year (WHO, 2011) This is largely a result of the persistence of the 
causative organism itself and also the treatment of a M. tuberculosis infection requires many 
months of therapy with multiple drugs.  
The epidemiology of TB varies substantially around the world. The highest are observed in 
sub-Saharan Africa, India, China, and the islands of Southeast Asia and Micronesia. 
Intermediate rates of tuberculosis occur in Central and South America, Eastern Europe, and 
northern Africa, while low rates occur in the United States, Western Europe, Canada, Japan, 
and Australia. From an epidemiological viewpoint, the vast majority of cases at present occur 
in the developing world. This poses a serious problem with regard to affordability of 
antibiotics and logistics involved in drug dispensing.  
Human9 Immunodeficiency Virus (HIV) infection remains a great influence in the rising 
TB trends. This has added to the current epidemic since the probability of TB infection is 
greatly increased in immunocompromised people. HIV co-infection raised the risk of 
developing active TB in a population with latent TB, from 5-10% during their lifetime, to the 
same risk in one year (Cole et al., 1998; Corbett et al., 2003). Hence, the synergy between 
HIV-1 and TB has lead to increased mortality due to both the diseases.  
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 Figure 1.2. Map showing estimated TB incidence rates, by country, 2010. Adapted from WHO 
TB report 2011. 
Figure 1.3. Map showing estimated HIV prevalence in new TB cases, by country, 2010 (WHO TB 
report 2011). 
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1.4 Immune response to Mycobacterium tuberculosis infection 
M. tuberculosis infection is transmitted by the airborne route. Infection is initially and 
primarily of the lungs, alveolar macrophages, infection also occurs in the brain, knee, lymph 
nodes, other organs and bones. The bacterium is transmitted by the inhalation of aerosol 
droplets expelled in the cough or sneeze of an infected person (Cole, 2005).  Post inhalation of 
these aerosol droplets containing the bacilli, there are various fates of the inhaled bacteria. The 
bacilli maybe cleared off by a strong host immune system resulting in no infection 
establishment. The bacteria can also travel through the narrow passages to the alveoli.  
Alveolar macrophages act as the main defence against respiratory pathogens. The 
tubercle bacilli that reach the alveoli make contact with the macrophages and are ingested via 
various cell surface receptors (Ernst et al., 1998). A localised pro-inflammatory response is 
induced by the macrophages and mononuclear cells are recruited from proximal blood vessels 
to form a granuloma. Granuloma formation is characteristic of M. tuberculosis infection. The 
primary function of the granuloma is to contain and prevent the dissemination of mycobacteria 
(Russell et al., 1997;  Russell, 2007). The granuloma formed can be divided into three layers – 
a core with the infected macrophages which is surrounded by foamy macrophages. The 
external layer comprises of lymphocytes which are encircled by extracellular matrix 
components (Russell, 2007). Infected individuals with granuloma are non-infective. But any 
changes to their immunity may cause failure of the containment which leads to the rupture of 
the granuloma and release of infectious bacilli.  
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Figure 1.4. Schematic representation of granuloma formation in humans. Adapted from Russell, 
(2007).  
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During TB infection, the initial response to M. tuberculosis is the binding of the bacilli 
via the complement receptors (CR1, CR3, and CR4) and mannose receptors of the alveolar 
macrophages. A glycoprotein Surfactant protein-A on alveolar macrophage surface enhances 
the binding and uptake of bacteria by up-regulating mannose receptor expression (Beharka et 
al., 2002). This is followed by phagocytosis of the bacteria. The host cell now commences 
killing of the phagocytosed bacteria by using reactive nitrogen intermediates or nitrogen oxide 
(Rich et al., 1997), maturation and fusion of the phagosome to form the 
phagolysosome,apoptosis, cytokine production (interferon-) and chemokine production 
(interleukins IL-8, IL-10 and tumor necrosis factor-) (Figure. 1.4). However, it has been 
shown that M. tuberculosis is able to escape these mechanisms by various pathways. M. 
tuberculosis is known to arrest phagosome maturation (Fratti et al., 2003; Vergne et al., 2003) 
and prevents the phagosome-lysosome fusion by lowering the pH, and the phagocytic vacuole 
remains at a pH of approximately 6.5 (Vergne et al., 2005). Apart from this, genes such as the 
sodC, a superoxide dismutase (Wu et al., 1998) and cell wall components, such as 
lipoarabinomannan (LAM) confer resistance to intracellular oxidative stress (Chan et al., 
1991; Piddington et al., 2001). M. tuberculosis can also maintain its supply of nutrients for 
intracellular survival by intercepting the host endocytic system (Sturgill-Koszycki et al., 
1994).  
  M. tuberculosis is engulfed by both macrophages and dendritic cells (DCs) and the 
later represents the main interface between innate and adaptive immunity (Hickman et al., 
2002; Orme, 2004). DCs release cytokines that initiate Th1 like activity from T-cells. In order 
to accomplish this, the DCs have been reported to leave the site of infection and move towards 
Chapter 1  General Introduction 
10 
 
the lymph nodes, this also aids in distribution of the bacilli. Th1 response is extremely 
important as it contributes to containment and granuloma formation (Russell, 2007). 
 
Figure 1.5 Primary immunological events during tuberculosis infection. Adapted from Kaufmann, 
(2001). 
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Early literature reports the involvement of a variety of mycobacterial cell-wall products 
in manipulating the immune response and inducing granuloma formation (Granger et al., 
1976; Bekierkunst, 1968; Bekierkunst et al., 1969; White et al., 1964).  It has been reported 
that the virulent lipoglycan LAM and phosphatidylinositolmannosides (PIMs) are released 
inside infected cells and are presented by CD1b (Zajonc et al., 2006). Death of infected cells 
releases vesicles containing lipid antigens. These are responsible for cross priming DCs and 
subsequent antigen presentation by CD1b. 
1.5 Treatment  
1.5.1 Anti –TB drugs 
Initiation of TB chemotherapy was in the 1940s with the discovery of streptomycin (STR) 
(Jones et al., 1944; Schatz et al., 1944). STR was the main treatment against TB and 
development of resistance lowered its efficacy. The discovery of streptomycin was followed 
by the discovery of para-amino salicylic acid by Jorgen Lehman (Nagley, 1949; Nagley and 
Logg, 1949), isoniazid (INH) (Steenken and Wolinsky, 1952a; Steenken and Wolinsky, 
1952b), pyrazinamide (PZA) (Mc et al., 1954; Muschenheim et al., 1954; Tompsett et al., 
1954), cycloserine (Gold et al., 1955) , ethambutol (EMB) (Forbes et al., 1962) and rifampin 
(RMP)  (Table 1.2). The discovery of INH, established a combined regimen for treatment of 
TB along with STR and PZA.  
INH was the first anti-tuberculosis drug that exhibited high specificity for the tubercle 
bacilli with very low or no activity against other mycobacterial species and no activity against 
other bacteria. It was easy to synthesise compared to the other two drugs and considerably 
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lowered the cost of treatment in the 1950’s.  INH is a prodrug and is activated by catalase-
peroxidase (KatG) gene (Khasnobis et al., 2002; Zhang et al., 1992) and inhibits mycolic acid 
biosynthesis by targeting InhA (enoyl-ACP-reductase) and KasA (-ketoacylACP synthetase)  
(Banerjee et al., 1994). Today TB is treated using a combination of drugs mainly to avoid 
developing drug resistance during single drug usage. The standard treatment for active TB is 
usually divided into two phases: the initial phase aiming to kill actively growing and semi-
dormant bacilli. This employs the use of first line anti-TB drugs; INH, EMB, PZA, and RMP 
for a period of two months. Streptomycin is generally not used in this phase because of higher 
toxicity of STR but is used if resistance to INH has been established. This is followed by the 
continuation phase to eliminate any remaining bacilli and minimise the risk of relapse of 
infection. INH and RIF are used for four months during this period.  
Table 1.2. Commonly used drugs for tuberculosis treatment, adapted from (Zhang, 2005). 
        a
katG, ethA and pncA activate the prodrugs INH, ETH and PZA respectively. 
According to the WHO, anti-TB drugs are classified on their mode of action and side 
effects. The first line or essential drugs are INH, STR, PZA, EMB and RMP. The second line 
or reserved drugs show good efficacy but have relatively higher rates of side effects, toxicity 
Drug MICgl) 
Effect on 
bacterial cell 
Target 
Genes involved in 
resistance 
Isoniazid 0.01 - 0.2 Bactericidal 
Mycolic acid 
biosynthesis 
KatG
a
 /inhA/ndh 
Ethionamide 0.6 - 2.5 Bacteriostatic 
Mycolic acid 
biosynthesis 
inhA / ethA
a 
Rifampicin 0.05 - 2.5 Bactericidal RNA synthesis rpoB 
Ethambutol 1.0 - 5.0 Bacteriostatic 
Cell wall arabinan 
biosynthesis 
emb CAB 
Pyrazinamide 50 - 100 
Bactericidal /  
Bacteriostatic 
Disrupts membrane 
transport and energy 
depletion 
pncA
a 
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and unavailability in the developing nations. These are of six classes- aminoglycosides (e.g. 
kanamycin), polypeptides (e.g. capreomycin), fluoroquinolones (e.g. ciprofloxacin), 
thioamides (e.g., ethionamide), cycloserines and p-aminosalicylic acid). The third line drugs 
are those which are less effective compared to the above include rifabutin and macrolides 
(Janin, 2007). 
Due to the adverse side effects of these drugs and long treatment times, non-
compliance is often observed among patients. Relapse rates of 3-4% have still been reported 
with this treatment. Non-compliance to this treatment regime is one of the major causes of 
relapse and also leads to drug resistance. The emergence of multi-drug resistant (MDR) and 
recently extensively drug resistant (XDR) strains of M. tuberculosis pose a serious threat to 
the TB control programmes all over the world (Gandhi et al., 2006). 
 
Figure 1.6. Anti-tuberculosis drugs and their target in the cell wall. Adapted from Abdallah et al. 
(2007).  
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The past 40 years have not witnessed the discovery of any anti-TB drugs. There is a 
necessity of development of more efficient drugs that have shorter treatment times when 
compared with the present treatment regimes to combat the worldwide threat of TB. The 
unique mycobacterial cell wall remains the most attractive target for chemotherapeutics 
development. High throughput screenings have identified few potential candidate drugs in 
recent years. SQ109 (Protopopova et al., 2005), TMC207 (Andries et al., 2005) and a class of 
benzothiaziones are the newly discovered anti-TB drugs, and SQ109 and TMC207 are in 
human clinical trials. SQ109 is an N-geranyl-N’-(2-adamantyl)-ethane-1,2-diamine based on 
the ethylenediamine core as found in EMB. SQ109 is reported to inhibit mycolate export by 
targeting mmpl3 (Tahlan et al., 2012), which is involved in transporting trehalose 
monomycolate. It has been found to be most effective against MDR strains of TB. TMC207 
belongs to the diarylquinoline class of compounds and is thought to inhibit the proton pump of 
the M. tuberculosis ATP-synthase (Koul et al., 2007). Its low MIC, long half-life (~173 h in 
humans) and potent bactericidal activity reduces the time of treatment. TMC207 does not 
affect any other bacteria apart from mycobacteria, effective against EMB, RIF, PZA, INH and 
STR resistant strains of TB, and can also be used in conjunction with anti-retroviral drugs and 
has no cross-resistance with the current anti-TB drugs (Matteelli et al., 2010, Andries et al., 
2005). A novel and potent antimycobacterial class of drugs was discovered during the 
synthesis of sulfur containing antibacterial and antifungal compounds. Known as 
benzothiazionone (BTZ), these show high specificity for mycobacteria, have a low MIC (1-
30ng/ml for members of the M. tuberculosis complex) and are comparatively non-toxic 
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(Makarov et al., 2006). BTZ acts on the decaprenylphosphoryl--D-ribose 2-epimerase, and 
blocks production of DPA, a precursor of arabinan biosynthesis (Makarov et al., 2009). 
1.5.2 Directly Observed Therapy, Short-course  
 DOTS stand for “Directly Observed Therapy, Short-course” and is a major strategy of the 
World Health Organization global TB eradication programme. The number of deaths due to 
tuberculosis remains alarming inspite of the introduction of DOTS by World Health 
Organization (WHO) in 1991 which follows the patient from positive testing for the disease 
through proper medication and monitored outcome (Obermeyer et al., 2008). The WHO also 
initiated a “Stop TB” campaign in 2006 to increase the uptake of DOTS as well as promoting 
awareness of the rising MDR and XDR TB cases. Despite being a called short course, DOTS 
chemotherapy requires a strict therapeutic regimen involving a cocktail of drugs administered 
over a minimum of six months. The current DOTS treatment involves taking INH, EMB, RIF, 
PZA and (in some cases) STR daily for the first two months, followed by INH and RIF thrice 
weekly for the ensuing four months (Cox et al., 2006).  
The DOTS strategy focuses on five main points of action. These include government 
commitment to control TB, diagnosis based on sputum-smear microscopy tests done on 
patients who actively report TB symptoms, direct observation short-course chemotherapy 
treatments, a definite supply of drugs, and standardised reporting and recording of cases and 
treatment outcomes.  Treatment with properly implemented DOTS has a success rate 
exceeding 95% and prevents the emergence of further multi-drug resistant strains of 
tuberculosis. 
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Figure 1.7. Anti-tuberculosis drugs targeting DNA metabolism. Adapted from CDC 2008 photo 
release and www.health-healths.com. 
 
1.6 Drug resistance  
The term ‘drug resistance’ most commonly refers to the resistance acquired by pathogens 
under selective pressure from chemotherapeutics. The TB bacilli have been reported to 
develop resistance at a much quicker rate than other human pathogens (Sassetti and Rubin, 
2003). 
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1.6.1 Multi drug resistant TB (MDR-TB)  
Multi drug resistant TB (MDR-TB) is resistance picked up by M. tuberculosis to at least INH 
and RIF, the two most effective first line anti-TB drugs. MDR-TB results from either primary 
infection with resistant bacteria or is developed during the treatments phase. Incomplete 
treatment and non-compliance during therapy are the main reasons of developing MDR-TB. 
Drug resistance also arises due to the ability of the M. tuberculosis pathogen to mutate various 
drug targets. This usually happens in cases where the treatment time is prolonged (WHO, 
2007; Yew and Leung, 2008). The World Health Organisation (WHO) reported about 440,000 
cases of MDR-TB globally in 2008 and deaths caused due to MDR-TB were more than 
110,000 every year. Recent MDR-TB cases reported globally ranges from 0 to 28.3%. 
Amongst new TB cases, 2.9% were MDR-TB, compared with 15.3% amongst previous treated 
cases ((WHO)) M/XDR TB global surveillance report 2010). Treatment of MDR-TB requires 
usage of the reserved and more toxic second-line anti-TB drugs. The DOTS-Plus program (an 
alternative to the DOTS strategy)  is used for treatment of reported MDR-TB cases (Farmer et 
al 2000). The drugs used under this strategy are the most potent second-line reserve drugs – 
Aminoglycosides and Fluoroquinolones. The usual regimen includes at least 4 to 6 drugs 
selected on the basis of efficacy and susceptibility testing and treatment history.WHO 
recommends treatment duration of minimum 18 months post smear negativity, even for HIV-
negative patients. 
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Figure 1.8. Global incidence of MDR TB. A) Map showing the distribution of proportion of 
MDR-TB among new TB cases, 1994–2009 B) Distribution of proportion of MDR-TB among 
previously treated TB cases, 1994–2009. Adapted from  (WHO, 2010) Multidrug and extensively 
drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 
B) 
A) 
B) 
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1.6.2  Extensively drug resistant TB (XDR-TB)  
The urgency for new drugs for TB was recently highlighted by the report of XDR-TB strains 
of TB. XDR strains of M. tuberculosis are resistant to INH, RIF and  any fluoroquinolones 
along with resistance to ateast one of the three following injectable  second line anti-TB drugs, 
for instance amikamycin, kanamycin or capreomycin (Raviglione, 2006).  
XDR-TB has been reported throughout the world even in HIV-seronegative individuals. 
Incidence of cases generating from hospital infections have also been reported. The first XDR-
TB strains were reportedly found between 1993 to 2004 in the USA, where 4% of the isolated 
MDR-TB strains during this period were XDR. Representative data from Europe show 19% 
MDR-TB cases identified in 2000 – 2004 were XDR strains. Asia reported 15% MDR strains 
as XDR in 2004. 
In 53 cases identified in South Africa, between 2005 – 2006, 52 patients died within a 
median period of 16 days (from sputum smear collection to death)(Gandhi et al., 2006). The 
epidemic of XDR-TB amongst individuals in South Africa is a major challenge. Of the XDR 
cases reported, 34% tested HIV positive. Epidemiological data shows that although 64% of the 
XDR cases have been diagnosed with TB and have been admitted to the hospital, 36% had no 
history of TB or hospitalisation. This suggests that factors like poor control practices, non-
adherence to treatment play a major role in the origination of XDR-TB cases. Infections may 
also have been acquired at community levels (Migliori et al., 2007). 
The United States Centers of Disease Control and Prevention (CDC) has reported the 
spread of XDR-TB in all continents (CDC, 2006). This form of TB now reported to be present 
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in 58 countries is almost incurable and represents a serious public health issue globally (WHO 
report 2011) (Figure.1.9.). 
 
Figure 1.9. Map depicting distribution of countries and territories (in red) reporting at least one 
case of XDR-TB as of January 2010. Adapted from  (WHO, 2010) Multidrug and extensively 
drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 
 
1.7 The Mycobacterium tuberculosis complex (MTBC) 
The M. tuberculosis complex includes the closely related species – M. tuberculosis, M. bovis, 
M. africanum, "M. canettii" and M. microti. Although they differ in epidemiology, these four 
species have between 85 to 100% similarity in their DNA (Imaeda T. et al., 1988).  
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M. tuberculosis is the major cause of tuberculosis in humans and infects one third of the 
world’s population annually (WHO). The natural host of M. tuberculosis is humans but it has 
also been reported to infect animals which are in close contact with infected humans. 
 M. bovis is the causative agent of bovine tuberculosis.  M. bovis infection is responsible 
huge agricultural losses globally and public health and animal welfare. It has been reported in 
various domestic animals e.g., cattle, camels etc.  
M. africanum has been isolated from tuberculosis patients in the continent of Africa. 
Approximately 60% of all isolates from pulmonary tuberculosis patients from some regions in 
Africa have been identified as M. africanum (Haas et al., 1997). 
M. microti was identified in 1946 as a pathogen of small mammals like voles, rodents 
and shrews. Wells in 1946 described an acid-fast bacilli causing tuberculosis like infections in 
voles. This organism was later identified as  M. microti (Wells, 1949). Live  M. microti strains 
have also been used for vaccine trials in the 1950’s and they seemed to be of the same efficacy 
as the Bacillus Calmette Guerin (BCG) vaccine used then (Hart and Sutherland, 1977). In 
1998 first reports of M. microti infection in immunocompetent and immunocompromised 
individuals were obtained from Netherlands and subsequently from Germany, Switzerland, 
England and Scotland (Kremer et al., 1998) . 
 M. canettii, identified as M. tuberculosis, subspecies Canettii, (now M. canettii) was 
first isolated from a French farmer, by George Canettii in 1969 (van Soolingen et al., 1997). 
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1.8 Non-tuberculous mycobacteria 
Non tuberculous mycobacteria are also known as atypical mycobacteria and some of these 
cause pulmonary diseases resembling tuberculosis, skin infections and disseminated diseases. 
These bacteria have been usually classified into four groups, namely –  
 Photochromogens – this includes species which develop a pigment after being exposed 
to light. e.g., M. kansasii, M. marinum  
 Scotochromogens –these species develop pigmentation in dark. e.g., M. szulgai, M. 
scrofulaceum. 
 Non chromogens – this includes a group of opportunistic pathogens like the 
Mycobacterium avium complex (MAC), M. ulcerans, M. xenopi, M. malmoense, M. 
terrae, M. haemophilum and M. genavense. 
 Rapid growers – this includes some rapidly growing non chromogenic species some of 
which are pathogenic e.g., M. chelonae, M. abscessus, M. fortuitum. Other non disease 
causing species in this group are M. smegmatis and M. flavescens. 
1.9  Surrogate systems in tuberculosis research - 
Deciphering the mechanisms of pathogenesis of M. tuberculosis is very central in finding 
novel drug targets. The two most significant hindrances in M. tuberculosis research are - 
 Highly infectious nature of M. tuberculosis poses risks for researchers necessitates 
working in a high containment Bio-safety level- 3 (BSL-3). 
 M. tuberculosis has a long doubling time (~24 hrs generation time) and hence 
experiments take unusually longer time as compared to working with other fast 
growing organisms.. 
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This lead to the usage of surrogate models for research on M. tuberculosis pathogenesis. 
Many non-pathogenic mycobacteria and related species are being used as an alternative model 
to assess M. tuberculosis.  
1.9.1 Corynebacterium glutamicum 
C. glutamicum was first discovered in 1950 in Japan. C. glutamicum  and M. tuberculosis 
belong to the same family Corynebacterianeae  and has similar cell wall architecture and  
biosynthetic machinery (Dover et al., 2004). Inspite of sharing similar cell wall ultrastructure, 
the cell wall of C. glutamicum is less complex when compared to M. tuberculosis and also 
gives the advantage over other mycobacterial strains in having a 30 minute generation time 
and ease of genetic manipulation (Cerdeno-Tarraga et al., 2003).  
C. glutamicum has also been reported to tolerate mutations in the homologues of 
essential M. tuberculosis genes, e.g. Cg-emb (Seidel et al., 2007). Also C. glutamicum is a 
good model for studying essential genes in the mycolic acid biosynthesis e.g., pks13 (Gande et 
al., 2004; Portevin et al., 2004). Hence it has been used as a model organism to study 
mycobacterial cell wall biosynthesis (Gande et al., 2004; Gibson et al., 2003).  
1.9.2 Mycobacterium smegmatis 
M. smegmatis is most widely used for M. tuberculosis research as it is non pathogenic and has 
a generation time of 4 to 5 hours. This species shares the same cell wall structure of M. 
tuberculosis and other mycobacterial species and genome analysis shows that M. smegmatis 
shares more than 2000 homologues with M. tuberculosis. M. smegmatis is more tolerant to cell 
wall alterations as compared to M. tuberculosis and some genes essential in M. tuberculosis 
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are non-essential in M. smegmatis. This makes M. smegmatis an attractive model for 
tuberculosis research.  
On the other hand, there are limitations of using M. smegmatis as a model system. 
Approximately 30% proteins of M. tuberculosis do not possess orthologues in M. smegmatis 
and this species is non-pathogenic in nature. Hence even if M. smegmatis offers many  
benefits with working in BSL-1 settings and very short generation time, it still has limitations 
in screening for an effective anti-tuberculosis drug and potential drug targets (Altaf et al., 
2010). 
1.9.3 Mycobacterium bovis (BCG) 
M. bovis is the causative agent of bovine TB (tuberculosis in cattle). The Bacillus Calmette-
Guerin (BCG) is an attenuated strain of M. bovis and shares a high sequence homology to M. 
tuberculosis and the genes involved in the central metabolic pathway are identical in both the 
species. The BCG strain takes about 4-5 days to grow and can be used in a BSL-2 facility. 
Also the BCG strain responds to various molecular /genetic manipulation tools used for 
metabolic studies, e.g.;– electroporation, transposon mutagenesis etc.  
The BCG strain was developed by 230 serial passages of the pathogenic M. bovis strain 
to serve as a vaccine against TB. The disadvantage of this model is that it is an attenuated 
strain and hence virulence cannot be followed as the strain lacks the RD1 and RD3 (region of 
difference) regions in the the genome. The RD1 and RD3 are present in the virulent M. bovis 
strain. 
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1.9.4 Mycobacterium marinum 
M. marinum, a pathogen of amphibians and an opportunistic pathogen of humans has been 
recently developed as a model to study M. tuberculosis pathogenesis (Clark and Shepard, 
1963; Ramakrishnan et al., 1997; Ramakrishnan and Falkow, 1994). M. marinum infects 
macrophages and also  causes chronic tuberculosis like disease in pokilothermic hosts like fish 
and frogs (Rogall et al., 1990). The M. marinum genome is 6.6Mb and shares high similarity 
with the M.tuberculosis genome (Stinear et al., 2008; Tonjum et al., 1998). M. marinum has a 
much shorter generation time (~ 4 hrs) compared to M. tuberculosis,  grows at an optimum  
temperature of 25°C to 35°C (Clark and Shepard, 1963) and possess similar cell wall lipid 
profiles as M. tuberculosis . 
 M. marinum can be used to study mechanisms of pathogenesis using its natural host – 
fish (Swaim et al., 2006) and also in in-vitro macrophage infection models. Zebrafish is a 
natural host for M. marinum and although the fish immune system is not clearly understood, it 
posesses both innate and adaptive immunity (Traver et al., 2003). Zebrafish infected with M. 
marinum develops granuloma – the hallmark of TB infections and hence suggests that the 
mechanism of disease formation is conserved between the two species. Host-pathogen 
interactions can be easily followed in a zebra-fish model using M. marinum (Stamm and 
Brown, 2004; Pozos and Ramakrishnan, 2004). The other advantage of the zebrafish model of 
infection is transparent embryos, which makes it easy to analyse bacterial migration using 
fluorescent M. marinum strains. M. marinum has been shown to enter and replicate within 
macrophages in a way similar to M. tuberculosis (Stamm and Brown, 2004). M. marinum has 
most of the advantages of M. smegmatis and is a pathogen, hence can be used for studying 
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virulence. As it is an opportunistic human pathogen the strain and can be manipulated in BSL-
2 settings and do not pose much risk to researchers. This gives M. marinum an edge over the 
non pathogenic M. smegmatis for use as a surrogate system for TB research. 
1.10 The Mycobacterial cell wall 
  The cell envelope of mycobacteria differs greatly from other bacteria; it is lipid rich, 
extremely hydrophobic with very low permeability to drugs (Brennan and Nikaido, 1995). 
This unique cell wall protects the bacterium from various harsh conditions and confers the 
property of acid-fastness. Acid-fastness refers to the ability of phenol-based dyes to penetrate 
the cell wall and resistance to decolourisation by acid-alcohol. Mycobacteria are still detected 
using the Ziehl-Neelsen staining method which uses the acid-fastness of the mycobacterial cell 
wall. The cell wall lipids and the arabinogalactan-mycolic acid complex contribute to this 
ability to retain phenolic dyes (Harada et al., 1976). 
Research on the cell envelope of M. tuberculosis shows that it consists of  the plasma 
membrane composed of a phospholipid bilayer, similar to the ones found in all free living 
organisms, the cell wall which is made up of a large complex known as the mycolyl-
arabinogalactan-peptidoglycan (mAGP) core and solvent extractable lipids that are 
intercalated to the mAGP layer and in some cases, a capsule like outermost layer.  
M. tuberculosis is reported to form a capsule (Daffé and Etienne, 1999).  This capsule 
forms an interface between the bacterium and its environment (Brennan and Nikaido, 1995). 
The capsule consists of proteins and polysaccharides with small amounts of lipids and the ratio 
of proteins to polysaccharides varies from species to species (Daffé and Lanée, 2001). For 
example, the capsular contents of M. tuberculosis, M. kansasii, M. gastri are mainly 
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polysaccharides, whereas those of M. smegmatis and M. phlei are mainly proteins.  The 
architecture of the mycobacterial cell wall was first proposed by Minnikin (1982) and 
subsequently modified by McNeil and Brennan (1991) and Minnikin et al., (2002). This model 
as representated in Figure. 1.10 shows that the cell wall is a complex arrangement of various 
macromolecules which can be divided into  
 Cell wall composed of a mycolyl-arabinogalactan-peptidoglycan (mAGP) complex. 
 Non covalently bound polysaccharides, phospholipids, glycolipids, waxes and proteins. 
The cell wall is mainly composed of a large cell-wall core or complex that contains three 
different covalently linked structures -peptidoglycan, arabinogalactan and mycolic acids and 
additional lipids attached to outer layer or plasma membrane. The peptidoglycan layer is 
hydrophobically attached to the plasma membrane (Amar and Vilkas, 1973; McNeil et al., 
1991), to which an extended array of polysaccharide is linked (through linker unit) which 
consist of a highly-ordered galactan attached to a branched arabinan domain which is 
esterified to a family of long-chain lipids known as mycolic acids. This is known as the 
mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Brennan and Besra, 1997). 
The covalent linkage of mycolic acids results in a hydrophobic layer of extremely low 
fluidity. This layer is also referred to as the mycomembrane. The outer part of the membrane 
contains various lipids, such as phenolic glycolipids (PGL), phthiocerol dimycocerosates 
(PDIM), cord factor or dimycolyltrehalose (TDM), sulfolipids (SL) and phosphatidylinositol 
mannosides (PIM). Most of these lipids are specific for mycobacteria. The outer layer, which 
is generally called the capsule, mainly contains polysaccharides and glucans. 
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Figure 1.10. Representation of the M. tuberculosis cell wall. Adapted from Minnikin et al., (2002).  
DAT – Diacyl trehalose , PAT – Pentaacyl trehalose, PDIM – Phthiocerol dimycocerosate , LAM 
– Lipoarabinomamman , mAG –mycolyl arabinogalactan , PG - Peptidoglycan, PIM6- 
Phosphatidylinositol hexamannosides. 
1.11 Structural components of cell wall skeleton  
1.11.1 Peptidoglycan (PG)  
The principal structural constituent of the cell wall in mycobacteria is the insoluble cross-
linking peptidoglycan (PG) (Alderwick et al. 2007). The PG in M. tuberculosis is similar to 
Gram-negative bacteria. It is composed of alternating (14)- N-acetylglucosamine 
(GlcNAc) and N-glycolyl muramic acid (Mur) residues. Oligopeptide chains of between three 
and five amino acids, usually L/D-alanine, D-glutamate, meso-diaminopimelic acid (DAP) and 
occasionally glycine, are connected to the muramic acid components. Cross linking occurs 
between two mDAP residues or mDAP and D-alanine (Zhang et al., 2003). Following  the 
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transglycosylation of the (GlcNAc-(14)-Mur), these  linkage formations are catalysed by a 
transpeptidase (Scheffers and Pinho, 2005). Biosynthesis of the mycobacterial PG has not 
been investigated in great detail, but is considered to be similar to the biosynthetic process in 
Escherichia coli (van Heijenoort, 2001). 
1.11.2  Arabinogalactan (AG)  
The arabinogalactan (AG) is one of the major serologically active components of the 
mycobacterial cell wall and is a branched hetero-polysaccharide. The AG consists of 
arabinofuranose (Araf) and galactofuranose (Galf) residues. The galactan of AG is made up of 
a linear chain of 30 -D-Galf residues, alternately linked by (1 5) and (16) linkages. 
These attach to the muramic acid residues in the PG layer via a unique disaccharide bridge and 
a phosphodiester bond. The arabinan domain is made up of arabinofuranose (Araf) residues in 
linear  (1 5) linkages. The arabinan chains are also branched to form a fork-like motif 
(Alderwick et al., 2007; Besra et al., 1995; Daffé et al., 1990). Mycolic acids are esterified to 
at least two thirds of the terminal Araf . 
1.12 Cell wall lipids in Mycobacteria 
Over 60 % of the mycobacterial cell wall consists of lipids of which the majority are mycolic 
acids. It was during the 1930s that the strongly hydrophobic lipid components were first 
studied and the mycolic acids, which make up approximately half of the lipids, were identified 
(Minnikin et al., 2002). These are either esterified to the terminal arabinofuranosides or 
present as solvent-extractable, non covalently bound mycolates, e.g; trehalose di or 
monomycolates (TDM or TMM). Other cell wall solvent-extractable lipids are pthiocerol 
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dimycocerosate (DIM/PDIM), sulfolipids (SL), glycopeptidolipids (GPL), phenolic 
glycolipids, acylglycerols and lipoglycans (LAM/LM/PIMs). 
The cell wall lipids differ in terms of modifications and proportions in different 
mycobacterial species. But they all have a similar organisation in the cell wall. This similarity 
allows the use of non-pathogenic mycobacteria like M. smegmatis for research on the 
mycobacterial cell wall. 
1.13 Cell wall lipids in Mycobacteria 
Over 60 % of the mycobacterial cell wall consists of lipids of which the majority are mycolic 
acids. It was during the 1930s that the strongly hydrophobic lipid components were first 
studied and the mycolic acids, which make up approximately half of the lipids, were identified 
(Minnikin et al., 2002). These are either esterified to the terminal arabinofuranosides or 
present as solvent-extractable, non covalently bound mycolates, e.g; trehalose di or 
monomycolates (TDM or TMM). Other cell wall solvent-extractable lipids like phthiocerol 
dimycocerosate (DIM/PDIM), sulfolipids (SL), glycopeptidolipids (GPL), phenolic 
glycolipids, acylglycerols, glycans - phosphatidyl innositol mannoside (PIMs) and 
Lipoglycans - (LAM/LM) are also present.  
The cell wall lipids differ in terms of modifications and proportions in different 
mycobacterial species. But they all have a similar organisation in the cell wall. This similarity 
allows the use of non-pathogenic mycobacteria like M. smegmatis for research on the 
mycobacterial cell wall. 
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1.13.1 Mycolic acids  
Mycolic acids are an essential part of the mAGP domain and also play an important role in the 
virulence of M. tuberculosis; eg TDM (trehalose dimycolate) (Takayama et al., 2005). 
Mycolic acids are alkylhydroxy fatty acids (C70-C90) with long alkyl side chain unique 
-branched fatty acids found in the cell walls of Mycobacterium. They may make up 50% of 
the dry weight of the mycobacterial cell envelope. There are five known types of mycolic acid 
in M. tuberculosis. All have the same general structure of a branch of C26 and a longer 
chain meromycolate of C50-56, but modifications to this give rise to -mycolates, which 
contain cyclopropane rings, methoxy-mycolates, which have –OCH3 groups and keto-
mycolates, which have keto groups. The latter two are found in both the cis and trans 
configuration of their cyclopropane rings. 
These conformations and modifications of the mycolic acid structures have a significant 
effect on their properties. Cyclopropanation of the mycolic acids is reportedly essential for 
cord formation in mycobacteria and influences virulence (Glickman et al., 2000). The 
mycobacterial gene pcaA is required for cyclopropanation of -mycolates. A  M. tuberculosis  
pcaA mutant strain  displayed growth defects in lungs post infection and failed to persist 
during infection (Glickman et al., 2000). Cyclopropanation modifications have also been 
shown to affect activation of macrophages in immune responses (Rao et al., 2005; Rao et al., 
2006). 
A lot of variations are observed in the classes of mycolic acids in various 
Mycobacterium species. For example, M. tuberculosis possesses , methoxy and keto 
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mycolates while M. smegmatis possesses and epoxy mycolates The representative 
structures of some mycolic acids are shown in Figure 1.11.  
 
Figure 1.11. Representative structures of different types and classes of mycobacterial mycolic 
acids, adapted from Barry et al. (1998).  , 1 and lacking the oxygen functions M – 
methoxy, K – keto, W – wax ester, E – epoxy, -1M - -1 methoxy.   
Mycolic acids serve as a second permeability barrier. Mycolic acids are also found 
esterified to the non-reducing terminal of arabinogalactan, forming the mycolyl-
arabinogalactan (mAG). They are also found embedded within the outer layer of the cell wall, 
associated with glucose and trehalose to form glucose monomycolate (GMM), trehalose 
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monomycolate (TMM), trehalose dimycolate (TDM). Such a distinctive arrangement in the 
outer layer of M. tuberculosis provides limited fluidity to the outer membrane to the cell wall. 
Cell wall components like TDM has been reported to have adjuvant activity, 
antigenicity, innate and adaptive immunity stimulating activity and immunomodifying activity 
(Dubnau et al., 2000).  
1.13.2 Lipoglycans in mycobacterial cell wall  
Interspersed within the mAGP framework of the mycobacterial cell are found LAM, LM and 
various lipoglycans. According to current understanding, lipoglycan biosynthesis in 
mycobacteria can be simplified as PI  PIM  LM  LAM (Besra and Brennan, 1997), 
where each step involves formation of an increasingly glycosylated molecule. LAM and its 
precursor LM and PIMs are related biosynthetically. LM and LAM are attached to the cell 
wall via the PI anchor (Hunter and Brennan, 1990).   
The PI unit is based on a sn-glycero-3-phosphate and is acylated. Addition of 
mannopyranosyl (Manp) units to PI generates the PIMs (Ballou and Lee, 1964). The smallest 
PIM  is PIM1 which is PI glycosylated at the hydroxyl group O-2. Further glycosylation with a 
Manp residue at the O-6 position of the myo-inositol ring of PIM1 yields PIM2. Upto five 
Manp units can be added to the O-6 position of the myo-inositol ring to give rise to PIM6. 
PIMs are always present in the acylated forms –Ac1PIM (acyl group at the 3-OH of the myo-
inositol ring or 6-OH of the Manp residue) and Ac2PIM (acylated at both 3-OH of the myo-
inositol ring and 6-OH of the Manp residue). 
LM consists of a linear α-(1→6)-linked mannan backbone (17 -19 Manp residues) which 
extends from the mannose (Manp) residue linked to the O-6 position of inositol in PIM2 
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(Chatterjee et al., 1991; Besra et al., 1997) and 7-9 single branched α-(1→2) Manp units. 
Glycosylation of the LM with arabinan forms LAM. LAM consists of three domains – a 
polysaccharide backbone, the PI-anchor and a capping motif. In LAM, the mannan backbone 
is further elaborated by the addition of a branched arabinan polymer similar to that found in 
AG, and mannosylation or capping (Chatterjee et al., 1993; McNeil et al., 1994). The arabinan 
polymer consists of 60 α-(1→5) - Araf units with branched hexaarabinofuranosides and linear 
tetraarabinofuranosides.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. The general structure of LAM (Man-LAM) from M. tuberculosis, and its 
relationship with different PI derivatives. R1 and R2 indicate the acylation position on the 
glycerol in the MPI anchor, R3 – acylation at 3OH of the inositol, and R4acylations at the 6-OH of 
the Manp. m, n,o,p indicate species specific amounts of glycosylation. ? - unknown linkage 
between arabinan and mannan. Adapted from (Jankute et al., 2012). 
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LAM is the major immune modulator leading to immune suppression ,induction of 
inflammatory cytokines , inhibition of various interferon gamma (IFN-) induced activities 
such as microbicidal and tumoricidal functions of macrophages and  neutralization of 
cytotoxic free radicals (Sibley et al., 1988).  
Based on the capping motif, three types of LAM have been identified.  
 Mannose-capped LAM (ManLAM) (Nigou et al., 2003) which is found in slow 
growing pathogenic mycobacterial strains -  M. tuberculosis, M. bovis BCG, M. 
leprae, M. avium, M. xenopi, M. kansasii and M. marinum. 
 Phospho-myo-inositol-capped LAM (PILAM) (Khoo et al., 1995a) which is 
found in the fast growing, non pathogenic M. smegmatis and M. fortuitum. 
 Non-capped or Ara-LAM (Guerardel et al., 2002) found in M. chelonae. 
1.14 Solvent extractable lipids in the mycobacterial cell wall 
A variety of covalently bound lipids are found interspersed within the hydrophobic 
environment provided by mycolic acids of the mAGP complex. Some of these lipids are 
common to all mycobacteria and these include TDMs while others are species / strain specific 
like PDIM, PGL, SLs, GPLs and LOSs. 
1.14.1 Trehalose monomycolate and dimycolate 
Trehalose (-D-glucopyranosyl--D-glucopyranoside) is a non-reducing disaccharide of 
glucose and is found abundantly in bacteria, yeast, fungi, plants, insects and invertebrates and 
mainly acts as a storage molecule. In mycobacteria, trehalose is either found in the free forms 
in the cytosol or as acylated forms (esterified to various fatty-acyl groups) in the cell wall. In 
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mycobacteria, trehalose plays the role of a carrier molecule. Based on these esterifications, 
acylated trehaloses in mycobacteria can be grouped under three classes:  
 Mycolyl trehaloses – trehalose monomycolate and trehalose dimycolate (TMM and 
TDM). 
 Methyl-branched acyl trehaloses – Di-acyl, Tri-acyl and Pent-acyl trehaloses (DATs, 
TATs, PATs). 
 Sulfated acyl-trehaloses – Sulfolipids (SLs). 
TDM is also known as ‘cord factor’ and is the most abundant lipid produced by virulent 
M. tuberculosis (Bloch and Noll, 1953). Removal of the non-covalently bound surface 
exposed lipids of M. tuberculosis cells by petroleum ether showed reduced viability and 
caused loss of virulence. This petroleum ether extract was known as ‘cord-factor’ and its 
composition was found out to be primarily trehalose-6-6’- dimycolate (Noll and Bloch, 1953; 
Noll et al., 1956). The basic structure comprises of a trehalose sugar esterified to two mycolic 
acid residues. In TDMs, the trehalose is esterified to mycolates at positions 6 and 6’. TDM is 
found only extracellularly. This supports the transport of mycolates in the form of TMM 
(Belisle et al., 1997). TDM constitutes majority of the non-covalently bound surface exposed 
lipids in mycobacteria and is reported to play an important role in the recruitment of cells for 
granuloma formation (Hunter et al., 2006), and also modulates expression and production of 
cytokines and NO (Lima et al., 2001). TMM is the precursor of TDM and is found both 
intracellularly and extracellularly. It posessess a single mycolate residue esterified to the 
trehalose sugar (Figure 1.13). 
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Figure 1.13. Structure of trehalose dimycolate from M. tuberculosis. A specific example of the 
sugar esterified with the -mycolate is shown. 
 
1.14.2 Methyl-branched acyl trehaloses  
Methyl-branched acyl trehaloses carry various methyl branched acyl chains such as 
mycosanoic acids in diacyl-trehaloses (DATs) and mycolipenic acids in triacyl-trehaloses  and 
pentaacyl-trehaloses (PATs). DATs (Lemassu et al., 1991; Besra et al., 1992), TATs (Munoz 
et al., 1997) and PATs (Minnikin et al., 1985; Daffé et al., 1988) are exclusively found in the 
virulent Mycobacterium strains suggesting the importance of these molecules in the virulence 
of M. tuberculosis. These molecules are amphiphillic in nature and hence contribute to the 
structure of the cell wall by interacting both with the mycolic acid core and the outermost 
capsule layer (Minnikin et al., 2002). DATs are non-covalently linked to the peptidoglycan in 
the outer layer of the mycobacterial cell wall (Ortalo-Magne et al., 1996).  
While not much is not known about their effects on virulence, both DATs and TATs 
have been reported to be useful in detection of TB infection. Immunoglobulin G 
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corresponding to these molecules are detected with very high specificity and sensitivity 
(Munoz et al., 1997). 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.14. Structures of diacyl trehalose (DAT), triacyl trehalose (TAT) and pentaacyl 
trehalose (PAT) from M. tuberculosis. 
1.14.3 Phthiocerol dimycocersate (PDIMs) and Phenolic glycolipids (PGL)  
Genes involved the biosynthesis of PDIM and PGL play a role in the pathogenesis of the 
tubercle bacillus (Camacho et al., 2001). PDIMs are composed of a long chain phthiocerol or 
phthiodiolone esterified with two multimethyl-branched long-chain mycocerosic acids 
DAT 
TAT 
PAT 
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(Minnikin et al., 2002). Studies by Kolatukuddy and co-workers showed the involvement of 
PKS genes in biosynthesis of PDIMs in M. bovis (Mathur and Kolattukudy, 1992; Azad et al., 
1996). Although not much is known about the role of PDIMs in host-pathogen interactions, it 
has been shown that their presence is essential for successful M. tuberculosis infection. Loss 
of PDIMs was responsible for attenuation of M. tuberculosis in mice lungs (Cox et al., 1999). 
PDIMs have been reported to be involved in the early stages of M. tuberculosis infection and 
protects the bacilli from reactive nitrogen intermediates (Rousseau et al., 2004), arrests 
acidification of phagosome and is also involved in modification of host cell membranes  
(Simeone et al., 2007).  
Mycobacteria that produce PDIMs, also synthesize the structurally related PGL. In 
these, the hydroxyl group of the phenol moiety is glycosylated by species/type-specific mono-, 
tri- or tetrasaccharide units (Daffé et al., 1987). Known as phenolic glycolipids (PGLs), these 
are found in pathogenic mycobacterial strains such as members of the M. tuberculosis 
complex, especially M. tuberculosis strain Canettii, M. leprae, M. kansasii, M. marinum, M. 
gastri, and M. ulcerans (Daffé et al., 1987). They are similar in structure to PDIMs, and are 
comprised of a conserved lipid core with varying carbohydrate residues (Minnikin et al., 1982; 
Chatterjee et al., 1988). The sugar moiety of PGLs consists of one to four sugar residues, most 
of which are O-methylated deoxysugars.  
A precursor of phenolphthiocerols, p-hydroxybenzoic acid (p-HBA) is found in all 
strains of M. tuberculosis, but only few strains produce PGLs. The gene pks15/1 is involved in 
the elongation of p-HBA derivatives to generate phenolphthiocerols. Based on the sequence of 
pks15/1, M. tuberculosis strains are grouped into different clusters. "M. canettii" and strain 
210 (belonging to the Beijing strain) carries a six nucleotide insertion in the pks15/1 gene 
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resulting in a functional Pks15/1 synthase (Brosch et al., 2002; Constant et al., 2002).  PGL-1 
from M. leprae has been used for serodiagnosis of leprosy and TB (Gaylord et al., 1987, 
Simonney et al., 1995). PGLs have been reported to be involved in immunomodulation during 
infection by inhibiting release of proinflammatory chemokines (Reed et al., 2004; Prasad et 
al., 1987), e.g. M. leprae PGL-1 inhibits proliferation of T-lymphocytes (Mehra et al., 1984; 
Fournie et al., 1989)   
Figure 1.15.  Structure of PDIMs and PGLs from M. tuberculosis. 
 
1.14.4 Sulfolipids (SL) 
Sulfated metabolites are very sparse in prokaryotes. Mycobacteria are one of the three genera 
in which there is an abundance of sulfolipids. The other two being the plant pathogen 
Xanthomonas oryzae and plant symbiont Sinorhizobium meliloti (Schelle and Bertozzi, 2006). 
Sulfolipids are found in virulent mycobacterial strains (Middlebrook et al., 1959).They are 
composed of sulfated trehalose esters, acylated with three to four fatty acyl groups which 
Chapter 1  General Introduction 
41 
 
consist of one short chain saturated fatty acid (e.g. palmitic acid or stearic acid ) and different 
long chain multi-methyl branched fatty acids (e.g., phthioceranic acid and 
hydroxyphthioceranic acids). The most abundant SL in mycobacterial cell wall is SL-1 which 
is a 2,3,6,6’-tetraacyl 2’ sulfate (Raynaud et al., 1998; Goren et al., 1976).  SLs block the 
release of tumor necrosis factor-alpha (TNF-) from macrophages stimulated by TDMs. This 
in turn has an inhibitory influence on granuloma formation. SLs deficiency in mutant strains 
derived from H37Rv have shown to play a significant effect in persistence and pathogenicity 
of M. tuberculosis in guinea pigs and cultured macrophages (Rousseau et al., 2003b). 
 
Figure 1.16. Structure of sulfated tetra acyl trehalose (SL) from M. tuberculosis. 
1.14.5 Oligosaccharide containing lipids 
Oligosaccharide containing lipids in mycobacteria are divided into two major classes, the 
lipooligosaccharides (LOSs), which are acylated by long chain fatty acids, and phenolic 
glycolipids  and glycopeptidolipids (Asselineau and Lanéelle, 1998). 
SL 
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1.14.5.1 Glycopeptidolipids (GPL) 
GPLs are non polar mycosides produced by several mycobacterial species such as the non 
pathogenic, fast growing M. smegmatis, mycobacterial pathogens M. chelonae and M. 
abscessus (Ripoll et al., 2007), opportunistic human pathogens like members of the 
Mycobacterium avium complex (MAC) that include M. avium and M. intracellulare, animal 
pathogens M. porcinum and M. senegalense (Lopez Marin et al., 1991). GPL’s are composed 
of a common lipopeptide core that is made up of D-phenylalanine- D -allo-threonine- D -
alanine-L-alaninol, with varying glycosylations in pathogenic and non-pathogenic species. 
Some mycobacterial species such as M. smegmatis and M. avium display an ability to produce 
biofilms on PVC surfaces (Recht et al., 2001).This correlates with their ability of sliding 
motility and GPLs have been identified to play an important role in this process (Martinez et 
al., 1999). A correlation between virulence and biofilm formation has also been reported. 
GPLs from M. smegmatis have been reported to be involved in inhibition of receptor mediated 
phagocytosis of Mycobacterium by macrophages (Villeneuve et al., 2003). It was observed 
that clinical strains of M. avium were capable of forming biofilms while the strains defective 
in genes responsible for biofilm formation were retarded in sliding motility when compared to 
the wild type clinical isolates (Carter et al., 2003; Yamazaki et al., 2006).  
1.14.5.2  Lipooligosaccharides (LOS) 
LOSs are highly polar, trehalose containing surface immunogens of many environmental 
mycobacteria. They were first found and  characterised from the opportunistic pathogen M. 
kansasii (Hunter et al., 1985), M. gastri (Gilleron et al., 1993), M. szulgai (Hunter et al., 
1988), M. malmoense (McNeil et al., 1987), M. gordonae (Besra et al., 1993), the fish tank 
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granuloma causing M. marinum (Minnikin et al., 1989),  M. mucogenicum (Munoz et al., 
1998) and the M. tuberculosis complex strain, M. canettii (Daffé et al., 1991).  
LOSs have a poly-acylated trehalose core with further glycosylations. Varying residues 
of D-xylose, 3-O-methylrhamnose, fucose, and a N-acyl aminosugar are linked to the core and 
these sugar compositions are species-specific and responsible for immunogenic properties of 
LOSs. Depending on the species, the oligosaccharide is linked either on carbon 3, 4 or 6 of the 
trehalose, and this oligosaccharide is further glycosylated to possess 2 to 6 sugar residues, 
some of which are new and specific carbohydrates, like the caryophyllose (-3,6 dideoxy-4-C-
(D-altro-1,3,4,5-tetrahydroxyhexyl)-D-xylo-hexopyranose) and an N-acyl aminosugar (N-
acylated dideoxy galactose) residues. 
LOSs have been extensively studied in M. marinum and four types of LOSs, LOS-I to 
LOS-IV have been identified. M. gastri is also reported to possess a novel C-4 branched 3,6-
dideoxy--hexopyranose, and four classes of LOSs were identified from this species (Gilleron 
et al., 1994). M. kansasii has eight different types of these antigenic glycolipids (Hunter et al., 
1983; Hunter et al., 1985). The variable sugar residues in this species are xylose, 3-O-methyl-
rhamnose, fucose and a 4,6-dideoxy-2-O-methyl-3-methyl-4-(2’-methoxypropionamido)--L-
mannohexopyranosyl.  
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Table 1.3 Composition of LOS from different mycobacterial species. Multiple number of 
identical residues are denoted by ‘n’.  
M. kansasii 
LOS I’ 
3-O-Me-α-L-Rhap-(1→3)-α- D-Glcp-(1↔1)-α-D-Glcp-β-D-Glcp-
(1→4) 
LOS-I (n=1) 
LOS II (n=2) 
LOS  III (n = 3) 
(β- D -Xylp)n-(1→4)- 3-O-Me-α-L-Rhap-(1→3)-β-D-Glcp-(1→3)- 
β- D -Glcp-(1→4)-α-D-Glcp-(1↔1)-α- D –Glcp 
LOS IV (n=4), 
LOS- V (n=5), 
LOS- VI (n=6) 
KanNacyl-(1→3)-Fucp-(1→4)-(β-D-Xylp)n-3-O-Me-α-L-Rhap-
(1→3)-β- D -Glcp-(1→3)-β- D -Glcp-(1→4)-α-  D -Glcp-(1↔1)-
α- D –Glcp 
LOS VII 
 
KanNacyl-(1→3)-Fucp-(1→4)-[(β-L-Xylp)6-(1→4)]6-α-L-3-O-
Me-α-L-Rhap-(1→3)-β- D -Glcp-(1→3)-β- D -Glcp-(1→4)-α- D-
Glcp-(1↔1)-α- D –Glcp 
M. malmoense LOS II 
α- D -Manp-(1→3)-α- D -Manp-(1→2)-α-L-Rhap-(1→2)-[α-L-3-
O-Me-Rhap-(1→2)]2-α-L-Rhap-(1→3)- α-  D -Glcp-(1↔1)-α- D –
Glcp 
M. szulgai LOS I 
α-L-2-O-Me-Fucp-(1→3)-α-L-Rhap-(1→3)-β-L-Rhap-(1→3)-β- D 
-Glcp-(1→6)-α- D -Glcp-(1↔1)-α- D -2-O-Me-Glcp 
M. tuberculosis 
“Canettii” 
LOS I 
N-acyl-4-amino-4,6-dideoxy-Galp-(1→4)-2-O-Me-α-L-
Fucp-(1→3)-β- D -Glcp-(1→3)-[2-O-Me-α-L-Rhap-(1→3)]2-β- D 
-Glcp-(1→3)-4-O-Me-α-L-Rhap-(1→3)-6-O-Me-α- D -Glcp-
(1↔1)-α- D –Glcp 
 
M.  gordonae (989) 
LOS I 
N-acyl-4-amino-4,6-dideoxy-2,3-O-Me-α-Galp-(1→3)-2-O-Me-4-
O-Ac-α-L-Fucp-(1→3)-β- D -Glcp-(1→3)-2-O-Me-α-L-Rhap-
(1→3)-β- D -Xylp-(1→2)-α-L-Rhap-(1→3)-β- D -Glcp-(1→3)-α-
L-Rhap-(1→3)-6-O-Me-α- D -Glcp-(1↔1)-α- D –Glcp 
M.  gordonae (990) LOS I 
α-L-Rhap-(1→2)-3-O-Me-Rhap-(1→3)β-D-Xylp-(1→2)-α-L-
Rhap-(1→3)-β-D-Glcp-(1→3)-β-D-Glcp-(1→3)-α-L-Rhap-(1→3)-
6-O-Me-α- D -Glcp-(1↔1)-α-D–Glcp 
M. gastri 
 
LOS I (n = 1) 
LOS II (n = 2) 
[β-L-Xylp-(1→4)]n-3-O-Me-Rhap-(1→3)-β- D -Galp-(1→3)-β- D 
-Glcp-(1→4)-α- D -Glcp-(1↔1)-α- D –Glcp 
LOS III (n = 6) 
LOS IV (n = 7) 
3,6-dideoy-4-C-(1,3-dimethoxy-4,5,6,7-tetrahydroxy-heptyl)-α-
xylo-Hexp-(1→3)-[β-L-Xylp-(1→4)]n-3-O-Me-Rhap-(1→3)-β- D -
Galp-(1→3)-β- D -Glcp-(1→4)-α- D -Glcp-(1↔1)-α- D –Glcp 
M. marinum 
LOS I 
3-O-Me-Rhap-(1→3)-β- D -Galp-(1→3)-β- D -Glcp-(1→4)-α- D -
Glcp-(1↔1)-α- D –Glcp 
LOS II 
[3,6-dideoxy-4-C-(D-altro-1,3,4,5-tetrahydroxyhexyl)-D-xylo-
hexopyranose (1→4)]n- [β-L-Xylp-(1→4)]-3-O-Me-Rhap-(1→3)-
β- D -Galp-(1→3)-β- D -Glcp-(1→4)-α-D-Glcp-(1↔1)-α-D-Glcp 
LOS III 
-Car (1→4)- [β-L-Xylp-(1→4)]-3-O-Me-Rhap-(1→3)-β-D-Galp-
(1→3)-β- D -Glcp-(1→4)-α- D -Glcp-(1↔1)-α- D –Glcp 
LOS IV 
-4-amino-4,6-dideoxy-Galp (1→c)- -Car (1→c)- -Car (1→4)- 
[β-L-Xylp-(1→4)]-3-O-Me-Rhap-(1→3)-β-D-Galp-(1→3)-β- D -
Glcp-(1→4)-α- D -Glcp-(1↔1)-α-D-Glcp 
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The Canettii strain of M. tuberculosis is characterised by the presence of only two LOSs 
(Daffé et al., 1991). The trehalose residues were found to be methylated at position 6’ and 
were either 2,3,6- or 3,4,6-tri-O-acylated. LOSs from M. szulgai contains a 2-O-methyl--D-
fucopyranosyl unit and is glycosidically linked to a 2-O-methyltrehalose. M. gordonae clinical 
isolates were described to contain novel classes of LOSs. They were reported to possess 6’-O-
methyl-2,3,4,6-tetra-O-acyl-glucose unit and also a novel branched oligosaccharide backbone 
(Besra et al., 1993). 
LOSs are highly antigenic and have been used for serotyping (Munoz et al., 1998). LOSs 
from M. marinum have also been reported to be involved in sliding motility and biofilm 
formation (Ren et al., 2007). Although the gene cluster involved in LOS biosynthesis in M. 
marinum have been identified (Burguière et al., 2005; Etienne et al., 2009; Ren et al., 2007), 
the LOS biosynthetic pathway have not yet been deciphered completely. More about LOS 
biosynthesis from previous research and work reported in this thesis project is discussed in 
Chapter 2. 
1.15  Aims and Objectives  
The objectives of this thesis were to study pathways leading to biosynthesis and transport of 
complex mycobacterial cell wall lipids and their effects on virulence. The study focussed on 
two lipid metabolites, lipooligosaccharides (LOSs) and mycolic acids. 
The broad aim of the studies on LOSs was to identify genes involved in the LOS 
biosynthesis in M. marinum and M. kansasii with the long term aim of applying these findings 
to the M. tuberculosis complex strain "M. canettii". M. marinum was used predominantly in 
these studies as a model organism. A combination of transposon mutagenesis and directed 
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knockouts were used to achieve these goals and the results are discussed in chapters 2, 3,4 and 
5. Additionally, the effects of alteration in LOS profile on virulence were studied using 
zebrafish and macrophage models of infection. 
The studies on mycolic acids focussed on deciphering transport and processing pathways 
and make use of M. smegmatis as a surrogate. These results are described in Chapter 6. 
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2.1 Introduction  
As discussed in the previous chapter, solvent extractable glycolipids are 
predominant in mycobacteria and can vary between different mycobacterial 
species, and within strains of the same species.  While some ‘free’ lipids like 
TDM are common to all mycobacteria, others are only species and/or strain 
specific such as sulfolipids, glycopeptidolipids and phenolic glycolipids.  Included 
in the latter class are the highly polar lipooligosaccharides (LOSs) which are 
produced by a number of mycobacteria, including the opportunistic pathogen M. 
kansasii, the fish tank granuloma-causing M. marinum, and the M. tuberculosis 
complex strain, "M. canettii" (Daffé et al., 1987). 
Given the absence of LOSs in M. tuberculosis strains, the exact role of 
LOSs in virulence is unclear.  However, LOS-deficient M. kansasii strains were 
unable to establish infection in a mouse model and mutants of M. marinum with 
altered LOSs patterns were found to be defective in macrophage entry (Belisle 
and Brennan, 1989). Furthermore, purified M. marinum LOSs were found to 
inhibit TNF- secretion by LPS-stimulated macrophages (Rombouts et al., 2009).  
Collectively, these data suggested a significant role for LOSs in virulence of 
pathogenic mycobacteria. 
Earlier experiments on biochemical and genetic analysis of LOS 
biosynthesis were done on M. marinum. M. marinum produces four subclasses of 
LOSs; LOS-I, LOS-II, LOS-III and LOS-IV. Each of these subclasses contains a 
common glycan core consisting of four glucose residues and one methylated 
rhamnose (Burguière et al., 2005). The structures are shown in Figure 2.1. 
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Figure 2.1. Structures of LOS-I to LOS-IV from M. marinum. The tetraglucose core 
(in blue) with the methylated rhamnose (red) in LOSI , with a xylose (red) and 
caryophyllose (brown) in LOSII, an additional caryophyllose in LOSIII , and 
LOSIV with the terminal N-acylated 4,6, dideoxygalactose (purple) . ‘R1’ in the core 
stands for either 2,4,-dimethylhexadecanoate, or 2,4-dimethyl-2-pentadecenoate; 
and R2 is either -H or –OH, R3 is either –H or -OCH3 and R4 is –H or –COOH. 
 
A D-Xylp residue is found in LOS-II, LOS-III and LOS-IV in addition to the 
glycan core.  LOS-II contains a further caryophyllose sugar that was initially 
referred to as sugar ‘X’(Burguière et al., 2005), and now has been characterized to 
be a 3,6-dideoxy-4-C-(D-altro-1,3,4,5–tetrahydroxyhexyl)-D-xylo-hexopyranose  
(Rombouts et al., 2009), while LOS-III and LOS-IV contain two caryophyllose 
residues, with LOS-IV containing an extra, sugar that has been characterised as an 
N-acylated--amino-4,6-dideoxy galactose (Rombouts et al., 2010). The glycan 
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core is also acylated, predominantly with a dimethylated C18:0 fatty acid, and to a 
lesser extent with a range of non-methylated and dimethylated C15-C20 fatty acids 
(Burguière et al., 2005).  By isolating M. marinum transposon mutants with 
altered colony morphology, Ren et al., (2007) identified the genetic locus for LOS 
biosynthesis. 
 Surprisingly, M. tuberculosis H37Rv which is not known to produce LOSs, 
contains a similar locus which is however missing a number of genes that are 
present in the equivalent locus in M. marinum.  MMAR2313 (losA), encoding a 
glycosyl transferase was the first mycobacterial gene demonstrated to play a role 
in LOS biosynthesis. A losA transposon mutant was reported to be defective in 
synthesising LOS-IV. This suggested that LosA was involved in the transfer of 
the N-acylated--amino-4, 6-dideoxy galactose to LOS-III resulting in the 
formation of LOS-IV (Burguière et al 2005).  The only other LOS biosynthesis 
genes identified by mutational analysis in M. marinum include MMAR2309 
(encoding a UDP-glucose dehydrogenase) and MMAR2332 (encoding a 
carboxylase); disruption of either gene led to the accumulation of intermediates.  
Further progress in delineating LOS biosynthesis pathways in M. marinum has 
recently been made by comparative study on a M. marinum strain Mma7 that fails 
to produce LOS-IV and instead accumulates large quantities of LOS-III 
(Rombouts et al., 2009).  M. marinum Mma7 contained a chromosomal deletion 
that extended from the 3´-end of losA to MMAR2318, suggesting that genes in this 
region were likely involved in the biosynthesis of the terminal N-acylated--
amino-4,6-dideoxy galactose that is found in LOS-IV. Based on the sugar rich 
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composition of LOSs, numerous glycosyltransferases (GTFs) potentially play a 
substantial role in LOS biosynthesis pathways. 
However, at the start of the studies described in this chapter, losA remained 
the only GTF-encoding gene shown to be involved LOS biosynthesis in M. 
marinum. The gene cluster involved in LOS biosynthesis in M. marinum has five 
GTFs as shown in Table 2.1. 
Table 2.1. Predicted glycosyltransferases in the LOS biosynthesis gene cluster in M. 
marinum. 
 
 
The protein encoded by MMAR2311 is a type II GTF and contains a 
methyltransferase domain at the N-terminus and a type II DPM1 like domain at 
the C-terminus. These GTFs are known to transfer sugars to various substrates 
like dolichol-phosphate. MMAR2313 (losA) is involved in the transfer of a 
dideoxy-galactopyranose residue to LOS-III to form LOS-IV. Burguiére et al., 
(2005) reported that inactivation of losA results in the inability of the mutant 
strain to produce LOS-IV. MMAR2349 (wbbl2) posesses a rhamnosyltransferase 
domain and belongs to type 2 GTFs. MMAR2351 is a type 2 GTF with a dolichol 
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phosphate mannose - dolichol phosphate glucosyltransferase (DPM-DPG) 
synthase like domain. The effects of disruption of MMAR2351 are described in 
Chapter 4 of this thesis. A transposon mutant disrupted in MMAR2332 was found 
to be defective in LOS biosynthesis (Ren et al.,2007). Given the proximity of 
MMAR2333 to genes involved in LOS biosynthesis it was likely that the 
MMAR2333-encoded GTF was involved in the transfer of one or more sugar 
residues found in M. marinum LOSs.  In this study we report the identification 
and characterisation of a null mutant of M. marinum MMAR2333 generated by 
specialised transduction, a highly efficient, phage-based, knockout methodology 
that has proven successful in generating targeted mutants in other mycobacteria.  
The mutant strain was also assessed for changes in virulence by infecting cultured 
bone marrow-derived murine macrophages, and zebrafish larvae.  
2.2 Materials and Methods 
2.2.1  In silico analysis of MMAR2333 (WcaA) 
The MMAR2333 (wcaA) gene sequence was obtained from 
http://genolist.pasteur.fr/MarinoList.  Multiple sequence alignments of WcaA 
from different mycobacterial species were rendered using CLUSTAL W 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and ESPript (http://espript.ibcp.fr/ 
ESPript/ESPript/). Expasy server (http://expasy.ch/) and Mobyle portal 
(http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::toppred) were used to predict 
the transmembrane domains. 
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2.2.2 Plasmids, DNA manipulations and bacterial growth conditions 
 Plasmids, bacterial strains and phages used in this study are listed in Table 2.1. 
Escherichia coli strains were routinely cultured in Luria-Bertani (LB) broth at 
37⁰C. M. smegmatis strain mc2155 was used for generation and propagation of 
mycobacteriophages and was routinely grown at 37°C in Tryptic Soy Broth with 
0.05% Tween-80. All M. marinum strains were grown either in 7H9 broth 
supplemented with 10% OADC (oleic acid/albumin/dextrose/catalase, BD) or in 
7H10 broth (composition based on Middlebrook’s 7H10 agar components) 
supplemented with 10 % OADC, at 30°C, with 0.05% Tween-80.  M. marinum 
1218R (ATCC 927) was used as the wild type (parental) strain for generation of 
the MMAR2333 null mutant. For plate growth, 7H10 agar plates were incubated at 
either 30°C, or when required, at 37°C (for selecting transductants; see below).   
For experiments involving the usage of phages, Tween 80 was not used in media. 
Mycobacteriophages were routinely propagated on soft agar lawns of M. 
smegmatis mc
2155 on basal Middlebrook’s 7H9 agar with 0.2% glycerol. Phage 
high titres were generated using protocols described by Larsen et al., (2007). 
Antibiotics were added as required: Hygromycin B (Roche) 150µg/ml for E. 
coli, 100µg/ml
 
for M. smegmatis, 75µg/ml for M. marinum. Kanamycin sulfate 
(Sigma) 50µg/ml
 
for E. coli and 25µg/ml for M. marinum, Apramycin 25µg/ml 
for M. marinum. 
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Table 2.2. Bacterial strains, plasmids and phages used in this study 
Plasmids, phages and strains Description Reference 
Plasmids   
p0004S 
Cosmid vector containing 
Hyg-SacB cassette 
(Larsen et al., 2007) 
 
pMMAR2333 
Derivative of p0004S obtained 
by cloning the right and left 
PCR flanks of MMAR2333 
This work 
pMV261 
KanR , E. coli-mycobacterial 
shuttle vector (ColE1 oriM 
Phsp60) 
Stover et al., 1991   
 
pMV261-MMAR2333 
pMV261 containing a copy of 
the gene MMAR2333 
This work 
pMSP12-dsRed-Apr 
E. coli-mycobacterial shuttle 
plasmid, containing dsRed and 
AprR 
J. Chen Ph.D. thesis, 
University of Birmingham 
2010 
Phages   
phAE159 
Conditionally replicating 
shuttle phasmid derived from 
lytic mycobacteriophage TM4. 
(Larsen et al., 2007) 
 
phMMAR2333 
Derivative of phAE159 
obtained by cloning 
pMMAR2333 into its PacI 
site 
This work 
Bacterial strains   
E.coli TOP 10 
 
F– mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 
Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
 
Invitrogen 
 
HB101 
 
E. coli K-12 F__(gpt-proA)62 
leuB1 glnV44 ara-14 galK2 
lacY1 hsdS20 rpsL20 xyl-5 
mtl-1 recA13 
Stratagene 
M.smegmatis mc2155 
Wild type strain, Ept mutant of 
M. smegmatis strain mc26 
Snapper et al., 1990 
M. marinum 1218R 
Wild type strain of M. 
marinum 
ATCC927 
MAR 2333 
 
M. marinum  strain with 
replacement of MMAR2333 
with hyg 
This work 
MMAR2333-C 
 
MAR2333 complemented 
with pMV261-MMAR2333. 
This work 
2.2.3 Construction of knockout phage for deletion of MMAR2333  
Approximately 1 kb sequences of the upstream and downstream regions of 
MMAR2333 were PCR-amplified from M. marinum 1218R genomic DNA using 
the primer pairs listed in Table 2.3.  The PCR products were purified and the 
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primer incorporated Van91I sites were digested with Van91I, following which the 
digested PCR fragments were cloned into Van91I-digested p0004S to generate the 
allelic exchange plasmid pΔMMAR2333. Plasmids obtained by miniprep (Qiagen 
miniprep kit) were digested with Van91I and PacI and sequenced to confirm 
presence of the left and right flanks.  One positive plasmid was packaged into the 
temperature sensitive phage, phAE159. PacI digested pMMAR2333 was ligated 
to PacI digested phAE159 DNA. The ligation mix was then packaged into empty 
-phage heads and transduced into E. coli HB101. Cells containing phasmid DNA 
were selected for on LB agar containing Hygromycin at 37°C. Packaging of 
pΔMMAR2333 into phAE159 was confirmed by PacI digestion.The phasmid 
DNA was subsequently used to generate the phage phΔMMAR2333 using 
protocols described by (Larsen et al., 2007).  
  
Table 2.3. Primers used for generation of knockout construct in M. marinum 
 
The positive phasmids were transformed by electroporation into M. 
smegmatis at 1800V and recovered at 30°C for ~4 hours in TSB. The recovered 
cells were then harvested and resuspended in 200µl of MP buffer. This was mixed 
with 200µl of freshly growing M. smegmatis and 5ml molten soft agar (50°C) and 
poured on 7H9 basal agar plates and incubated at 30°C for 2 -3 days and allowed 
Primer Sequence 5' -3' Description Size 
MMAR2333_LL TTTTTTTTCCATAAATTGGGTCTGCACCGGCTACAAGAG left side flank 
sequence of  
MMAR2333 
960 
bp MMAR2333_LR 
TTTTTTTTCCATTTCTTGGGTCCTGGGTGGGCTGAAGTA 
 
MMAR2333_RL 
 
TTTTTTTTCCATAGATTGGCGTGGGTCGGCTTCAAATCG Right side flank 
sequence of  
MMAR2333 
902 
bp MMAR2333_RR 
 
TTTTTTTTCCATCTTTTGGCTTCAGACGGACCTGTGGGT 
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to form plaques. The plates were soaked in minimum amount of MP buffer for 5-6 
hours and the solution containing phages was filtered and stored at 4°C. This 
generated the recombinant phage - phMMAR2333 designed to replace the gene 
MMAR2333 with hyg. 
2.2.4 Generation of a MMAR2333 null mutant  
Specialised transduction of M. marinum 1218R was performed as described 
previously for other mycobacteria (Bardarov et al., 2002). M. marinum cultures 
were grown in 50ml of 7H9+10% OADC (0.05% Tween 80) to an OD600 of about 
0.8 and harvested by centrifugation at 4500xg for 10 minutes. The cell pellet was 
washed twice with 50ml of MP buffer. Finally the pellet was resuspended in 2ml 
of MP buffer and 2ml of high titre (10
-10
 pfu /ml) phage lysate was mixed with the 
cells. A control was set up where 0.5 ml of resuspended cells were mixed with 
0.5ml of MP buffer. The mix was incubated overnight at 37°C followed by 
harvesting and recovery with 10ml 7H9+10% OADC with Tween-80 overnight at 
37°C. This was plated onto 7H10+10% OADC-agar plates with hygromycin B 
and plates were incubated at 37°C for 2 weeks. Hygromycin resistant colonies 
obtained after transduction of M. marinum 1218R (wild type strain) were 
inoculated in 10ml 7H9+10% OADC -Tween 80 with hygromycin B for genomic 
DNA extraction and further characterisation. Allelic exchange of MMAR2333 
with a hygromycin resistance cassette in hygromycin resistant transductants was 
confirmed Southern blot. One such transductant was selected for subsequent 
experiments.  
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Restriction enzymes were selected based on the sequence of the knockout 
plasmids. For MMAR2333 the restriction enzyme used was Van91I. The 
wildtype genomic DNA was also digested with Van91I. Following digestion, the 
genomic DNA fragments were separated by gel electrophoresis. In the mutant 
strains the gene is replaced by a hyg-SacB gene, thus after digestion the expected 
sizes were 7123bp, 8316bp and 10,373 bp whereas in the wildtype the fragments  
sizes would be  3823 bp and 6971bp. PCR products of the left and right flanks of 
the gene were used as probes. The procedure was performed as described as 
suggested by manufacturer’s guidelines in (DIG High Prime DNA Labelling and 
Detection Starter Kit II; cat no – 11585614910, Roche). This kit uses digoxigenin, 
a steroid to label DNA probes by random priming. The hybridized probes are then 
detected by anti-digoxigenin-AP (Fab fragments), and subsequently visualised by 
chemiluminescence. 
2.2.5 Generation of complemented strain of MMAR2333 
The MMAR2333 ORF was PCR amplified from M. marinum 1218R genomic 
DNA using the primers listed in Table 2.4. Using the primer incorporated BamHI 
and HindIII restriction sites, the PCR product was cloned into the E. coli-
Mycobacterium shuttle vector pMV261 (containing the kanamycin resistance 
cassette aph) (Stover et al., 1991) and verified by sequencing.  The resultant 
plasmid pMV261-MMAR2333 was introduced by electroporation into M. 
marinum MMAR2333 and transformants were selected on 7H10-agar with 
kanamycin. One such transformant was named MMAR2333-C and was used for 
further characterisation.  
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Table 2.4. Primers used for generation of complemented strains 
Name Sequence (5' → 3') Product Size 
 
MMAR2333_F 
 
GCAGGATCCGGTGAGCGTGGGAGTGGGTG 
* MMAR2333 gene 
sequence 
 
 
957 bp 
MMAR2333_ R GCGAAGCTTTCACATGCCCACCTTTCGAG # 
 
*Underlined sequence shows BamHI restriction site, # Underlined sequence shows HindIII 
restriction site 
2.2.6 Analysis of growth patterns  
Growth of the wild type M. marinum 1218R, mutant MMAR2333 and 
complemented strain MMAR2333-C was monitored at O.D. 600nm over a period 
of 0 to 60 hours at intervals of  12, 24, 36 ,48 60 hours. All the strains were grown 
in 7H10 broth +10% OADC with 0.05% Tween 80 and appropriate antibiotics at 
30° C. The starting O.D. for all the cultures was 0.1. 
Mid-log cultures of the bacterial strains were streaked on 7H10 +10% 
OADC agar plates. The plates were incubated for 5 - 8 days at 30°C and isolated 
single colonies were observed under a binocular microscope.  
2.2.7  Extraction and analysis of M. marinum lipids  
For labelling lipids with [
14
C], M. marinum strains were grown to mid-logarithmic 
phase in 10ml of Middlebrook’s 7H10 broth at 30 degrees in a shaking incubator, 
following which 50 Ci of [1,2-14C] acetate (57 mCi/mmol, GE Healthcare, 
Amersham Bioscience) was added to the culture and the incubation was continued 
for another for
 
24 h.  The labelled bacterial cells were harvested, washed, and
 
freeze-dried, and polar and apolar lipids were extracted and analysed by 2D-TLC 
Chapter 2                                                  Glycosyltransferase in LOS Biosynthesis                         
59 
 
(Dobson et al., 1985). [
14
C]-labelled lipids were visualised by autoradiography
 
by 
exposing a Kodak BioMax MR film to the TLC
 
plates for 3 days.  
2.2.8 Purification of LOS-U 
For purification of LOS-U, 400 mg of polar lipids, extracted from 40 g dried cells, 
were applied to a DEAE cellulose column.  The column was eluted with 500ml 
CHCl3:CH3OH (2:1 v/v) and 10 ml fractions were monitored for elution of LOS-
U by TLC (CHCl3:CH3OH:H2O; 60:30:6;v/v/v) and spraying the plates with -
naphthol/sulfuric acid followed by charring revealed the sugar containing lipids.  
LOS-U containing fractions were pooled, concentrated and further purified by 
preparative TLC on a 10 x 20cm plastic backed silica gel TLC plates (Merck) run 
in CHCl3:CH3OH:H2O (60:30:6, v/v/v). The plates were sprayed with 0.01% 1,6-
di-phenyl-1,3,5-hexatriene in petroleum ether /acetone (9:1,v/v) and the 
glycolipids were visualised under UV light (wavelength 366nm), and the area was 
marked with a pencil.  The plates were then developed in toluene to remove the 
1,6-di-phenyl-1,3,5-hexatriene and after drying, the marked area was scraped from 
the TLC plates, extracted with CHCl3:CH3OH (2:1, v/v) and Per-O-methylation of 
LOS-U was performed (described in Chapter 8). MALDI-MS and ES were 
performed by Dr. P.R. Ashton and M r N.G. May (School of Chemistry) and 
described in Chapter 8. 
2.2.9 Extraction of bone marrow derived macrophages (from Balb/c mice) 
and infection by M. marinum 
Bone marrow derived macrophages (BMDM) were obtained as described in 
Chapter 8. 24 hours before infection, the BMDM were activated using 
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recombinant mouse INF- (Invitrogen) at a concentration of 1000units/ml. The 
concentration of BMDM used for this study was 1.0 X 10
6
 cells / ml. 
Late log phase bacteria (M. marinum 1218R, MMAR2333, MMAR2333-
C) were washed with PBS and resuspended in infection medium (DMEM with 
10% FBS) to 10
7
cfu/ml. Murine bone marrow macrophages treated with INF-
atU/ml (Invitrogen) was infected with M. marinum strains at an MOI of 10 
and incubated at 37
0
C under 5% (v/v) CO2 for 3-4 hours. The infection medium 
was removed and the cells were washed twice with PBS and once with complete 
medium (DMEM with 10% FBS and 50μg/ml gentamicin). Cells were incubated 
in 1ml complete medium at 37
0
C under 10% (v/v) CO2 overnight. On Day 1, the 
supernatant was removed and cells were washed once with PBS. Fresh complete 
medium without gentamicin was added. Cells were incubated at 37
0
C under 10% 
(v/v) CO2 for 1 hour. This supernatant was collected as Day 1 sample for future 
cytokines study and cells were lysed with 1ml PBS with 0.1% TritonX-100. 
Samples were collected on Day 3 and Day 5. Cell lysates as well as infection 
medium were 10 fold serial diluted and plated out on 7H10 agar with OADC. The 
plates were incubated at 30
0
C for 1 week before counting colonies. Infection with 
each strain was triplicated. TNF- levels in the infection supernatant was 
estimated according to manufacturer’s instructions using QuantikineR Mouse 
TNF- Immunoassay Kit (MTA00B), RnD Systems. 
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2.2.10 Generation of a ds-Red M. marinum strain for visualizing infection in 
zebrafish embryos. 
The plasmid pMSP12-ds-Red-Apr was obtained as a gift from J. Chen and A. 
Bhatt, University of Birmingham, for this study. The plasmid was electroporated 
into the M. marinum 1218R (wild type), mutant strain MMAR2333 and 
MMAR2333-C (complemented strain) to generate red-fluorescent labelled 
bacteria. The electroporated strains were selected on apramycin (30g/ml). The 
positive clones were grown in 7H9 the culture visualized by fluorescence 
microscopy. Images were captured using Photometric Sensys CCD camera and 
Smart Capture 2 software (Digital scientific Ltd UK), courtesy Dr. Sue 
Armstrong, University of Birmingham. The red-fluorescence bacteria were used 
for infecting zebrafish embryo. The zebrafish infection studies were performed by 
our collaborators Dr. A. Van der Woude, VUMC, Amsterdam, The Netherlands.    
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2.3 Results 
2.3.1  In silico analysis of MMAR2333  
The gene MMAR2333 encodes a putative glycosyltransferase (GTF) and is present 
in a locus containing genes shown to be involved in LOS biosynthesis. It is 
annotated as WcaA in the M. marinum M genome due to similarity in domains 
with a GTF in enteric bacteria E. coli K-12 involved in the biosynthesis of the 
exopolysaccharide colanic acid (Stevenson et al., 1996). The protein is predicted 
to contain two transmembrane domains located near the C-terminus (Figure.2.2), 
which suggests that the enzyme is membrane associated. This is an attribute of 
many mycobacterial GTFs that associated with biosynthesis of cell wall 
components.  
 Additionally, MMAR2333 contains a characteristic domain found in 
eukaryotic dolichol-phophate mannose (DPM) synthases. Eukaryotic DPM 
synthases are members of the GTF-2 super family that catalyse the transfer of 
nucleotide sugars to dolichol phosphate.  In bacteria, homologues of DPM 
synthases use polyprenol phosphate, rather than dolichol phosphate. Example of 
such an enzyme from M. tuberculosis is Ppm1, which catalyses the transfer of 
Mannose (Man) from GDP-Man for subsequent use as substrate for biosynthesis 
of LAM (Gurcha et al., 2002).  The MMAR2333 protein sequence contains the 
characteristic residues found in GTF type II, including a conserved DXD motif 
(Figure.2.2).  Interestingly, the best matches obtained from a BLAST search using 
the MMAR2333 amino acid sequence as the query were putative GTFs from 
cyanobacteria, rather than than GTFs from other LOS-producing mycobacteria 
(Figure.2.3).  Given the proximity of MMAR2333 to genes involved in LOS 
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biosynthesis, it is likely that the MMAR2333-encodes a GTF that is involved in 
the generation of a lipid-bound sugar substrate, which can be subsequently utilised 
for the addition of one or more sugar residues found in M. marinum LOSs.  To 
test this, we generated a null mutant of MMAR2333 using specialised 
transduction, a highly efficient mycobacterial knockout method, not previously 
reported to be used in M. marinum. Phage delivery methods have earlier been 
used to generate transposon mutants in M. marinum (Alexander et al., 2004); this 
is the first report of the use of phages for delivering allelic exchange substrate for 
targeted gene knockouts in this species.  
 
 
 
 
 
  
 
Figure 2.2. Predicted topology of MMAR2333. The predicted transmembrane 
domains are denoted by L1 and L2. N, N terminus; C, C terminus. Amino acid 
residues in blue belongs to L1, and in red to L2. The residue numbers are shown 
next to the transmembrane helices.  
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2.3.2 Effect of deletion of MMAR2333 on colony morphology 
Colony morphology changes often relate to changes in cell wall lipid composition (Chen et al., 
2006; Alexander et al., 2004). Thus, alteration in LOSs would be expected to alter colony 
morphology in the mutant strain. M. marinum 1218RMMAR2333 and MMAR2333-C 
strains were grown on Middlebrook 7H10 agar supplemented with 10% OADC in the 
presence of 0.05% Tween-80. The MMAR2333 mutant showed altered colony morphology 
as compared to the wild type strain (Figure 2.4) suggesting potential alterations in the cell 
wall. The MMAR2333 mutant had a rough colony. Colony morphology reverted to smooth 
type upon complementation with the wild type gene MMAR2333 (MMAR2333-C). 
 
Figure 2.4. Colonies of M. marinum strains 1218R (wild type), MMAR2333 and MMAR233-C 
grown on 7H10 agar supplemented with 10% OADC, after incubation at 30°C for 6-7 days. Scale 
bar represents 1mm. 
2.3.3 Effect of MMAR2333 deletion on growth characteristics in liquid media 
Growth of wild type M. marinum 1218R (WT)MMAR2333 and MMAR2333-C was 
compared in 7H10 broth supplemented with 10% OADC in the presence of 0.05% Tween-80. 
Growth of M. marinum 1218R was 1.31 after 60 hours at A600, but the MMAR2333 mutant 
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strain reached to an O.D of 0.79 (Figure 2.5). However, introduction of plasmid borne wild 
type copy of the gene MMAR2333 to generate a complemented strain MMAR2333-C appears 
to restore the growth rates to wild type phenotype. The complemented strain reached an O.D. 
of 1.24 after 60 hours.  
 
Figure 2.5. Consequences of deletion of MMAR2333 on the growth of M. marinum. Growth curve 
of M. marinum 1218R, MMAR2333 and MMAR2333-C strains in 7H10 broth medium 
supplemented with 10% OADC and Tween-80 at 12hours intervals up to 60 hours. 
2.3.4 Analysis of total lipids from the MMAR2333 mutant 
To assess the effects of loss of MMAR2333 function on cell wall lipid composition, cultures of 
wild type, mutant and complemented strains were pulsed with [
14
C]-acetate to label lipids. 
Labelled polar and apolar lipids were extracted and analysed by 2D-TLC using the five 
solvent systems as described by Dobson et al. (1985). Solvent system E is designed to separate 
LOSs and phospholipids. In order to visualize differences in the lipid profiles of the wild type 
andMMAR2333, 2D-TLCs were developed in solvent system E. The MMAR2333 mutant 
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showed presence of LOS-I, while LOS-II, LOS-III and LOS-IV were missing and instead the 
strain accumulated, a [
14
C]- labelled species that migrated to a position between that of LOS-I 
and LOS-II (Figure 2.6). Staining of TLC plates with -naphthol / sulfuric acid revealed that 
this accumulated species was a glycolipid, and as its appearance was accompanied by the 
disappearance of LOS-II, III and IV. It was quite likely that the accumulated glycolipid was a 
LOS intermediate and we thus termed this unidentified lipid LOS-U (LOS-unknown, later 
confirmed to be LOS-II’). 
 
Figure 2.6. 2D TLC autoradiograph of 
14
C labelled polar lipids from M. marinum 1218R, 
MMAR2333, MMAR2333-C grown in Middlebrook 7H10 broth. Direction 1- chloroform: 
methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: acetic acid: methanol: water, 40:25:3:6 
(v/v/v/v). MMAR2333 shows accumulation of a LOS species, named LOS-U (LOS-II*) and 
absence of higher LOSs. AcPIM2 and Ac2PIM2, mono and di-acyl phosphatidyl-inositol 
dimannosides; AcPIM6 and Ac2PIM6, mono and di-acyl phosphatidyl-inositol hexamannosides; 
LOS I-IV, lipoologosaccharides; PI, phosphatidylinositol; DPG, diphosphatidylglycerol; PE. 
Phosphatidylethanolamine; P, unknown phospholipids. 
2.3.5 Characterisation of LOS-U 
A LOS biosynthesis intermediate, LOS-II*, isolated from M. marinum MRS1178 (a 
transposon mutant of MMAR2332) was also reported to migrate to a position intermediate 
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between LOS-I and LOS-II on 2D-TLC plates (Ren et al., 2007).  LOS-II* is a precursor of 
LOS-II and contains D-Xylp attached to the glycan core, but the caryophyllose found in LOS-
II is missing in LOS-II*. When 
14
C-labelled lipids from the strains MMAR2332 and 
MMAR2333 were mixed and separated on the same 2D-TLC plate, LOS-II* and LOS-U 
migrated to same position, appearing as a single spot (Figure 2.7).  
Figure 2.7 Two dimensional TLC autoradiograph of 
14
C labelled M. marinum lipids. Polar lipids 
from (A) M. marinum 1218R, (B) MMAR2333, (C) MRS1178MMAR2332::ϕMycoMar) and (D) 
a mix of polar lipids from MMAR2333 and MRS1178MMAR2332::ϕMycoMar) grown in 
Middlebrook 7H10 broth. Lipids were analysed by 2D TLC using solvent systems chloroform: 
methanol: water, 60:40:6 (v/v/v) in the first direction, and chloroform: acetic acid: methanol: 
water, 40:25:3:6 (v/v/v/v) in the second direction.  
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This suggests that LOS-U and LOS-II* were likely the same glycolipid species. In order 
to ascertain this by determining the chemical nature of LOS-U, we first purified LOS-U using 
a combination of column chromatography and preparative TLC, and per-O-methylated LOS-U 
was analysed by MALDI-MS.  
 
Figure 2.8. Mass spectrometric analysis of per-O-methylated LOS-II* isolated from MMAR 
2333. The accumulating LOS-U afforded a signal at 1219.9 m/z which corresponds to the 
previously isolated intermediate LOS-II*. 
 
A prominent signal was obtained at m/z 1219.4 [M + Na] + (Figure. 2.8), which was 
identical to that obtained for LOS-II*. These results indicate that LOS-U, the intermediate 
isolated from MMAR2333, was the precursor of LOS-II, LOS-II* and similar to the 
MMAR2332 transposon mutant, the MMAR2333 deletion mutant also accumulated LOS-
II*. In other words, the addition of the first caryophyllose residue to the D-Xylp-glycan core 
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did not take place in the MMAR2333 null mutant. Given the similarity of MMAR2333 to 
DPM-like glycosyltransferases, these findings suggests the involvement of MMAR2333 in the 
cytoplasmic transfer of nucleotide bound caryophyllose residue (or its precursor ) to a 
polyprenol phosphate or other lipid-based carrier. This can be subsequently used as a sugar 
donor by another glycosyltransferase to extend LOS-II* to LOS-II (Sarkar et al., 2011).  
Additionally the identical LOS-pattern of the MMAR2332-Tn mutant and MMAR2333 
strain makes it likely that MMAR2332, which encodes a protein homologous to a putative 
thiamine pyrophosphate-containing carboxylase, is involved in the biosynthesis of the unique 
caryophyllose sugar.  
2.3.6 Intracellular survival of MMAR2333 null mutant in bone marrow derived 
macrophages  
Inability of LOS-IV deficient M. marinum mutants in entering murine macrophages have been 
reported previously (Burguière et al., 2005). The mutant strain MMAR2333 accumulated an 
intermediate LOS-II* and was deficient in production of the higher LOSs, LOS-II, LOS-III 
and LOS-IV. In order to assess the role of the MMAR2333 deficient strain in virulence an 
intracellular survival assay was performed with murine bone marrow derived macrophages. 
Macrophages were thus infected with MMAR2333 to determine the ability to enter and 
survive within the macrophages. Infection experiments were done using a multiplicity of 
infection (MOI) of 10. The survival of intracellular bacteria will be followed over a period of 
1, 3 and 5 days. The number of intracellular bacteria (colony forming units) was enumerated 
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by lysing the macrophages and plating on 7H10 agar. The infection experiments were done in 
triplicates and were repeated thrice. 
Transposon-mediated disruption of MMAR2332, also led to the accumulation of LOSII* 
and the ability of the mutant strain to survive inside cultured macrophages was not altered. 
Similarly in this case, no difference was observed in the ability of the mutant strain 
MMAR2333 to enter and survive inside the bone marrow derived macrophages (Figure 2.9).  
 
Figure 2.9. Survival of M. marinum strains in murine (Balb/c) bone marrow derived 
macrophages. BMDM cells were lysed and plated on 7H10 agar plates and the colony forming 
units /ml were enumerated.  
 
Previous studies have shown that the loss of a glycolipid may not necessarily influence 
bacterial loads in infected cells but may alter cytokine signalling thereby influencing the 
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inflammatory response (Rao et al., 2005; Glickman et al., 2000). M. tuberculosis infection 
induces production of the proinflammatory cytokine TNF-in macrophages and dendritic 
cells (Orme, 2004). TNF-levels released by infected bone marrow derived macrophages 
were measured using a mouse TNF- kit. Cell supernatant analysis for TNF- release in 
infection experiment with the strain MMAR2333 appear elevated as compared to levels of 
TNF- released by the wild type and complemented strains (Figure 2.10). TNF- release is an 
indication of infection establishment, but in this case, the whole bacterium was used to infect 
BMDMs. Further studies with LOS deficient strains will provide more insight into the role of 
LOSs in virulence and details are discussed in Chapters 3 and 4 of this thesis.  
 
 
 
 
 
 
Figure 2.10. TNF-  production by murine (Balb/c) bone marrow derived macrophages infected 
with different M. marinum strains.  
 
The natural host of M. marinum is the fish and hence to determine changes in virulence 
patterns, a whole animal model - the zebra fish-infection model was used. The M. marinum 
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strains were electroporated with ds-red plasmid (gift from J. Chen / A. Bhatt, University of 
Birmingham) with apramycin resistance and the ds-red positive clones were used for infecting 
zebra fish embryos. Infection experiments were repeated twice in triplicates by Dr. A. Van der 
Woude and colleagues (data shown was generated at VUMC, Netherlands). 
2.3.7 Generation of ds-red strains of M. marinum 
 
 
 
 
 
 
 
 
 
Figure 2.11 Survival of ds-Red M. marinum strains in zebrafish embryo. A) MMAR2333 with 
and without ds-red, viewed under a microscope under 40X zoom. B) Counts of intracellular 
bacteria (cfu) per embryo post infection with M. marinum strains. Data generated by Dr. Aniek 
van der Woude, VUMC, The Netherlands. 
A) 
B) 
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The plasmid pMSP12-ds-Red-Apr was electroporated into the M. marinum strains to generate 
red-fluroscence labelled bacteria. The apramycin resistant colonies were grown in 10% OADC 
supplemented 7H9 broth and visualized by fluroscence microscopy (Figure 2.11A). The red-
fluorescence M. marinum 1218R, MMAR2333 and MMAR2333-C were used for infecting 
zebrafish embryo. Our collaborators Dr. A. Van der Woude, VUMC, Netherlands, did the 
zebrafish embryo infection. The survival of the M. marinum strains in terms of CFU / embryo 
is  shown in Figure 2.11B.    
No difference was observed in bacterial loads in zebrafish embryos infected with the 
wild type compared to those infected with the mutant strains suggesting that loss of LOS-II, 
LOS-III and LOS-IV and accumulation of LOS-II* in the mutant strain MMAR2333 did not 
affect the survival of the mutant in the above models of infection. 
 
2.4 Discussion  
M. marinum causes tuberculosis like disease in poikilothermic animals and is an opportunistic 
pathogen of humans (Ramakrishnan, 2004). M. marinum has a comparatively faster generation 
time and can be handled without BSL-3 facilities. These factors make M. marinum an 
attractive model to study mycobacterial pathogenesis (Cosma et al., 2003).   
Mycobacterial cell wall associated lipids play a critical role in the virulence of 
pathogenic mycobacteria (Daffé and Draper, 1998). Recent studies have shown that 
approximately one third of the LOS gene cluster is conserved between M. tuberculosis and M. 
marinum, the former having the least number of genes. These lipooligosaccharides (LOSs) 
have been reported to play a role in sliding motility, biofilm formation and macrophage 
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infections (Ren et al., 2007). The basic structure of LOSs show that the core structure is 
formed of four glucose units with a methylated rhamnose. The higher LOSs contains complex 
sugars along with this basic structure and a number of sugar transferring enzymes are involved 
in their synthesis.  In a previous study, many glycosyltransferases have been identified in the 
LOS biosynthesis gene cluster in M. marinum (Burguière et al., 2005) . 
In this study, a glycosyltransferase involved in the LOS biosynthesis cluster in M. 
marinum have been identified.  The gene MMAR2333 encodes a glycosyltransferase and lies 
in the cluster identified to be involved in LOS biosynthesis (Burguière et al., 2005). This study 
also demonstrated the utility of Specialised Transduction to generate null mutants of M. 
marinum. While phage delivery methods have been used to generate transposon mutants in M. 
marinum, this is the first report of the use of phages for delivering allelic exchange substrates 
for targeted gene knockouts in this species. 
Inactivation of MMAR2333 led to an alteration in colony morphology. The mutant strain 
exhibited a rough colony as compared to the smooth type of the wild type strain. The smooth 
colony morphology reverted upon complementation with the wild type gene. The mutant 
strain was defective in the biosynthesis of three of the four subclasses of LOSs found in M. 
marinum, and accumulated a precursor of LOS-II, termed LOS-II*. The wild type phenotype 
was restored on complementation with a wild type gene indicating that the observed 
phenotypes in the mutant were solely due to loss of MMAR2333 function 
The polar glycolipid (LOS-II*) identified in our work corresponds to -Xylp-(1→4)--
3-O-Me-Rhap-(1→ 3)--Glcp-(1→ 3)--Glcp-(1→ 4)--Glcp-(1→ 1)--Glcp. This was 
different from LOS-I in having a terminal Xylp residue and also differed from LOS-II in 
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lacking the caryophyllose unit, described as ‘X’ in earlier work (Burguière et al., 2005). The 
LOS-II* corresponds to a previously described polar lipid accumulated by the MRS1178 
mutant. The strain MRS1178 is disruptied in the gene MMAR2332, the protein product of 
which is a carboxylase belonging to a family of TPP-requiring enzymes. Acetolactate synthase 
belongs to this family of enzyme, and these are known to be involved in branched amino acid 
synthesis. Ren et al., (2007), however showed that MMAR2332 was not involved in amino 
acid synthesis and was probably involved in the synthesis or transfer of the then unknown 
sugar  moiety in LOS-II. The unknown sugar has now been reported to be a 3, 6-dideoxy-4-C-
(D-altro-1, 3, 4, 5-tetrahydroxyhexyl) D-xylo-hexopyranose, which is termed Caryophyllose. 
This unit is a rather unusual 4-C- polysaccharide with a non-glycosidic linkage. These types of 
sugars have only been reported in a few gram-negative bacteria, and a similar sugar has been 
reported only in Pseudomonas caryophylli (Adinolfi et al., 1995).  
The resemblance of MMAR2333 to bacterial DPM-like synthases suggested that the 
GTF was not directly involved in the transfer of caryophyllose to LOS-II*, but it was more 
likely to catalyse the transfer of mucleotide-bound caryophyllose to a lipid (polyprenol) 
carrier. Alternatively, MMAR2333 could catalyse the formation of a polyprenol-bound 
precursor of caryophyllose, which is subsequently modified to caryophyllose. In vitro 
confirmation of the above functions could not be accomplished due to the unavailability of 
nucleotide-bound caryophyllose substrates. In addition to MMAR2333, 2 other ORFs 
MMAR2311 and MMAR2313 (losA) also encode DPM-like GTFs. The presence of this class of 
glycosyltransferases in LOS biosynthetis cluster suggests that some of these enzymes maybe 
involved in the generation of lipid bound sugar substrates which are ‘flipped’ to the 
extracytoplasmic side of the membrane. These lipid bound sugar substrates can then be used 
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by extracytoplasmic glycosyltransferases to extend the oligosaccharide moiety of LOSs.  
 
 
 
 
 
 
 
 
 
Figure 2.12 Proposed pathway of LOS biosynthesis in M. marinum showing the involvement of 
MMAR2333 in transferring a nucleotide sugar (caryophyllose) to a polyprenol unit. The 
polyprenoid bound caryophyllose is then used by other enzymes to finally add the caryophyllose 
to the LOS-II*. 
 
Indeed, the LosA mutant is devoid of LOS-IV suggesting that LosA could likely be 
involved in the generation of a lipid-bound N-acyl 4,6 dideoxygalactose which is subsequently 
transferred by an extracellular glycosyltransferase to  LOS-III. This affords a model for LOS 
biosynthesis (Figure 2.12), wherein the acylated hexasaccharide LOS-II* is synthesised 
intracellularly and transported across the membrane. This process could be initiated by 
MMAR2342, which encodes a transmembrane protein belonging to a group of larger 
mycobacterial proteins termed MmpLs, which are involved in the transport of mycobacterial 
glycolipids or their intermediates (Camacho et al., 2001; Converse et al., 2003; Domenech et 
al., 2004; Sonden et al., 2005). LOS-II* would then be extended by specific GTFs on the 
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extracytoplasmic side that use lipid-bound sugars (caryophyllose or the N-acyl 4,6 
dideoxygalactose) as sugar donors to yield LOS-II, LOS-III and LOS-IV. In an alternative 
model, LOS-I could be transported by the MmpL protein to the extracytoplasmic side with the 
addition of xylose as the initial sugar, a process that would require the generation of a lipid-
bound xylose substrate. 
MMAR2311, the third putative DPM-like glycosyltransferase in the LOS cluster, is a 
potential candidate for this function. In summary, later stages of LOS biosynthesis may 
involve a distinct set of glycosytransferases catalysing the formation lipid bound sugar donors, 
and another set that extends the LOSs. The generation of mutants of MMAR2311 and other 
putative glycosyltransferase genes in the LOS cluster will shed more light on the biosynthesis 
of these carbohydrate-rich mycobacterial glycolipids. 
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Role of a polyketide synthase gene 
(pks5) in lipooligosaccharide 
biosynthesis in Mycobacterium 
marinum 
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3.1 Introduction  
Cell wall lipids play an important immunomodulatory role during infection by 
pathogenic mycobacteria. Lipooligosaccharides (LOSs) are one such class of 
polar lipid antigens found in some mycobacterial species. LOSs were first 
reported in M. kansasii (Hunter et al., 1983) an opportunistic pathogen, the fish 
pathogen M. marinum (Burguière et al., 2005) , M. smegmatis (Saadat and Ballou, 
1983), "M. canettii" of the Mycobacterium tuberculosis complex (Daffé et al., 
1991) and six other mycobacteria M. gastri (Gilleron et al., 1993; Gilleron and 
Puzo, 1995) , M. gordonae (Besra et al., 1993), M. malmoense (McNeil et al., 
1987), M. szulgai (Hunter et al., 1988), M. mucogenicum (Munoz et al., 1998), 
and M. butyricum (Khoo et al., 1995b). LOSs are key factors contributing to 
biofilm formation, sliding motility, infection and infection of murine macrophages 
by M. marinum (Burguière et al., 2005; Ren et al., 2007). As discussed in the 
previous chapter, they possess an acylated trehalose core with various 
glycosylations. The trehalose in the core structure of LOSs is acylated by 
polymethyl branched fatty acids. These long chain methyl branches are a unique 
feature of mycobacterial cell wall lipids, some of which are involved in virulence 
e.g., phthiocerol dimycocerosate (DIM) (Cox et al., 1999; Camacho et al., 1999). 
The methyl branched component of DIM is synthesised by a specialised fatty acid 
synthase termed mycocersic acid synthase (mas) (Minnikin et al., 2002; Rainwater 
and Kolattukudy, 1983; Rainwater and Kolattukudy, 1985).  MAS resembles a 
type-I fatty acid synthase, i.e. it is a single polypeptide carrying multiple domains 
required for the reductive cycles of fatty acid biosynthesis: an acyl transferase 
(AT) domain for loading of the starter unit; acyl carrier proteins (ACP) which 
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holds the growing chain; keto-acyl synthases (KS) which catalyse chain 
extension; keto-reductase (KR) and dehydratase (DH) domains (reduction to an 
alcohol and generation of unsaturated thiol ester, respectively); enoyl reductase 
(ER) for catalysing the final reduction step and a releasing thioesterase (TE). 
MAS is a multifunctional enzyme and has the domains KS-AT-DH-ER-KR-ACP 
(Mathur and Kolattukudy, 1992), and the  KS and AT domains selectively utilises 
methyl-malonyl-CoA over malonyl-CoA for elongation  (Fernandes and 
Kolattukudy, 1997).  
The mycobacterial genome encodes many polyketide synthase genes 
including 7 MAS-like (msl) genes (Sirakova et al., 2001). Initially identified as 
Pks’s, they are fatty acid synthases involved in biosynthesis of long chain or 
methyl-branched fatty acids. Pks’s are involved in the synthesis of various 
glycolipids of M. tuberculosis.  Pks2 was shown to be responsible for synthesis of 
the hepta and octa-methyl hydroxyphthioceranic acid which constitutes the major 
acyl chains of sulfolipids (Sirakova et al., 2001). Mycolipenic acids, which are a 
constituent of the penta-acyl trehalose (PATs) of M. tuberculosis are synthesised 
by pks3/4 (Dubey et al., 2002) and pks12 was shown to be involved in mycoketide 
synthesis in M. tuberculosis (Matsunaga et al., 2004). A polyketide synthase gene 
was also shown to be involved in the synthesis of the lipopeptide core of GPLs in 
M. smegmatis (Sonden et al., 2005). A recent study also reported that the 
disruption of the M. smegmatis gene MSMEG4727, the pks5 orthologue of M. 
tuberculosis resulted in a strain deficient in LOS and polymethyl-branched fatty 
acid production (Etienne et al., 2009). 
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Mycobacterial LOSs possess upto four methyl branched fatty acids and also 
species specific linear fatty acids. The LOSs from M. kansasii have three 2, 4-
dimethyl tetradecanoic acid chains (Hunter et al., 1983) while LOSs from M. 
marinum are acylated by two different polymethyl-branched fatty acids, namely – 
2,4-dimethylhexadecanoate and 2,4-dimethyl-2-pentadecenoate (Rombouts et al., 
2011). This is reflected in the presence two separate pks genes and two 
polyketides associated acyl transferases (PapA3 and PapA4) in the LOS 
biosynthesis locus in M. marinum. Due to their similarity with the M. tuberculosis 
Pks5 the PKSs in M. marinum are annotated as pks5 (MMAR2340) and pks5_1 
(MMAR2344) but are probably not functionally related to M. tuberculosis pks5.  
Additionally,  acyltransferases encoded by polyketide associated proteins sharing 
high  similarity to the PapA2 gene from M. tuberculosis, are  annotated as papA3 
(MMAR2355) and MMAR2343 was shown to be involved in acylation of the LOSs 
and termed papA4 (Rombouts et al., 2011).  
The studies outlined in this chapter were aimed at deciphering the role of 
MMAR2340 and MMAR2344 in the biosynthesis of the acyl chains found in M. 
marinum LOSs. I planned to do this by generating a null mutant of the pks5 gene 
(MMAR2340) and of the pks5_1 (MMAR2344) gene by specialised transduction.  I 
was able to generate only the MMAR2340  mutant using this method and analysis 
of the polar lipid profiles of the mutant strain are presented in this chapter.  Also, 
the mutant was tested for changes in virulence using cultured murine bone 
marrow macrophages. 
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3.2  Materials and Methods 
3.2.1 In silico analysis of MMAR2340 (Pks5) 
The MMAR2340 (pks5) gene sequence was obtained from the Marinolist website 
(http://genolist.pasteur.fr/MarinoList).  Multiple sequence files were produced 
using CLUSTAL W (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and rendered 
using ESPript (http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi). Domain 
prediction was performed using PFAM (http://pfam.sanger.ac.uk/) and PKS-DB 
(http://www.nii.res.in/pksdb.html) web sites. 
3.2.2 Plasmids, DNA manipulations and bacterial growth conditions 
Plasmids, bacterial strains and phages used in this study are listed in Table 
3.1. E. coli strains were routinely cultured in Luria-Bertani (LB) broth at 37⁰C. M. 
smegmatis strain mc
2
155 was used for generation and propagation of 
mycobacteriophages and was routinely grown at 37°C in Tryptic Soy Broth with 
0.05% Tween-80. All M. marinum strains were grown either in 7H9 broth 
supplemented with 10% OADC (oleic acid/albumin/dextrose/catalase, BD) or in 
7H10 broth (composition based on Middlebrook 7H10 agar components) 
supplemented with 10 % OADC, at 30°C, with 0.05% Tween-80.  M. marinum 
1218R (ATCC 927) was used as the wild type (parental) strain for generation of 
the MMAR2340 null mutant. For plate growth, 7H10 agar plates were incubated at 
either 30°C, or when required, at 37°C (for selecting transductants; see below).   
For experiments involving the usage of phages, Tween 80 was not used in media. 
Mycobacteriophages were routinely propagated on Middlebrook’s 7H9 with 0.2% 
glycerol. Phage high titres were generated using protocols described by (Larsen et 
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al., 2007). Antibiotics were added as required: Hygromycin B (Roche) 150µg/ml 
for E. coli, 100µg/ml
 
for M. smegmatis, 75µg/ml for M. marinum. Kanamycin 
sulfate (Sigma) -50µg/ml
 
for E. coli and 25µg/ml for M. marinum. 
 
Table 3.1. Bacterial strains, plasmids and phages used in this study 
Plasmids, phages and 
strains 
Description Reference 
Plasmids   
p0004S 
Cosmid containing Hyg-
SacB casette 
(Larsen et al., 2007) 
 
pMMAR2340 
 
Derivative of p0004S 
obtained by cloning the right 
and left PCR flanks of 
MMAR2340 
This work 
Phages   
phAE159 
Conditionally 
replicating shuttle phasmid 
derived from lytic 
mycobacteriophage TM4 
(Larsen et al., 2007) 
phMMAR2340 
 
Derivative of phAE159 
obtained by cloning 
pMMAR2340 into its PacI 
site 
This work 
Bacterial strains   
E.coli TOP 10 
 
F– mcrA Δ(mrr-
hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara leu) 
7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen 
 
 
 
 
 
HB101 
 
 
E. coli K-12 F__(gpt-
proA)62 leuB1 glnV44 ara-14 
galK2 lacY1 hsdS20 rpsL20 
xyl-5 mtl-1 recA13 
Stratagene 
M. smegmatis mc
2
155 
 
Wild type strain, Ept 
mutant of M. smegmatis strain 
mc
2
6 
Snapper et al.,1990 

MMAR 2340 
 
 
M. marinum strain 
disrupted in gene MMAR2340 
was replaced by hyg 
This work 
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3.2.3 Construction of a knockout phage for deletion of MMAR2340 
Approximately 1 kb sequences of the upstream and downstream regions of 
MMAR2340 were PCR-amplified from M. marinum 1218R genomic DNA using 
the primer pairs listed in Table 3.2.  The PCR products were purified and the 
primer incorporated Van91I sites were digested with Van91I. The digested PCR 
fragments were then ligated into Van91I-digested p0004S to generate the allelic 
exchange plasmid pΔMMAR2340. Plasmids obtained by miniprep (Qiagen 
miniprep kit) were digested with Van91I and PacI and sequenced to confirm 
presence of the left and right flanks. One positive plasmid was selected for 
packaging into phAE159. The PacI digested knockout plasmids pMMAR2340 
was then ligated with PacI digested phAE159 DNA. The ligation mix was 
packaged in the temperature sensitive mycobacteriophage phAE159 heads, 
transduced into E. coli HB101, and selected on LB agar with hygromycin at 37°C. 
This yielded phasmid DNA, which was subsequently used to generate the phage 
phΔMMAR2340.     
Table 3.2. Primers used for generation of knockout construct in M. marinum 
 
Following protocols detailed in Larsen et al., (2007), the cosmids recovered 
from E. coli HB101 were confirmed by digestion with PacI digestion. The 
Primer  Sequence 5' -3' Description Size 
MMAR2340_LL 
 
TTTTTTTTCCATTTCTTGGGGTGATGCCGAAGAA
CT  
left side flank 
sequence of  
MMAR2340 
960 bp 
MMAR2340_LR 
 
TTTTTTTTCCATAAATTGGCTTCCCACTCGTGCTC
A  
 
MMAR2340_RL 
 
TTTTTTTTCCATAGATTGGGGGTCCAGCAAATTC
CG 
Right side 
flank 
sequence of  
MMAR2340 
902 bp 
 
MMAR2340_RR 
 
TTTTTTTTCCATCTTTTGGCCAGCGTCCTCAAACA
T 
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positive cosmids were transformed by electroporation into M. smegmatis at 
1800V and recovered at 30°C for ~4 hours in TSB. The recovered cells were then 
harvested and resuspended in 200µl of MP buffer. This was mixed with 200µl of 
freshly growing M. smegmatis and 5ml molten soft agar (50°C) and poured on 
7H9 basal agar plates and incubated at 30°C for 2 -3 days and allowed to form 
plaques. The plates were soaked in minimum amount of MP buffer for 5-6 hours 
and the solution containing phages was filtered and stored at 4°C. This generated 
the recombinant phage - phMMAR2340 designed to replace the gene 
MMAR2340 with hyg. 
3.2.4 Generation of a MMAR2340 null mutant  
Specialised transduction of M. marinum 1218R was performed as described 
previously for other mycobacteria (Bardarov et al., 2002) and as detailed in 
Chapter 8. A culture of M. marinum grown to an OD600 of 0.8 was harvested and 
the cell pellet was washed twice with 50ml of MP buffer. Finally the pellet was 
resuspended in 2ml of MP buffer and then mixed with 2ml of high titre (10
-10
 pfu 
/ml) phage lysate. Cells in MP buffer with no phage added were used as a control. 
The mix was incubated overnight at 37°C followed by harvesting and recovery 
with 10ml 7H9+10% OADC with Tween-80 overnight at 37°C. This was plated 
onto 7H10+10% OADC-agar plates with hygromycin B and plates were incubated 
at 37°C for 2 weeks. Hygromycin resistant colonies obtained after transduction of 
M. marinum 1218R (wild type strain) were inoculated in 10ml 7H9+10% OADC -
Tween 80 with hygromycin B for genomic DNA extraction and further 
characterization.  Allelic exchange of MMAR2340 with a hygromycin resistance 
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cassette in hygromycin resistant transductants was confirmed Southern blot.  One 
such transductant was chosen for subsequent experiments.   
Restriction enzymes were selected based on the sequence of the knockout 
plasmids. The restriction enzyme used was HindIII. Following digestion, the 
gDNA fragments were separated by gel electrophoresis. In the mutant strains the 
gene is replaced by a hyg-SacB gene; thus after digestion the expected sizes for a 
mutant were 6.5Kb and 7.7Kb, while those for wild type genomic DNA were 
16.4Kb. PCR products of the left and right flanks of MMAR2340 were used as 
probes. 
The procedure was performed as suggested by manufacturer guidelines in 
(DIG High Prime DNA Labelling and Detection Starter Kit II cat no – 
11585614910, Roche). This kit uses digoxigenin, a steroid to label DNA probes 
by random priming. The hybridized probes are then detected uisng anti-
digoxigenin-AP (Fab fragments), and subsequently visualised by 
chemiluminescence. 
3.2.5 Extraction and analysis of M. marinum lipids  
For labelling lipids with [
14
C], M. marinum strains were grown to mid-logarithmic 
phase in 10ml of Middlebrook 7H10 broth at 30°C in a shaking incubator, 
following which 50 Ci of [1,2-14C] acetate (57 mCi/mmol, GE Healthcare, 
Amersham Bioscience) was added to the culture and the incubation was continued 
for another for
 
24 h.  The labelled bacterial cells were harvested, washed, and
 
freeze-dried, and polar and apolar lipids were extracted and analysed by 2D-TLC 
according to the procedures of Dobson et al. (1985).  [
14
C]-labelled lipids were 
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visualised by autoradiography
 
by exposing a Kodak BioMax MR film to the TLC
 
plates for 3-5 days. 
3.3 Results 
3.3.1  In silico analysis of MMAR2340 
The LOS biosynthetic gene cluster in M.marinum was identified in the region 
between MMAR2307 to MMAR2344. The genes MMAR2340 and MMAR2344 
encode polyketide synthase Pks5 and Pks5_1, respectively. The other genes in this 
locus are believed to encode enzymes responsible for the transfer of the Pks- 
products. These include genes encoding a fatty acyl-AMP ligase 
(MMAR2341/fadD25), a mycobacterial membrane protein (MMAR2342 
mmpL12) and a polyketide synthase associated protein (MMAR2343/papA4).  
 
Figure 3.1. Map of pks5 (MMAR2340) and neighbouring genes. 
 
The 2090 amino acid protein encoded by MMAR2340 comprises of a 
ketoacyl synthase domain with catalytic sites at the N-terminal and C-terminal, 
acyltransferase domain, Gro-ES like alcohol dehydrogenase domain, zinc-binding 
dehydrogenase domains, ketoreductase domain and a phosphopantheteine 
attachment site towards the C-terminus (Figure 3.2 A). The second pks gene, 
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MMAR2344 encodes a 2084 amino acid and has similar domain architecture as 
pks5 (Figure 3.2 B). 
Predictions regarding the nature of the fatty acids produced by a Pks can be 
made based on the characteristic malonyl or methyl malonyl accepting motifs in 
the acyltransferase (AT) domains of the pks genes (http://linux1.nii.res.in/ 
~pksdb/DBASE/page.html). 
 
 
 
 
 
Figure 3.2. The Pks5 and Pks5_1 domain organisation of M. marinum. (A) Domain 
organisation of M. marinum Pks5 (B) Domain organisation of M. marinum Pks5_1, 
predicted using Pksdb and Pfam server. KS-Nterm/ Ct, keto acyl synthase domains ,  
ADH-alcohol dehydrogenase like domain, DH-zinc binding dehydrogenase domain, 
KR, ketoreductase domain and PPB- phosphopantetheine binding domain. 
 
MMAR2340 shares 76% identities with MKAN1200 (M. kansasii Pks5), 
74% identity with "M. canettii" Pks5, M. tuberculosis Rv1527 and M. bovis. 
MMAR2340 also shares 63% identity with MSMEG4727/Pks5, a MAS-like Pks 
responsible for synthesis of methyl branched fatty acyl chains in LOSs from M. 
smegmatis.  
A) 
B) 
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3.3.2 Analysis of total lipids from the MMAR2340 mutant 
One knockout strain confirmed by Southern blot was selected for analysis of cell wall 
lipids. To assess the effects of loss of MMAR2340 function on cell wall lipid composition, 
cultures of wild type, mutant and complemented strains were pulsed with [
14
C]-acetate to 
label lipids. Labelled polar and apolar lipids were extracted and analysed by 2D-TLC using 
the five solvent systems described by Dobson et al. (1985). Differences in the lipid profiles 
of the wild type andMMAR2340 were visible only in TLCs run in solvent system E that 
separates phospholipids and LOSs. The mutant strain MMAR2340 was completely 
defective in LOS production, as none of the four M. marinum LOS lipids were visible 
(Figure 3.4). A transposon mutant of MMAR2340 generated the M. marinum E11strain, 
described in Chapter 4 showed an identical similar phenotype. These results indicate that 
pks5 played a role in the biosynthesis of LOS and that deletion of pks5 results in the loss of 
all four LOS subtypes. 
 
Figure 3.4. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. marinum 
1218R (wild type) and MMAR2340 grown in Middlebrook 7H10 broth. Direction 1- 
chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: acetic acid: methanol: 
water, 40:25:3:6 (v/v/v/v). MMAR2340 is devoid of all the four LOS species. AcPIM2 and 
Ac2PIM2, mono and di-acyl phosphatidyl-inositol dimannosides; AcPIM6 and Ac2PIM6, mono and di-
acyl phosphatidyl-inositol hexamannosides; LOS I-IV, lipoologosaccharides; PI, phosphatidylinositol; 
DPG, diphosphatidylglycerol; PE. Phosphatidylethanolamine; P, unknown phospholipids. 
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3.3.3 Intracellular survival of the MMAR2340 mutant in bone marrow derived 
macrophages  
Studies using M. kansasii to infect murine models have reported that LOS producing 
strains, which had glossy colony morphology, were readily cleared from mice models of 
infection while the LOS negative rough appearing strains were able to survive and produce 
a systemic infection in mice. It was reported that LOS-IV deficient M. marinum mutants 
were unable to enter murine macrophages (Burguière et al., 2005). In the previous chapter 
a mutant strain MMAR2333 which produced LOS-I and accumulated an intermediate 
LOS-II* was found to be able to enter and survive in bone marrow macrophages with no 
apparent effect on survival and intracellular growth of the bacterium.   
In the case of MMAR2340, we had a mutant strain that could be used to assess the 
effects of complete loss of all the LOSs. In order to assess the role of a LOS deficient 
strain in virulence, an intracellular survival assay was performed with murine bone marrow 
derived macrophages. Macrophages were thus infected with MMAR2340 to determine the 
ability to survive in the macrophages. Infection experiments were done using a multiplicity 
of infection (MOI) of 10 and  survival of intracellular bacteria was followed over a period 
of 1, 3 and 5 days. The number of intracellular bacteria (colony forming units) was 
enumerated by lysing the macrophages and plating on 7H10 agar plates (Figure 3.5).There 
was no change in the ability of the mutant strain mutant MMAR2340 in surviving inside 
the macrophages, indicating the absence of LOSs did not affect intracellular survival of the 
bacteria.  
 
Chapter 3                                                                           Role of PkS5 in LOS biosynthesis                           
96 
 
 
Figure 3.5. Survival of M. marinum strains in murine (Balb/c) bone marrow derived 
macrophages. Counts of intracellular bacteria after lysing infected BMDM are expressed in 
colony forming units per ml.  
The loss of a glycolipid may not necessarily affect bacterial loads in infected cells 
but might alter cytokine signalling thus influencing the inflammatory response (Rao et al., 
2005; Glickman et al., 2000). M. tuberculosis infection induces production of the 
proinflammatory cytokine TNF-in macrophages and dendritic cells (Orme, 2004). TNF-
levels released by infected bone marrow deived macrophages were measured using a 
mouse TNF- kit. Cell supernatant analysis for TNF- release in infection experiment 
with the strain MMAR2340 revealed slightly lower levels in the mutant strain as 
compared to the wild type and complemented strains. Post infection at 72 hours, the 
wildtype strain infected BMDM TNF- levels were recorded at 95 pg /ml while it was 
126.67 pg/ml in case of the mutant strain. Post infection at 120 hours the values recorded 
was 76.7 pg/ml in case of the wildtype and 112.22 pg/ml for MMAR2340. 
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Figure 3.6. TNF-  production by murine (Balb/c) bone marrow derived macrophages 
infected with different M. marinum strains. 
 
3.4 Discussion  
Cell wall lipids of pathogenic mycobacteria play a crucial role in virulence (Daffé 
and Draper, 1998). LOSs play an important role in sliding motility, biofilm formation and 
virulence (Burguière et al., 2005). M. marinum is characterised by the presence four 
classes of LOSs. The core structure comprises of four units of glucose and a methylated 
rhamnose. Addition of xylose and complex sugars like caryophyllose and N-acyl 4, 6-
dideoxygalactose makes up the higher LOSs. In addition to this, the glucose core is 
acylated by the presence of two methyl branched fatty acyl chains (Rombouts et al., 2011).  
A MAS-like pks5 gene MSMEG4727 was reported to be essential in generation of 
the acyl chains in LOSs from M. smegmatis. Although, M. tuberculosis does not produce 
LOSs, the genes losA (Rv1500) and pks5 (Rv1527c) are present in M. tuberculosis. 
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Interestingly, a pks5 mutant of H37Rv was reported to be affected in virulence in mice 
(Rousseau et al., 2003a) but no missing metabolites were detected. The MTBC strain M. 
canettii produces LOSs and shares 74% identity to the pks5 from M. marinum. LOSs have 
been suggested to act as a mask for virulence or avirulence factors in mycobacteria (Daffé 
et al., 1991).  In this study, a polyketide synthase involved in the LOS biosynthesis cluster 
in M. marinum has been identified. The mutant strain MMAR2340 was defective in the 
biosynthesis of all the four subclasses of LOSs found in M. marinum and was not altered in 
survival and replication in cultured bone marrow macrophages. But infection with this 
strain elicited a strong release of TNF- which is a hallmark of infection.   
The gene MMAR2340 encodes a MAS like PKS enzyme –Pks5 and lies in the 
cluster identified to be involved in LOS biosynthesis (Burguière et al., 2005). The genome 
of M. marinum also reveals the presence of another polyketide synthase 5 gene, pks5_1 
(MMAR2344). The occurrence of two pks5 genes could relate to the unique structure of M. 
marinum LOSs which posess two methyl branched fatty acyl chains, 2,4-
dimethylhexadecanoate and 2,4-dimethyl-2-pentadecenoate. Based on this hypothesis, it is 
expected that deletion of either the pks5 or pks5_1 gene would give rise to a partially 
acylated intermediate of the lipooligosaccharide. On the contrary, we observed that 
deletion of MMAR2340 results in complete abolition of LOS production in the mutant 
strain. A similar phenotype was displayed by a transposon mutant of M. marinum E11 
strain, MMAR2340::aph (detailed in chapter 4 in this thesis) which was deficient in 
producing all the four LOS subtypes. Given the similarity of the MMAR2340/pks5 with 
MSMEG4727/pks5 and the LOS negative phenotype of MMAR2340, we predict that 
MMAR2340 (pks5) is involved in the synthesis of one of the two acyl chains -   2, 4-
dimethylhexadecanoate and 2,4-dimethyl-2-pentadecenoate. The acyl chains are further 
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transferred to the tetraglucose core of LOS by one of the acyl transferases (PapA3 or 
PapA4). It is possible that acyl chain generated by Pks5 is the first to be attached to the 
hexose ring; this then serves as an intermediate or substrate for addition of the second acyl 
chain, which is probably synthesized by Pks5_1. Thus a loss of pks5 would be expected 
not just in the loss of a specific fatty acyl chain on the LOSs, but a complete loss of the 
glycolipids due to unavailability of a partially acylated intermediate that serves as a 
substrate for subsequent enzymes in the LOS biosynthesis pathway. A deletion mutant of 
MMAR2344 (pks5_1) could clarify this and shed light on the type of acyl chains 
synthesized by the individual LOS-cluster associated pks genes. Unfortunately repeated 
attempts at generating a knockout strain of MMAR2344 by specialised transduction were 
unsuccessful. Further studies on the effect of deletion of putative transporter MMAR2342 
(mmpL12) and MMAR2344 (Pks5_1) will provide further insights into LOS biosynthesis.        
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4  
Identification of genes involved in 
the Mycobacterium marinum 
lipooligosaccharide biosynthesis using 
transposon mutagenesis. 
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4.1 Introduction 
Lipooligosaccharides (LOS’s) are antigenic glycolipids present in the outer 
membrane of many mycobacteria. Although this glycolipid is not present in 
Mycobacterium tuberculosis, they have been reported  in Mycobacterium 
marinum , Mycobacterium kansasii (Hunter et al., 1985; Hunter et al., 1983), 
Mycobacterium smegmatis , and "Mycobacterium canettii" of the M. tuberculosis 
complex (Daffé et al., 1987). Unlike most mycobacterial glycolipids, LOS’s vary 
in length and composition between different species. M. marinum produces under 
laboratory conditions four different LOS structures with increasing length, in 
which different unusual sugar moieties are added to a tetra glucose core which is 
acylated by two 2,4 dimethyl hexadecanoate and 2,4 dimethyl 2- pentadecenoate.  
The gene cluster involved in LOS biosynthesis of M. marinum has been proposed 
to comprise MMAR2302 through MMAR2341. In a study using transposon 
mutants, Ren et al. (2007), showed that a disruption in MMAR2309 leads to 
production of only LOS-I. The protein encoded by MMAR2309 belongs to the 
UDP-glucose/GDP-mannose dehydrogenase family and possess conserved NAD-
binding domains. Based on the sequence analysis and lipid profile, it was 
suggested that MMAR2309 was responsible for the biosynthesis of D-xylose. The 
same study also reported that a disruption in MMAR2332 resulted in a mutant 
strain that produces only LOS-I and LOS-II*, an intermediate between LOS-I and 
LOS-II, which contains Xylp but lacks caryophyllose. MMAR2332 encodes a 
protein which is similar to various thiamine pyrophosphate (TPP) requiring 
enzymes, like acetolactate synthetase. It is predicted that MMAR2332 is involved 
in the biosynthesis of the caryophyllose sugar residue and hence a disruption in 
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this gene resulted in LOS-II*. The losA gene (MMAR2313) was shown to have a 
role in LOS-IV production (Burguière et al., 2005). So far, only three selected 
genes and a genomic region of four genes have been demonstrated to be involved 
in the late steps of LOS biosynthesis in M. marinum.  
The previous chapter detailed the generation of targeted mutants in the 
LOS biosynthetic cluster in M. marinum.  The work discussed in this chapter 
describes a parallel approach that makes use of a library of transposon mutants to 
isolate mutant strains defective in LOS biosynthesis. We made use of two 
resources to isolate LOS-deficient mutants.  The first was a mariner transposon 
library generated in this study to isolate LOS deficient mutants based on altered 
colony morphology.  The second made use of a transposon library generated in 
the laboratory of our collaborators. In a unrelated screen for PE-PGRS mutants, 
Dr. A. Van der Woude and Prof W. Bitter (VUMC, Netherlands) noticed that a 
number of mutants defective in the secretion of the Esx-5 substrate EsxN had a 
transposon insertions in genes located near known LOS biosynthesis genes (the 
LOS cluster). The work described in this chapter reflects the lipid analysis done 
by me as a part of this collaboration. In total, we have identified ten M. marinum 
genes with a role in different stages of LOS biosynthesis.   
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4.2 Materials and Methods 
4.2.1 Bacterial strains and culture conditions 
Wild-type M. marinum strains 1218R, M
USA
 and E11, and corresponding mutants 
were routinely grown at 30°C in Middlebrook 7H9 (Difco), 7H10 liquid medium 
and on Middlebrook 7H10 plates (Difco) supplemented with 10% Middlebrook 
OADC (BD, Biosciences) and 0.05% Tween 80.  
4.2.2 Plasmids, DNA manipulations and bacterial growth conditions 
Plasmids, bacterial strains and phages used in this study are listed in Table 4.1. 
Escherichia coli strains were routinely cultured in Luria-Bertani (LB) broth at 
37⁰C. Mycobacterium smegmatis strain mc2155 (wild type) was used for 
generation and propagation of  mycobacteriophages and was routinely grown at 
37°C either in Middlebrook 7H9 Tween 80 or Tryptic Soy Broth (TSB) / agar 
supplemented with 0.05%. All M. marinum strains were grown either in 7H9 
broth supplemented with 10% OADC (oleic acid/albumin/dextrose/catalase, BD) 
or in 7H10 broth (composition based on Middlebrook 7H10 agar components) 
supplemented with 10 % OADC, at 30°C.  For plate growth, 7H10 agar plates 
were incubated at either 30°C, or when required, at 37°C (for selecting 
transductants; see below).   For experiments involving the usage of phages, Tween 
80 was not used in media. Mycobacteriophages were routinely propagated on 
Middlebrook’s 7H9 with 0.2% glycerol. Phage high titres were generated using 
protocols described by Larsen et al (2007). Antibiotics were added as required : 
hygromycin B (Roche) 150µg/ml for E. coli, 100µg/ml
 
for M. smegmatis, 
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50µg/ml for M. marinum; kanamycin sulfate (Sigma) - 50µg/ml
 
for E.c oli and 
25µg/ml for M. marinum; chloramphenicol 30µg/ml for M. marinum.    
4.2.3 Generation of transposon mutants   
Transposon mutagenesis was performed on M. marinum 1218R using the 
mycobacterial Transposon delivery phage phAE181 to produce a transposon 
library with an objective of generating disruption mutants in the LOS cluster, 
primarily to isolate mutants in glycosyltransferases. M. marinum cultures were 
grown in 50ml of 7H9+OADC with 0.05% Tween 80 to an optical density (OD 
600nm) of 0.8. The cells were harvested by centrifugation at 4500g for 10 minutes 
and washed twice with 50 ml MP buffer. The cell pellet was then gently 
resuspended in 2 ml MP buffer and mixed with 1 ml of high titre phage lysate (10
-
8
 to 10
-10
 pfu/ml). Separately, 500 l cells were mixed with 500 l of MP buffer to 
serve as control. The cell – phage mix was incubated at 37°C overnight ( static) , 
the cells were then harvested by centrifugation and resuspended in 10 ml 7H9 
broth+OADC with 0.05% Tween 80. M. marinum cells were recovered by 
overnight incubation at 37°C. Cells were again harvested and resuspended in 1 ml 
fresh media and plated on 7H10+OADC agar plates (100 l per plate) with 
50g/ml hygromycin B. Plates were incubated at 37°C for 2 to 3 weeks. 
Additionally we had access to a set of transposon mutants of M. marinum 
E11 and M
USA
 strains as a part of an ongoing collaboration with Dr. Aniek Van 
der Woude and Prof. Wilbert Bitter of VUMC, Amsterdam, The Netherlands.  
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Table 4.1. Bacterial strains, plasmids and phages used in this study 
Plasmids, phages and strains Description Reference 
Plasmids   
pVV16 
HygR/KanR , E.coli-
mycobacterial shuttle vector 
(ColE1 oriM Phsp60) 
Gift from Dr. V. Vissa, 
Colorado State University 
Phages   
phAE181 
Conditionally 
replicating phage TM4 
derivative carrying Tn-5371 
(Kriakov et al., 2003) 
Bacterial strains   
E. coli TOP 10 
F– mcrA Δ(mrr-
hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara leu) 
7697 galU galK rpsL (StrR) 
endA1 nupG 
 
 
Invitrogen 
 
 
 
 
 
M. smegmatis mc2155 
 
Wild type strain, Ept 
mutant of M.smegmatis strain 
mc26 
 
Snapper et al., 1990 
M. marinum 1218R 
 
 
 
 
M. marinum E11 
 
 
 
M. marinum MUSA 
 
 
Wild type strain used 
for generation of transposon 
mutants 
 
 
Wild type strain used 
for generation of transposon 
mutants 
 
Wild type strain used 
for generation of transposon 
mutants 
ATCC927 
 
 
 
 
(van der Sar et al., 
2004) 
 
 
 
(Talaat et al., 1998) 
 
4.2.4  Isolation and sequencing of Tn insertion sites 
Transductants obtained were selected based on their colony morphology. Selected 
mutants were grown in 10ml of 7H9+OADC with 0.05% Tween 80 +50μg/ml 
hygromycin B, and genomic DNA was extracted. The gDNA was digested with 
BssHII (NEB) and ligated with T4 ligase (NEB). The ligation mix was used to 
transform E. coli cc118λpir competent cells. To select self-ligated genomic DNA 
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fragments containing the transposon, the transformation mix was plated on LB-
plates with 150μg/ml hygromycin B and incubated overnight at 37°C. Colonies 
obtained were inoculated in LB-broth with hygromycin to obtain plasmid DNA. 
Plasmid DNA isolated from the hygromycin resistant transformants was digested 
with BssHII and checked on gel. The plasmids were then sequenced using the 
primers HOPS1 (5’ GCTTACAATTTAGGTGGCACT 3’) and KMN1 (5’ 
AGTGCCACCTAAATTGTAAGC 3’) to get the sequence of the left and right 
flanks of the transposon insertion sites. 
4.2.5 Generation of complemented strains of E11 MMAR2327::aph and E11 
MMAR2336::aph. 
The MMAR2327 and MMAR2336 genes were PCR amplified from M. marinum 
E11 genomic DNA using the primers listed in Table 4.2. Using the primer 
incorporated NdeI and PstI restriction sites, the PCR products were cloned into 
the E. coli-Mycobacterium shuttle vector pVV16 (containing hygromycin and 
kanamycin resistance cassette) and verified by sequencing.  The resultant 
plasmids pVV16-MMAR2327 and  pVV16-MMAR2336 were introduced by 
electroporation (Snapper et al., 1990) into M. marinum E11 MMAR2327::aph and  
M. marinum E11 MMAR2336::aph to generate the complemented strains 
E11MMAR2327::aph-C and E11MMAR2336::aph. 
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Table 4.2. Primers used for generation of complemented strains 
Name Sequence (5' → 3') 
 
Product 
Size 
MMAR2327_F 
GATCGATCCATATGAGTCGACCTG
TGGAGGTT 
 
MMAR2327 gene 
sequence 
1569 bp 
MMAR2327_R 
GATCGATCCTGCAGTCATCCAGGC
TTTCGAATG  
MMAR2336_ F 
GATCGATCCATATGCATTACCTGA
TTACTGG MMAR2336 gene 
sequence 
 
MMAR2336_R 
GATCGATCCTGCAGCTACCGCAGT
TGCCTAGCCTC 
1017 bp 
 
*Underlined sequence shows NdeI restriction site, # Underlined sequence shows PstI restriction 
site. 
Table 4.3 Table of complemented strains generated in this study 
Complemented strains Description  Reference 
 
E11MMAR2327::aph-C  
 
 
 
 
E11MMAR2336::aph-C  
 
MMAR2327::aph 
complemented with wild type 
copy of the gene MMAR2327 
in p VV16. 
 
MMAR2336::aph 
complemented with wild type 
copy of the gene MMAR2336 
in pVV16. 
 
 
This work  
 
 
 
 
This work 
 
4.2.6 Lipid extraction and analysis 
For labelling lipids with 
14
C-acetate, M. marinum strains were grown to mid-
logarithmic phase in 10ml of Middlebrook 7H10 broth supplemented with 10% 
OADC, 0.05% Tween 80 with appropriate antibiotics where required in a shaking 
incubator at 30 degrees, following which 1 mCi/ml [1,2-
14
C] acetate (57 
mCi/mmol, GE Healthcare, Amersham Bioscience) was added to the culture and 
the incubation was continued for another for
 
24 h. The labelled bacterial cells 
were harvested, washed, and
 
freeze-dried, and polar and apolar lipids were 
extracted and analysed by 2D-TLC according to the procedures described by 
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Dobson et al. (1985), detailed in Chapter 8. 
14
C-labelled lipids were visualised by 
autoradiography
 
by exposing a Kodak BioMax MR film to the TLC
 
plates for 3-5 
days.  
4.2.7 Large scale extraction of accumulating LOS’s from mutant strains 
For purification of accumulating LOSs, 400 mg of polar lipids, extracted from 40 
g dried cells, were applied to a DEAE cellulose column.  The column was eluted 
with 500ml CHCl3:CH3OH (2:1 v/v) and 10 ml fractions were monitored by 
separation of LOSs by 1D-TLC (CHCl3:CH3OH:H2O; 60:30:6) and spraying the 
plates with alpha-naphthol/sulfuric acid followed by charring.  Fractions 
containing LOSs were pooled, concentrated and further purified by preparative 
TLC on a 10 x 20cm plastic backed silica gel TLC plates (Merck) run in 
CHCl3:CH3OH:H2O (60:30:6, v/v/v). The plates were sprayed with 0.01% 1,6-di-
phenyl-1,3,5-hexatriene in petroleum ether /acetone (9:1,v/v) and the glycolipids 
were visualised under UV light, and the area was marked with a pencil.  The 
plates were then run in toluene to remove the di-phenyl hexatriene and after 
drying, the marked area was scraped from the TLC plates, extracted with 
CHCl3:CH3OH (2:1, v/v), per methylated and subjected to mass spectroscopy 
analyses (described in Chapter 8). 
4.2.8 Extraction of bone marrow derived macrophages (from Balb/c mice) 
and infection by M. marinum 
Bone marrow derived macrophages (BMDM) were obtained as described in 
Chapter 8. 24 hours before infection, the BMDM were activated using 
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recombinant mouse INF- (Invitrogen) at a concentration of 1000units/ml. The 
concentration of BMDM used for this study was 0.5 X 10
6
 cells / ml.  Late log 
phase bacteria (M. marinum E11WT, MMAR2327::aph, MMAR2327::aph-C, 
MMAR2336::aph, MMAR2336::aph-C, and MMAR2340::aph) were washed with 
PBS and resuspended in infection medium (DMEM with 10% FBS) to 10
7
cfu/ml. 
Murine BMDM was infected with M. marinum strain at  an MOI of 10 and 
incubated at 37
0
C under 10% (v/v) CO2 for 3-4 hours. Infection protocol was 
followed as described in chapter 6. Infection with each strain was triplicated and 
TNF- levels in the infection supernatant was estimated using QuantikineR Mouse 
TNF- Immunoassay Kit (MTA00B), RnD Systems.Cell lysates were 10 fold 
serial diluted and plated out on 7H10 agar with OADC. The plates were incubated 
at 30
0
C for 1 week before counting colonies.  
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4.3 Results 
4.3.1 Selection of transposon mutants in this study 
 In the transposon screen using colony morphology change, we were able to 
isolate a strain disrupted in the gene MMAR2351, a glycosyltransferase in the M. 
marinum LOS gene cluster. The mutant strain was first isolated based on colony 
morphology (Figure 4.1).  
Additionally we had access to a set of transposon mutants of M.marinum 
E11 and M
USA
 strains as a part of an ongoing collaboration with Dr. Aniek Van 
der Woude and Prof. Wilbert Bitter of VUMC, The Netherlands.  The following 
table (Table 4.4) lists all the mutant strains discussed in this study. 
 
Table 4.4 Table of all LOS Tn-insertions with putative genes that are disrupted.  
Mutant strain Gene product Parental strain 
MMAR2307::aph 
hypothetical transmembrane 
protein 
M. marinum MUSA 
MMAR2319::aph 
conserved hypothetical 
transmembrane protein 
M. marinum E11 
MMAR2320::aph sugartransaminase (WecE) M. marinum E11 
MMAR2327::aph 
conserved hypothetical 
transmembrane protein 
M. marinum E11 
MMAR2336::aph GalE6 epimerase M. marinum E11 
MMAR2340::aph Pks5 M. marinum E11 
MMAR2341::aph 
 
FadD25 
M. marinum E11 
MMAR2351::hyg 
 
glycosyltransferase 
M. marinum 1218R 
MMAR2353::aph UDP-glycosyltransferase M. marinum E11 
MMAR2355::aph PapA3 M. marinum E11 
MMAR2356::aph isoleucine t-RNA synthetase M. marinum E11 
MMAR5170::aph WhiB4 M. marinum E11 
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Figure 4.1 Colony morphology of M. marinum wild type and Tn-mutant strain. A 
10μl spot of a mid-log phase culture and single colony on 7H10 agar and 7H10 agar 
containing 0.05% Tween 80 plates. Scale bar represents 1mm. 
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4.3.2 2D TLC analysis of mutant strains within the LOS gene cluster  
M. marinum produces four different classes of LOS’s, designated LOS-I to LOS-
IV. The biosynthesis of these LOS variants is proposed to be sequential. The 
structure of LOS-I is 3-O-Me-Rhap-(1-3)-Glcp-(1-3)-Glcp-(1-4)-Glcp-(1-1)-Glcp 
(Burguière et al., 2005). The addition of xylose together with one or two 
molecules of the highly unusual sugar caryophyllose (Rombouts et al., 2009) 
produces LOS-II and LOS-III, respectively. The molecule added to produce LOS-
IV has been partially characterized and seems to be a heterogenic group of mainly 
one acidic form of a N-acylated 4-amino-4,6-dideoxy-Galp residue (Rombouts et 
al., 2010). The biosynthetic pathway for LOS and the genes involved remains 
largely unknown. In Chapter 2 a mutant strain of MMAR2333 was detailed which 
was unable to produce LOS-II to LOS-IV but accumulated a LOS species- LOS-
II*, which lacked the unique caryophyllose sugar. To determine the effects of 
genes disruption on LOS biosynthesis in the newly identified mutant strains the 
polar lipid profiles of these mutants were examined by two-dimensional thin-layer 
chromatography (2D-TLC).  
4.3.2.1 Mutant strains defective in LOS-IV production  
The mutant strain MMAR2320::aph, disrupted in MMAR2320, showed a 
distinctive 2D-TLC pattern with a specific accumulation of a LOS species that 
migrated to a position similar to LOS-III (Figure 4.2). MMAR2320 a homologue 
of E. coli WecE, has been shown to be a sugar aminotransferase (Hwang et al., 
2004). LOS-IV has a unique aminosugar and given the loss of LOS-IV in the 
mutant strain it seemed likely that MMAR2320 was involved in the biosynthesis 
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of the aminosugar residue.  Complementation of the MMAR2320::aph mutant 
with a copy of MMAR2320 either on the shuttle vector pSMT3 or the integrative 
vector pUC-int-cat restored wild type LOS patterns in the strain (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type), MMAR2320::aph, MMAR2320::aph-C grown in 
Middlebrook 7H10 broth. Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), 
direction 2- chloroform: acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). 
MMAR2320 shows accumulation LOS-III. AcPIM2 and Ac2PIM2, mono and di-acyl 
phosphatidyl-inositol dimannosides; AcPIM6 and Ac2PIM6, mono and di-acyl 
phosphatidyl-inositol hexamannosides; LOS I-IV, lipoologosaccharides; PI, 
phosphatidylinositol; DPG, diphosphatidylglycerol; PE. Phosphatidylethanolamine; 
P, unknown phospholipids. 
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Biochemical analysis of the accumulating LOS biosynthesis intermediates 
was performed to ascertain the sugar compositions and to relate it to the 
associated gene function. This was ascertained by determining the chemical nature 
of the accumulating LOS-III from the mutant strain MMAR2320::aph. The LOS-
III was   purified using a combination of column chromatography and preparative 
TLC, and per-O-methylated LOS was analysed by MALDI-MS and ES.  A 
prominent signal was obtained at m/z 1915.9 [M + Na] + (Figure 4.3), for the LOS 
species isolated from MMAR2320::aph  which corresponds to the mass of the 
tetraglucose core, methylated rhamnose, xylose with 2 caryophyllose residues.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Mass spectrometric analysis of per-O-methylated LOS-III isolated from 
MMAR 2320::aph. The accumulating LOS species afforded a signal at m/z 1915.9 
(M+Na), which corresponds to the mass of the tetraglucose core, methylated 
rhamnose, xylose with 2 caryophyllose residue; LOS-III. 
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These data indicates that mutant strain with a disruption in MMAR2320 
(WecE) is unable to synthesise LOS-IV, which has an additional N-acyl 4,6 
dideoxygalactose added to the LOS-III structure. In other words, the addition of 
the N-acyl 4, 6 dideoxygalactose residues to the D-Xylp-glycan-caryophyllose 
core did not take place in the MMAR2320 mutant. MMAR2320 is a sugar 
transaminase and is believed to play a major role in the synthesis of the N-acyl 4,6 
dideoxy galactose residue. Other glycosyltransferases maybe involved in the later 
stages of transferring a lipid-bound N-acyl sugar to the LOS-III moiety on the 
extracytoplasmic side. 
Figure 4.4 Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2319::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2319 shows over production 
of LOS-II and LOS-III. 
Another mutant strain MMAR2319::aph had a disruption in the gene 
downstream of the wecE gene, MMAR2319, which encodes a hypothetical 
transmembrane protein. Similar to the MMAR2320::aph strain, 2D-TLC analysis 
showed the strain to be deficient in LOS-IV biosynthesis. However, in contrast to 
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the MMAR2320::aph strain, it was found to accumulate two LOS species that 
migrated to a position similar to both LOS-II and LOS-III (Figure 4.4).  
4.3.2.2  Mutant strains defective in production of LOS-III and LOS-IV 
Other mutants in the LOS region also showed various defects in LOS 
biosynthesis. Mutant strain MMAR2327::aph, which was disrupted in 
MMAR2327, a gene encoding a multiple transmembrane protein, accumulated 
large amounts of a LOS species with TLC migration patterns similar to LOS-II 
and the strain was devoid of LOS-III and LOS-IV (Figure 4.5).  
Figure 4.5 Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type), MMAR2327::aph, MMAR2327::aph-C grown in 
Middlebrook 7H10 broth. Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), 
direction 2- chloroform: acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). 
MMAR2327 shows over production of LOS-II. 
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Introduction of a plasmid borne copy of the wild type gene into this strain 
restored the LOS profile to that of the wild type strain (Figure 4.5). MS - analysis 
of the accumulating LOS species in the mutant strain MMAR2327 revealed a 
mass corresponding to LOS-II, previously reported from the wild type species 
(Burguière et al., 2005). A signal was obtained at m/z 1567.9 (M+Na) which 
corresponds to the mass of the tetraglucose core, methylated rhamnose, xylose 
and one caryophyllose residue (Figure 4.6). The protein MMAR2327 is conserved 
across mycobacterial species and has a high identity to a transmembrane protein 
in "M. canettii" and M. tuberculosis gene Rv1508. Rv1508 is a highly conserved 
protein with similarities to glycosyltransferases from various mycobacteria and 
has 42% identity in a 105 amino acid overlap (http://tuberculist.epfl.ch). The 
mutant strain with a disruption in the gene MMAR2327 was not able to produce 
LOS-III, or add a caryophyllose residue onto the LOS-II* moiety (described in 
Chapter 2). 
 
Chapter 4                                                     LOS biosynthesis genes in M. marinum 
                           
118 
 
  
Figure 4.6. Mass spectrometric analysis of per-O-methylated LOS-II isolated from 
MMAR 2327::aph. The accumulating LOS species afforded a signal at m/z 1567.9 
(M+Na), which corresponds to the mass of the tetraglucose core, methylated 
rhamnose , xylose with one caryophyllose residue ; LOS-II. 
4.3.2.3  Mutant strains defective in production of LOS-II, LOS-III and 
LOS-IV 
The mutant strain MMAR2336::aph was disrupted in MMAR2336 a gene encoding 
a putative UDP-glucose 4-epimerase. An intermediate between LOS-I and LOS-
II, named LOS-II* was observed in two other mutant strains MMAR2333 
(Chapter 2) and MMAR2332 . The LOS intermediate detected in this strain had 
the same migrating pattern as the LOS-II* from above two mutant strains. 
Complementation of this mutant strain with a copy of the gene MMAR2336 on the 
replicative plasmid pVV16 restored LOS biosynthesis patterns similar to the wild 
type strain (Figure 4.7). 
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Figure 4.7. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type), MMAR2336::aph, MMAR2336::aph-C grown in 
Middlebrook 7H10 broth. Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), 
direction 2- chloroform: acetic acid: methanol: water, 40:25:3:6 (v/v/v/v).  
 
MMAR2336 encodes a UDP-glucose 4 epimerase, which is    involved in 
catalysing the conversion of a UDP-glucose to UDP-galactose. These groups of 
enzymes have a structurally conserved Rossmann fold, an NADP (H) binding 
region and a diverse C-terminal region. 2D-TLC analysis of polar lipids extracted 
from this mutant strain revealed a LOS species, LOS-II’ which migrated to a 
position similar to that of an intermediate between LOS-I and LOS-II,. This sugar 
lacked the unique caryophyllose residue that is characteristic of LOS-II and LOS-
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III. Complementation of the mutant strain with a plasmid borne copy of the wild-
type gene completely restored the phenotype to wild type. Mass spectrometric 
analysis afforded a signal at m/z 1175.7 (M+Na), which corresponds to 43 units 
less than the mass of the tetraglucose core, methylated rhamnose and xylose 
(Figure 4.8). These enzymes are known to catalyse the conversion of a nucleotide 
bound sugar to a nucleotide nucleotide bound keto-deoxy sugar. The inability of 
the MMAR2336 disrupted strain, to produce LOS-II indicates a possible role in 
production of the caryophyllose sugar essential for producing LOS-II. 
Figure 4.8. Mass spectrometric analysis of per-O-methylated LOS isolated from 
MMAR 2336::aph. The accumulating LOS species afforded a signal at m/z 1175.7 
(M+Na). 
The M
USA
 mutant strain was disrupted in the gene MMAR2307. 
MMAR2307 encodes a hypothetical transmembrane protein and in silico analysis 
reveals no conserved domains. The closest identity is with a hypothetical 
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transmembrane domain of M. kansasii MkanA1_010100001085c which lies in 
the LOS biosynthesis cluster of M. kansasii. MMAR2307 shows a LOS profile 
similar to the earlier reported mutant strain with a disruption in MMAR2309 
(Ren et al., 2007). The mutant strain accumulated a species migrating to the 
position of LOS-I (Figure 4.9). 
 
Figure 4.9. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum M
USA
 (wild type) and MMAR2307::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2307::aph shows 
accumulation of LOS-I. 
 
A mutant strain was generated in the M. marinum strain M
USA
. This mutant 
had a disruption in the gene MMAR2307. This gene encodes a transmembrane 
protein and no conserved domains were detected. 2D–TLC analysis revealed that 
the mutant strain accumulated a polar lipid that migrated to the position of LOS-I. 
MALDI-MS analysis of the accumulating LOS species afforded a signal at 1059.3 
m/z which corresponds to the tetraglucose core present in M. marinum LOSs 
(Figure 4.10) 
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Figure 4.10 Mass spectrometric analysis of per-O-methylated LOS-I isolated from 
MMAR 2307::aph. The accumulating LOS species afforded a signal at m/z 1059.3 
(M+Na) which corresponds to the tetraglucose core. 
 
4.3.2.4 Mutant strains defective in production of LOS-I to LOS-IV. 
The gene MMAR2340 encodes a polyketide synthase, pks5. MMAR2340 shares 
76% identities with MKAN1200 (M. kansasii Pks5), 74% identity with "M. 
canettii" Pks5, M. tuberculosis Rv1527 and M. bovis. MMAR2340 also shares 
63% identity with MSMEG4727/Pks5, a MAS-like pks responsible for synthesis 
of methyl branched fatty acyl chains in LOSs from M. smegmatis (Etienne et al., 
2009). The 2090 amino acid protein comprises of a ketoacyl synthase domain 
with catalytic sites at N-terminal and C-terminal, acyltransferase domain, Gro-ES 
like alcohol dehydrogenase domain, Zinc-binding dehydrogenase domains, 
ketoreductase and phosphopantetheine binding. 
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The 2D-TLC patterns for polar lipids of the mutant strains disrupted in the 
polyketide synthase 5 genes, involved in the biosynthesis of the fatty acyl chain 
MMAR2340aphrevealed that the strain is completely defective in LOS 
production, as none of the four M. marinum LOS structures were visible (Figure 
4.11). A null mutant of MMAR2340, generated by specialised transduction in the 
M. marinum 1218R strain, described in Chapter 3 also showed the similar 
phenotype. Repeated attempts at generating a complementation construct for this 
mutant strain was unsuccessful. This suggests that the gene plays a role in the 
biosynthesis of the core acylated trehalose structure of LOS. 
 
Figure 4.11. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2340::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v).  
 
The gene downstream of the pks5 gene is MMAR2341 is annotated as a 
fatty acyl AMP ligase, fadD25.  MMAR2341 has a proposed role in activation of 
fatty acyl-AMP intermediates and loading the adenylated metabolite onto the Pks5 
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multienzyme for extension. Disruption of this gene also resulted in a similar 
phenotype to the pks5 mutant (Figure 4.12). 
 
Figure 4.12. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2341::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2341::aph is devoid of all 
the 4 LOS species. 
 
2D-TLC analysis of mutant MMAR2355::aph revealed that this mutant 
strain was not able to produce LOS’s (Figure 4.13). This gene encodes the 
conserved polyketide synthase-associated protein PapA3. PapA3 might function 
as an acyltransferase associated with Pks5, explaining its role in the biosynthesis 
of the LOS core structure of acylated trehalose.  
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Figure 4.13. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2355::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2355::aph is devoid of all 
LOSs. 
 
MMAR2356 encodes an isoleucyl-tRNA-synthetase. It has a conserved 
ATP-binding domain. Disruption in this gene resulted in a strain which was 
devoid of any of LOSs. 
 
Figure 4.14. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2356::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2356::aph is deficient in 
production of all LOSs. 
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4.3.2.5 Mutant strains with no difference in LOS production profile 
From the transposon library generated in M. marinum 1218R strain in-
house, a mutant strain with altered colony morphology was selected and genetic 
analysis revealed a disruption in the gene MMAR2351. MMAR2351 encodes a 
type II glycosyltransferase and shares 83% amino acid identity with a 
glycosyltransferase in M. kansasii LOS biosynthesis cluster. These groups of 
enzymes catalyze the transfer of sugar moieties to form glycosidic bonds. 2D-
TLC analysis of polar lipids extracted from this strain revealed that a disruption in 
this gene did not affect the LOS biosynthesis in M. marinum. 
 
Figure 4.15. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum 1218R (wild type) and MMAR2351::hyg grown in Middlebrook 7H10 
broth. Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- 
chloroform: acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2351::hyg does 
not differ in LOS production as compared to the wildtype. 
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Rough colony morphology is a characteristic phenotype of strains lacking 
the presence of LOSs. Rough-dry phenotype observed for some mutants located 
downstream of the proposed LOS biosynthesis region, i.e. in genes MMAR2355, 
and for one mutant strain located far from the LOS biosynthesis region, in gene 
MMAR5170. To examine whether these mutants strains have a role in LOS 
production, their polar lipid contents were analysed.  
The mutant strain MMAR2353::aph was disrupted in the gene 
MMAR2353, located downstream of the glycosyltransferase MMAR2351 in the 
same operon. MMAR2353 encodes a UDP-glycosyltransferase. 
Glycosyltransferases play an important role in synthesis of the LOSs. Loss of 
MMAR2315 (losA) revealed that the strain was defective in production of LOS-IV   
(Burguière et al., 2005) and loss of another glycosyltransferase MMAR2333 was 
responsible for a strain in deficient in LOS-II to LOS-IV (Sarkar et al., 2011). 2D-
TLC analysis of the mutant strain MMAR2353::aph showed no effect on LOS 
production as shown in Figure 4.16.  
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Figure 4.16 Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR2353::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). MMAR2353::aph does not differ in 
LOS production as compared to the wildtype. 
 
4.3.2.6 Mutant strains with diminished  LOS production  
The mutant strain MMAR5170::aph was  disrupted in the gene MMAR5170 
which encodes for the transcriptional regulatory protein WhiB4. 2D-TLC analysis 
of polar lipids of this mutant showed that LOS production was highly diminished, 
although some traces of LOS, especially LOS-III, seem to be present (Fig 4.17). 
Wildtype phenotypes were restored upon complementation with vector pUCintCat 
containing the whiB4 gene.  
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Figure 4.17. Autoradiograph of a 2D-TLC showing labelled polar lipids from M. 
marinum E11 (wild type) and MMAR5170::aph grown in Middlebrook 7H10 broth. 
Direction 1- chloroform: methanol: water, 60:40:6 (v/v/v), direction 2- chloroform: 
acetic acid: methanol: water, 40:25:3:6 (v/v/v/v).  
 
 This result together with the characteristic rough colony morphology 
suggests that WhiB4 has a role in LOS biosynthesis, which could be regulation of 
the LOS gene cluster. Together, these results show that the LOS biosynthesis 
region is even more extended than proposed by Ren et al. (2007) (Figure 4.24). 
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4.3.3 Intracellular survival in bone marrow derived macrophages  
M. marinum mutant strains defective in LOS-IV production were previously 
reported to have an inability in entering entering bone marrow derived murine 
macrophages (Burguière et al., 2005). We selected three mutant strains 
characterised in this study for infecting murine macrophages - MMAR2327::aph 
which accumulated LOS-II, MMAR2336::aph which accumulated an intermediate 
LOS-II* and the mutant strain MMAR2340::aph which was deficient in 
production of all LOSs. These strains would allow us to assess the effects of : 
1) Complete loss of all LOSs. 
2) Loss of LOS-IV 
3) Loss of LOS-III and LOS–IV. 
4) Loss of LOS-II and the effect of accumulation of the intermediate LOS- II* and 
LOS-II’. 
In order to assess the roles of MMAR2327, MMAR2336 and MMAR2340 
disrupted strains in virulence, an intracellular survival assay was performed with 
bone marrow derived murine macrophages. Activated macrophages were infected 
with the mutant strains using a multiplicity of infection of 10 to determine the 
ability to enter and survive within the macrophages. The survival of intracellular 
bacteria was followed over a period of 1, 3 and 5 days. The number of 
intracellular bacteria (colony forming units) was enumerated by lysing the 
macrophages and plating on 7H10 agar supplemented with 10% OADC.   
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In a previous study it was reported that transposon-mediated disruption of 
MMAR2332, which led to the accumulation of LOSII* was not altered in the 
ability to survive inside cultured murine J774 macrophages. We wanted to check 
the ability of the transposon mutant strains generated in this study to enter and 
survive in murine bone marrow derived macrophages. Also, as reported in 
Chapter 2 of this thesis, a knockout strain of MMAR2333 was not affected in the 
ability to enter and survive inside the bone marrow derived macrophages.  
In this study we observed that the mutant strains MMAR2327::aph and 
MMAR2336::aph were not altered in their abilities  in entering macrophages as 
observed from the colony forming units/ml counts obtained after lysing the 
infected BMDMs (Figures 4.18 and 4.19). The strain MMAR2327::aph produced 
only LOS-I and LOS-II and was deficient in producing LOS-III and LOS-IV, 
while the strain MMAR2336::aph accumulated an intermediate, LOS-II’ that 
migrated to positions between LOS-I and LOS-II on a 2D-TLC. The intermediate 
species had the same migration patterns as LOS-II* on 2D-TLC but differed in 
mass. 
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Figure 4.18. Survival of M. marinum strains in infected murine (Balb/c) bone 
marrow derived macrophages. BMDM cells were lysed and plated on 7H10 agar 
plates and the colony forming units /ml were enumerated.  
 
 Figure 4.19. Survival of M. marinum strains in infected murine (Balb/c) bone 
marrow derived macrophages. BMDM cells were lysed and plated on 7H10 agar 
plates and the colony forming units /ml was enumerated.  
 
MMAR2340 encodes a polyketide synthase Pks5 and a disruption in this 
gene resulted in a strain lacking all the four classes of LOSs. In case of infection 
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with the mutant strain MMAR2340::aph, no change was detected in the ability of 
the mutant strain in entering the macrophages as shown in Figure 4.20. 
  
 
Figure 4.20. Survival of M. marinum strains in infected murine (Balb/c) bone 
marrow derived macrophages. BMDM cells were lysed and plated on 7H10 agar 
plates and the colony forming units /ml were enumerated. 
Cell counts obtained from macrophages infected by different mutant 
strains did not show any significant difference in terms of entry and survival of 
the bacterium. In a previous study (Rao et al., 2005; Glickman et al., 2000) it was 
shown that a pcaA mutant of M. tuberculosis did not show any defects in entry 
and persistence in cultured macrophages, but was deficient in granuloma 
formation and also induced lower levels of the proinflammatory cytokine TNF- 
as compared to the wild type strain.  Thus, mutant strains that do not show any 
differences in cell counts may still affect the pro-inflammatory response.  
Tumour necrosis factor–alpha (TNF-) belongs to a superfamily of 
proinflammatory cytokines that play an important role in regulating inflammation, 
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host defense, adaptive immunity, apoptosis, autoimmunity and organ 
development. Macrophages are the primary source of TNF- production but TNF-
 is also produced by many different cell types; T and B cells, osteoblasts, smooth 
muscle cells etc. (Levine et al., 1995). TNF production can be stimulated by a 
variety of substances for e.g., bacterial lipopolysaccharide, or cytokines like 
interferon-gamma (IFN-). Studies have reported that M. tuberculosis infection 
induces production of the proinflammatory cytokine TNF-in macrophages and 
dendritic cells (Orme, 2004). Based on these, TNF-levels released by infected 
bone marrow deived macrophages were measured. 
Studies using M. kansasii to infect murine models have reported that 
strains, which had a glossy colony morphology, were readily cleared from the 
mice models while the rough appearing strains were able to survive and produce a 
systemic infection in mice (Collins and Cunningham, 1981). The glossy and 
rough colony morphologies were later attributed to production of LOSs. LOS 
producing strains had smooth / glossy colonies while LOS negative strains had 
rough colonies (Belisle and Brennan, 1989). Previous reports of studies on M. 
marinum mutant strains devoid of LOS-III and LOS-IV showed that the strains 
were impaired in entering macrophages (Ren et al., 2007). In contrast to these, it 
has been shown in another study that purified LOS-IV was responsible for 
inhibition of TNF- secretion in activated macrophages in a dose dependant 
fashion (Rombouts et al., 2009). Also, it was reported that loss of TNF signalling 
resulted in accelerated bacterial growth and granuloma formation (Clay et al., 
2008). 
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TNF is an important regulator of immune responses and crucial to host 
defense mechanisms to M. tuberculosis infection (Flynn et al., 1995; Zganiacz et 
al., 2004). On the contrary it has also been shown that TNF can facilitate early 
growth of M. tuberculosis in macrophages (Byrd, 1997;Engele et al., 2002). In 
this study we observed that the MMAR2340::aph strain was efficient in entering 
and surviving within bone marrow macrophages but the TNF-levels detected in 
the infected cell supernatants were much higher than the levels obtained using the 
wild type strains (Figure 4.21) indicating a pro-inflammatory response 
accompanied by cytokine release and establishment of infection.  
 
 
 
 
 
 
Figure 4.21 TNF-  production by murine (Balb/c) bone marrow derived 
macrophages infected with different M. marinum E11 strains.  
Absence of all the four classes of LOSs from this strain might be 
responsible in interfering with the host immune pro-inflammatory responses 
which is crucial to the events involved in granuloma formation. A similar 
cytokine profile was observed in an infection model using a knockout strain of 
MMAR2340 in M. marinum 1218R, detailed in Chapter 3. Unfortunately due to 
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the unavailability of a complemented strain and the BMDM being infected with 
whole cells, further insights into the role of Pks5 in virulence could not be 
obtained. 
It has been proposed that LOSs mask the virulent activities of other cell wall 
glycolipids like, LAM and PGL (Belisle and Brennan, 1989). The elevated levels 
of TNF-due to the loss of all the four classes of LOSs agree with the above 
hypotheses. The TNF- levels detected in this experiment were obtained from 
activated macrophages infected with the mutant bacterium, hence in this case, 
macrophage cell surface antigen presentation needs to be taken in account.   
Further research is required to study the exact mechanism of the observed 
virulence in the absence of LOSs. 
Cell supernatant analysis for TNF- release in infection experiment with the 
strain MMAR2327::aph revealed a slight lower levels in the mutant strain as 
compared to the wild type and complemented strains. Post infection at 72 hours 
the wildtype strain infected BMDM TNF- levels were recorded at 366.5 pg/ml 
while it was 299 pg /ml in case of the mutant strain. Post infection at 120 hours 
the values recorded was 221 pg /ml incase of the wildtype and 91.5 pg /ml for the 
strain MMAR2327::aph (Fig 4.22). 
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Figure 4.22. TNF-  production by murine (Balb/c) bone marrow derived 
macrophages infected with different M. marinum E11 strains.  
TNF- released by infected BMDM supernatants in case of infection using 
the strain MMAR2336::aph were 251.5 pg /ml as compared to 366.5 pg /ml 72 
hours post infection. The levels of TNF- released decreased to 54 pg /ml 120 
hours post infection as compared to 221 pg /ml in the wild type infection set 
(Figure 4.23).  
 
 
 
 
 
 
 
Figure 4.23 TNF- production by murine (Balb/c) bone marrow derived 
macrophages infected with different M. marinum strains.  
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Table 4.5 Effects on TNF-levels in the presence of the different LOS classes.  
Type of LOSs Effect on TNF- levels 
No LOS increased levels of TNF-  
LOS-I , LOS-II' decreased TNF levels- 
LOS-I , LOS-II * increased levels of TNF-  
LOS-I, LOS-II Slight decrease levels of TNF- 
LOS-I, LOS-II and LOS-III - 
 
Table 4.5 lists the effects on the levels of TNF- release in the presence of the 
different LOS classes. TNF- is a proinflammatory cytokine and has been shown 
to e released by macrophages upom infection with M. tuberculosis (Orme, 2004). 
It has been proposed that LOSs act as a mask for the cryptic virulent glycolipids 
like the LM and TDM in the mycobacterial cell wall (Belisle and Brennan, 1989). 
A study using purified LOS-IV seconds these hypotheses. It was shown that 
purified LOS-IV was able to inhibit release of TNF-Romboutset 
al.Also in out study we show that a strain deficient in production of all the 
LOSs MMAR2340::aph is able to enter and persist in activated BMDM and shows 
increased production of TNF- from macrophages indicating infective stage.  
Infection with strains of M. marinum producing only LOS-I and LOS-II, 
 MMAR2327::aph did not affect the TNF- production levels. While a 
strain producing LOS-I and LOS-II* (MMAR2333, Chapter 2) showed an 
increase in TNF- levels. These findings hints at a possibility that the higher 
LOSs, LOS-III and LOS-IV probably supress inflammatory responses during 
mycobacterial infection. Surprisingly it was noticed that infection with a mutant 
strain MMAR2336::aph that produces LOS-II’ and an intermediate species 
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between LOS-I and LOS-II was able to reduce TNF- levels as compared to 
infection with wild type M. marinum.  
4.4  Discussion 
Presence and absence of LOSs have always been linked to rough-dry /smooth   
colony morphology in LOS producing mycobacteria. Based on the colony 
morphology, the Tn-mutants were selected for analysis and the gene disruptions in 
the mutant strains were identified. Polar lipid analysis of these strains led to the 
identification of ten genes in the LOS biosynthesis pathway, which greatly 
extends our knowledge of LOS biosynthesis in M. marinum.  
The LOS biosynthesis gene cluster was identified to extend from 
MMAR2302 to MMAR2340 in a previous study by Ren et al., (2007). In this study 
mutant strains with disruptions in genes on either side of the above cluster were 
isolated and characterised. The LOS mutants detected in this screen show a 
specific deficit in higher order LOS production and a concomitant accumulation 
of the lower order LOS structures. The genes affected in these mutants also show 
a specific spatial genomic clustering according to their role in LOS biosynthesis. 
LOS-I accumulation, indicating a deficiency to synthesize, attach or transport the 
xylose unit to the LOS structure, is found at the beginning of the LOS 
biosynthesis cluster in genes MMAR2307 and MMAR2309. The region responsible 
for the synthesis and attachment of caryophyllose to produce LOS-II and LOS-III 
seems to be localised roughly between genes MMAR2327 and MMAR2336. Also a 
rather large part of the genome cluster, genes MMAR2313 to MMAR2320, seems 
to be reserved for the synthesis and transfer of the terminal 4.6 dideoxy N acyl 
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galactopyranose to produce LOS-IV. Together, these results greatly contribute to 
understanding the genes involved in LOS biosynthesis. 
 
The region downstream of losA (MMAR2313), MMAR2314-2317, have been 
described earlier to have a role in the biosynthesis of LOS-IV, hence it is 
predicted that the gene cluster extending from MMAR2313 (LosA) to MMAR2320 
(WecE) is possibly responsible for LOS-IV production. An accumulation of LOS-
I and loss of LOS-II to LOS-IV was attributed to the loss/disruption of the genes 
MMAR2307 and MMAR2309. Loss of MMAR2327 resulted in accumulation of 
LOS-II and absence of LOS-III and LOS-IV, while the ORF MMAR2332 to 
MMAR2336 was shown to be responsible for loss of LOS-II to LOS-IV and 
accumulation of an intermediate LOS-II*. The gene cluster MMAR2340 to 
MMAR2406 was shown to be involved in pivotal steps in LOS biosynthesis. As 
this cluster have genes necessary for the synthesis of the core LOS structure. 
MMAR2340 and MMAR2341 encode Pks5 and FadD25 which are involved in the 
synthesis and activation of the acyl chains linked to the trehalose core. The gene 
disruption of MMAR2353 encoding PapA3 also resulted in a LOS deficient 
phenotype. Although this gene is located downstream of the putative LOS region, 
the role of an acyltransferase in the synthesis of the LOS core structure is not 
surprising. In M. smegmatis, the putative acyltransferase MSMEG4728 was also 
postulated to have a role in LOS biosynthesis.
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The decrease in LOS production of the whiB4 mutant suggests that this 
regulatory protein also has a role in LOS biosynthesis regulation. The paralogue 
WhiB3 was shown to regulate lipid biosynthesis by regulation of pks2 and pks3 
expression (Singh et al., 2009). Therefore, it seems likely that WhiB4 regulates 
LOS biosynthesis, perhaps by regulation of pks5 expression. The distinctive 
phenotype of this mutant on filter assay suggests that WhiB4 could have 
additional functions. 
A disruption in the MMAR2320 gene of M. marinum, resulting in LOS-IV 
deficiency and concomitant LOS-III accumulation, leads to significantly increased 
early granuloma formation in zebrafish embryos (A.van der woude, 
communicated). A disruption in the Pks5 gene lead a strain which was deficient in 
production of all the four LOSs and higher levels of the proinflammatory cytokine 
TNF- was detected in murine bone marrow derived macrophages infected with 
whole cell of the M. marinum mutant strain. Also in our study we show that a 
strain deficient in production of all the LOSs, MMAR2340::aph is able to survive 
in activated BMDM and shows increased production of TNF- from macrophages 
indicating infective stage while infection with MMAR2327::aph (producing only 
LOS-I and LOS-II) did not affect the TNF- production levels. These findings 
hints at a possibility that the higher LOSs, LOS-III and LOS-IV probably supress 
inflammatory responses during mycobacterial infection. The only deviation was 
observed with MMAR2336::aph, a strain that produces LOS-II’ and an 
intermediate species between LOS-I and LOS-II. Suppression was observed in 
TNF- levels as compared to infection with wild type M. marinum.  
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It has been proposed that the presence of LOS might act as a mask for 
other surface-associated factors, such as LAM and PGL (Belisle and Brennan, 
1989). LOSs may express key effector molecules capable of interfering with the 
host immune response which is key to the pathophysiological events that 
culminate into granuloma formation The fact that LOS production is absent in 
most species of the M. tuberculosis complex, except for M. canettii, also fits 
within this hypothesis. Further research is required to study the exact mechanism 
of the observed virulence in infection caused by the absence of LOS-IV, and 
deficiency of LOSs, which would help understand more about the interaction of 
mycobacteria with its host.   
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5  
 Lipooligosaccharide biosynthesis 
in Mycobacterium kansasii 
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5.1 Introduction  
Mycobacterium kansasii was first described in by (Buhler and Pollak, 1953).  It is 
slow growing, photochromogenic and has a characteristic yellow colour and was 
hence termed ‘yellow bacillus’. The bacterium was the first to be shown to cause 
nontuberculous mycobacterial infections in humans and is the second-most 
common opportunistic non-tuberculous mycobacteria (Choudhri et al., 1995; 
Bittner et al., 1996). Five subtypes of M. kansasii have been identified based on 
the genetic analyses of the hsp65 gene, intergenic region between the 16S and 23S 
rRNA gene and the 16S rRNA gene of M. kansasii (Alcaide et al., 1997; 
Picardeau et al., 1997; Ross et al., 1992; Richter et al., 1999, Rogall et al., 1990). 
Type I is the most common subtype associated with human infections (Taillard et 
al., 2003). M. kansasii infections have been reported throughout the world and 
immunocompromised individuals are at a higher risk of infection. The 
resemblance of M. kansasii infections to tuberculosis and high incidence of 
occurrence in immunocompromised individuals revealed the importance of 
nontuberculous mycobacteria as important human pathogens (Wolinsky, 1979). 
The most common site of infection is the lungs and symptoms are clinically 
indistinguishable from pulmonary tuberculosis as they are accompanied by similar 
histopathological observations such as tubercles and caseation. The symptoms of 
pulmonary M. kansasii infections include cough, sputum production, chest pain, 
breathlessness, weight loss, fever and sweats. M. kansasii also causes skin 
infections and disseminated disease. Cutaneous infections include formation of 
nodules, pustules, erythematous plaques, abscesses and ulcers.  
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Patients with AIDS/ immunocompromised individuals usually present a 
disseminated infection (Sherer et al., 1986; Selik et al., 1987). Patients with HIV 
infection, who develop M. kansasii infection, can develop M. kansasii meningitis 
similar to M. tuberculosis meningitis, bacteraemia, oral ulcers, chronic sinusitis, 
scalp abscess and disseminated infection. Cutaneous M. kansasii in 
immunocompromised hosts does not show granuloma formation and is sometimes 
the cause for delayed diagnosis.  
M. kansasii has a cell envelope lipid profile similar to that of 
Mycobacterium tuberculosis and Mycobacterium gastri (Ortalo-Magne et al., 
1996). These bacteria have a unique characteristic of expressing variations in 
colony morphology ranging from rough forms to smooth/ glossy forms. These 
variations in physical appearances are attributed to the presence of polar antigenic 
glycolipids on the cell wall of the bacterium. Presence of immunogenic 
glycolipids is central to the cell wall of mycobacteria. Most of these are common 
to the mycobacterial species while some are species specific. Two distinct classes 
of these glycolipid surface antigens have been identified in M. kansasii – phenolic 
glycolipids and the trehalose containing lipooligosaccharides  (Hunter et al., 1983; 
Hunter et al., 1985; Hunter et al., 1984; Belisle and Brennan, 1989). 
Phenolic glycolipids have been reported and extensively characterised in 
slow growing pathogenic mycobacteria such as Mycobacterium leprae, M. 
tuberculosis, M. kansasii, M. tuberculosis strain Canettii, Mycobacterium bovis , 
Mycobacterium marinum, M. gastri, and Mycobacterium ulcerans (Daffé et al., 
1987; Puzo, 1990). PGLs consist of a conserved lipid core with varying 
carbohydrate residues (Minnikin et al., 1982; Chatterjee et al., 1988). The lipid 
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core is made up of long chain -diols (C33-C41) known as phenolpthiocerols. The 
-diols are further esterified to poly-methyl branched fatty acids. The sugar 
moiety of phenolic glycolipid consists of one to four sugar residues, most of 
which are O-methylated deoxysugars. These vary between species. The structure 
of the M. kansasii major phenolic glycolipid differs considerably from the above 
and was reported to be 2,6-dideoxy-4-O-methyl--D-arabino-hexopyranose 
(Gilleron et al., 1990), although similarities have been established with glycolipid 
antigens from M. gastri. Phenolic glycolipids have been reported to have 
immunomodulatory properties (Prasad et al., 1987), for example inhibition of 
inflammatory cytokine release (Reed et al., 2004). It has also been reported that a 
loss of phenolic glycolipids resulted in attenuation of M. bovis in a Guinea pig 
infection model (Collins et al., 2005). 
The trehalose containing lipooligosaccharides (LOSs) have been reported to 
play a role in virulence of M. kansasii. M. kansasii produces seven classes of 
LOSs, LOS-I to LOS-VII. Chemically these antigenic molecules contain a 
tetraglucose core, glycosidically linked to a triacyl trehalose unit. The core is 
common to all the seven classes and is D-Glcp (1→ 3) D-Glcp (1→ 4) D-
Glcp(1→ 1)D-Glcp. In addition to this, the LOSs have a 3-O-methylrhamnose 
residue and varying amounts of xylose. The higher (IV-VII) and more polar LOSs 
are characterized by the presence of fucose and a novel species-specific N-
acylamino sugar {4, 6-dideoxy-2-O-methyl-3C-methyl-4-(2’-
methoxypropionamido) hexopyranose}, now known as N-Acylkanosamine 
(Hunter et al., 1984). The LOSs from M. kansasii are acylated at the 3,4 and 6 
position of the terminal glucose by 2,4-dimethyl tetradecanoic methyl esters. In 
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contrast M. marinum has four classes of LOSs - LOS-I, LOS-II, LOS-III and 
LOS-IV, each containing a common glycan core consisting of four glucose 
residues and one methylated rhamnose (Burguière et al., 2005).They are acylated 
by two different classes of polymethylbranched fatty acids – 2,4 dimethyl 
hexadecanoate and 2,4 dimethyl 2-pentadecenoate.    
Analysis of the rough and smooth strains of M. kansasii showed that the 
phenolic glycolipid profile did not differ between the two but LOS production was 
only observed  in the smooth strains of M. kansasii but not in the rough strains 
(Belisle and Brennan, 1989). This indicated that the variations in colony 
morphology were caused by presence of LOSs in the cell envelope. This variation 
also translated into differences in virulence observed in the rough strains. It has 
been reported that the rough strains were able to develop a systemic infection 
within the infected host while the smooth strains were cleared away (Collins and 
Cunningham, 1981). 
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The LOS biosynthesis gene cluster of M. marinum has been identified in a 
study by Ren et.al. (2007). The aim of this project was to identify the LOS gene 
cluster in M. kansasii. The first step involved analyses of the homologous regions 
between M. marinum and M. kansasii and annotation of the LOS cluster from M. 
kansasii based on protein identities. The next step was to generate strains 
defective in these to further study their effects on LOS biosynthesis. Transposon 
mutagenesis was used for generation of mutant strains in M. kansasii.   
5.2  Materials and methods 
5.2.1  Bacterial strains, phages and growth conditions 
All M. kansasii strains were grown in 7H9 broth supplemented with 10% OADC 
(oleic acid/albumin/dextrose/catalase, BD) and 0.05% Tween 80 at 37°C, (5% 
CO2). Hygromycin B was added at a final concentration of 50g/ml for selection 
of M. kansasii strains where required. Escherichia coli cc118λpir strains were 
used for rescue of the transposon and was  grown in LB broth or on LB agar at 37 
°C, using 150 g/ml hygromycin B where required. 
Mycobacterium smegmatis strain mc
2
155 was used for generation and 
propagation of mycobacteriophages and was routinely grown at 37 °C either in 
Middlebrook 7H9 or Tryptic Soy Broth (TSB) / agar. 
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Table 5.1 Bacterial strains, plasmids and phages used in this study 
 
Strains and phages 
 
Description 
 
Reference 
Bacteria   
E. coli cc118λpir 
 
 
M. smegmatis mc
2
155  
    
 
M. kansasii  
 
 
 
Wild type strain, Ept mutant   of 
M.smegmatis strain mc
2
6 
 
 
Wild type strain 
 
 
(Snapper et al., 
1990) 
Phages  
pHAE181 
 
Conditionally replicating phage 
TM4 derivative carrying Tn-
5371 
 
(Kriakov et al., 
2003) 
 
5.2.2  Transposon mutagenesis 
M. kansasii cultures were grown in 50ml of 7H9+OADC with 0.05% Tween 80 to 
an optical density (OD 600nm) of 0.8. The cells were harvested by centrifugation at 
4500g for 10 minutes and washed twice with 50 ml MP buffer. The cell pellet was 
then gently resuspended in 2 ml MP buffer and mixed with 1 ml of high titre 
phage lysate (10-
8
 to 10
-10
 pfu/ml). Separately, 500 l cells were mixed with 500 
l of MP buffer to serve as control. The cell – phage mix was incubated at 37°C 
overnight (static), the cells were then harvested by centrifugation and resuspended 
in 10 ml 7H9 broth with OADC and 0.05% Tween 80. The transduced M. kansasii 
cells were recovered by overnight incubation at 37°C. Cells were centrifuged and 
resuspended in 1 ml fresh media and plated on 7H10+OADC agar plates (100 l 
per plate) with 50g/ml hygromycin B. Plates were incubated at 37°C (5% CO2) 
for 2 to 3 weeks. 
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5.2.3 Isolation and sequencing of Tn insertion sites 
Transductants obtained were selected on the basis of altered colony morphology. 
Selected mutants were grown in 10ml of 7H9+OADC + 0.05% Tween 80 
+50μg/ml hygromycin B, and genomic DNA was extracted. The genomic DNA 
was then digested with BssHII (NEB) and ligated with T4 ligase (NEB). The 
ligation mix was used to transform E. coli cc118λpir competent cells. To select 
self-ligated genomic DNA fragments containing the transposon, the 
transformation mix was plated on LB-plates with 150μg/ml hygromycin B and 
incubated overnight at 37°C. Colonies obtained were inoculated in LB-broth with 
hygromycin to obtain plasmid DNA. Plasmid DNA isolated from the hygromycin 
resistant transformants was analysed by BssHII digestion and sequenced using the 
primers HOPS1 (5’ GCTTACAATTTAGGTGGCACT 3’) and KMN1 (5’ 
AGTGCCACCTAAATTGTAAGC 3’) to get the sequence flanking the left and 
right of the transposon insertion sites. 
5.3 Results  
5.3.1  Identification of the LOS gene cluster in M. kansasii by alignment 
with M. marinum LOS genes 
M. kansasii produces seven different types of LOSs with unique sugar moieties. 
Hence it was presumed that the M. kansasii LOS cluster would encompass a large 
region in the genome as compared to M. marinum which synthesises only four 
LOSs. As some of the genes would be common between M. kansasii and M. 
marinum, I used the gene sequences from the M. marinum LOS cluster to probe 
the M. kansasii genome in an attempt to identify the M. kansasii LOS cluster. An 
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alignment was produced using the region between MMAR2302 to MMAR2367. 
The genetic region was compared using the gene information and the BLAST 
search tool provided by the following website - 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome&cmd=Retrieve&dopt=Ove
rview&list_uids=6107 and also comparing the translated protein products of the 
genes. The website address has now moved and the information is available on 
http://www.xbase.ac.uk/genome/mycobacterium-kansasii-atcc-12478 (whole 
genome shotgun sequence NZ_ACBV01000002, 200.4KB, 166 CDS). The 
comparison search is presented Table 5.2  
Table 5.2. List of genes of M. kansasii with a homologue in M. marinum LOS cluster. 
M. kansasii gene ID Function 
M. marinum 
homologue 
Function 
MKanA1_010100001025 
cobalmin 
biosynthesis 
no homology 
 
MKanA1_010100001030 Permease no homology 
 
MKanA1_010100001035c hypothetical protein no homology 
 
MKanA1_010100001040 hypothetical protein no homology 
 
MKanA1_010100001045c PE_PGRS no homology 
 
MKanA1_010100001050c PE_PGRS no homology 
 
MKanA1_010100001055c hypothetical protein MMAR2301 
conserved 
membrane protein of 
unknown function 
MKanA1_010100001060 
methylmalonyl-
CoA mutase small 
subunit, MutA 
MMAR2302 
methylmalonyl-
CoA mutase small 
subunit, MutA 
MKanA1_010100001065 
methylmalonyl-
CoA mutase 
MMAR2303 
methylmalonyl-
CoA mutase large 
subunit, MutB 
MKanA1_010100001070 ATPase MMAR2304 
LAO/AO 
transport system kinase 
MKanA1_010100001075 Esterase LipL MMAR2305 
conserved 
hypothetical esterase 
LipL 
MKanA1_010100001080c hypothetical protein MMAR2306 
conserved hypothetical 
protein 
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MKanA1_010100001085c hypothetical protein MMAR2307 
hypothetical trans-
membrane protein 
MKanA1_010100001090c 
hypothetical 
protein (GtrA 
domain) 
MMAR2308 
hypothetical membrane 
protein 
MKanA1_010100001095 dehydrogenase MMAR2309 
UDP- glucose/GDP-
mannose 
dehydrogenase  
MKanA1_010100001100 
UDP glucose 
epimerase 
MMAR2310 
UDP-glucose 4-
epimerase 
MKanA1_010100001105 Glycosyltransferase MMAR2311 Glycosyltransferase 
MKanA1_010100001110 hypothetical protein MMAR2802 
conserved membrane 
protein 
MKanA1_010100001115 hypothetical protein MMAR2307 
hypothetical trans-
membrane protein 
MKanA1_010100001125c 
hypothetical protein 
(Gtr domain) 
MMAR2337 
conserved hypothetical 
membrane protein 
MKanA1_010100001130c hypothetical protein MMAR2924 Methyltransferase 
MKanA1_010100001135 hypothetical protein No homology 
 
MKanA1_010100001140 
Glycosyltransferase
,GT-A type (DPM-
DPG) 
No homology 
 
MKanA1_010100001145c 
NAD-dependent 
epimerase/dehydrat
ase family protein 
No homology 
 
MKanA1_010100001150 
Glycosyltransferase 
(GTA) 
No homology 
 
MKanA1_010100001155 
glucose-1-
phosphate 
cytidylyltransferase 
No homology 
 
MKanA1_010100001160 
NAD-dependent 
epimerase/dehydrat
ase family protein 
No homology 
 
MKanA1_010100001165 
Rhamnose 
epimerase 
No homology 
 
MKanA1_010100001170 methyltransferase No homology 
 
MKanA1_010100001175 
perosamine 
synthetase 
No homology 
 
MKanA1_010100001180 
carbamoyl 
phosphate synthase 
No homology 
 
MKanA1_010100001185 
 
No homology 
 
MKanA1_010100001190 methyltransferase No homology 
 
MKanA1_010100001195 
SAM 
methyltransferase 
MMAR2339 
SAM 
methyltransferase 
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MKanA1_010100001200 Pks5 MMAR2340 Pks5 
MKanA1_010100001205 
acyl CoA 
synthetase 
MMAR2341 FadD25 
MKanA1_010100001210c 
hypothetical 
conserved protein 
No 
homology 
Oxidoreductase 
MKanA1_010100001215 
hypothetical 
conserved protein 
MMAR4618 
hypothetical conserved 
protein 
MKanA1_010100001230 WhiB4 
  
MKanA1_010100001240 
hypothetical 
conserved protein   
MKanA1_010100001250c 
 
MMAR2343 
hypothetical conserved 
protein 
MKanA1_010100001255c Pks5_1 MMAR2344 Pks5_1 
MKanA1_010100001260c 
 
No homology 
 
MKanA1_010100001265 
 
MMAR2345 
hypothetical conserved 
protein 
MKanA1_010100001270c 
hypothetical 
conserved protein 
No homology 
 
MKanA1_010100001275 Dioxygenase MMAR2346 
hypothetical conserved 
protein 
MKanA1_010100001280 
transcription 
regulator   
MKanA1_010100001285 
   
MKanA1_010100001290 
rhamnosyl 
transferase 
MMAR2349 Wbbl2 
MKanA1_010100001295 Glycosyltransferase MMAR2351 Glycosyltransferase 
MKanA1_010100001300c Methylase MMAR2350 
methylase 
/SAM-dependent 
methyltransferase 
MKanA1_010100001305c 
hypothetical 
conserved protein 
MMAR2352 
hypothetical 
conserved protein 
MKanA1_010100001310c 
UDP 
glycosyltransferase 
MMAR2353 
hypothetical 
conserved protein 
MKanA1_010100001315c 
hypothetical 
conserved protein 
MMAR2354 
hypothetical 
conserved protein 
MKanA1_010100001320c PapA3 MMAR2355 
Polyketide 
associated protein 
PapA3 
MKanA1_010100001325c 
hypothetical 
conserved protein,    
MKanA1_010100001330 
isoleucyl t-RNA 
synthase 
MMAR2356 
hypothetical 
conserved protein 
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MKanA1_010100001335 Arylsulfatase MMAR1375 
hypothetical 
conserved protein 
MKanA1_010100001340c 
hypothetical 
conserved protein, 
vls 
MMAR2358 
hypothetical 
conserved protein 
MKanA1_010100001345 
DNA polymerase 
IV 
MMAR2359 
DNA 
polymerase IV, DinP_1 
MKanA1_010100001350 L-Asparginase MMAR2360 L-Asparginase 
MKanA1_010100001355 
lipoprotein signal 
peptidase 
MMAR2361 
lipoprotein 
signal peptidase LspA 
MKanA1_010100001360 
Rlu family 
pseudouridine 
synthase 
No homology 
 
MKanA1_010100001370 
RNA 
polymerase ECF-
subfamily sigma 
factor 
No homology 
 
MKanA1_010100001375c 
putative 
haemoglobin 
No homology 
 
MKanA1_010100001380 
fatty acyl-
CoA reductase 
MMAR2366 
Fatty-acyl-CoA 
reductase 
MKanA1_010100001385 
ketoacyl 
reductase 
MMAR2367 ketoacyl reductase 
 
 The expanse of the LOS gene cluster in M. kansasii is much larger in 
comparison to M. marinum, accounting for the more complex and higher LOSs in 
M. kansasii. The LOS cluster in M. marinum has five glycosyltransferase genes – 
MMAR2311, MMAR2313, MMAR2333, MMAR2349 and MMAR2351. Earlier 
studies have shown that MMAR2313 annotated as LosA is essential for 
biosynthesis of the tetraglucose core as the M. marinum strain defective in 
MMAR2313 was unable to produce LOS-IV. Deletion of MMAR2333 results in a 
strain producing a LOS intermediate LOS-II* and is deficient in production of 
LOS-II to LOS-IV. LOS-II* is essentially the LOS-I molecule with an additional 
xylose residue but lacking the unique caryophyllose sugar present in higher LOSs 
(Chapter 2). A disruption in MMAR2351 did not alter LOS biosynthesis and the 
strain was efficient in producing all the four LOSs, as detailed in Chapter 4. The 
LOS gene cluster in M. kansasii extends from MKanA1_010100001060 to 
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MKanA1_010100001330 based on the homology with M. marinum genes as 
shown in Table 5.2. Various genes encoding glycosyltransferases were identified 
in the M. kansasii gene locus homologous to M. marinum. Some of these genes 
were unique to M. kansasii and did not posess any conserved domain. The 
identities of these genes with other M. marinum genes were ≤65%.   
5.3.1.1 Glycosyltransferases (GTFs) – 
The LOS gene locus of M. kansasii contains many more GTFs compared to M. 
marinum, which also explains the different sugars in M. kansasii LOSs. The genes 
MKanA1_010100001085c and MKanA1_010100001090c share ≥81% identity to 
the M. marinum genes MMAR2307 and MMAR2308. The gene 
MKanA1_010100001085c encodes a hypothetical protein and no conserved 
domains were detected. Loss of MMAR2307 generated a strain with an inability in 
the production of the LOSs II to IV in M. marinum. The gene downstream of this, 
MKanA1_010100001090c possesses a GtrA domain and is unique to M. kansasii. 
These enzymes are thought to be involved in the translocation of an undecaprenyl 
phosphate linked sugar across the cytoplasmic membrane. The next GTF 
identified is MKanA1_010100001105 (86% identities with MMAR2311, type 2 
GTF). It posesss a DPM-DPG synthase domain and a S-adenosyl methionine 
dependant transferase domain. The gene MKanA1_010100001125c has a 
glycosyltransferase GtrA type domain and shares 83% identitity to MMAR2337 
(hypothetical protein with no conserved domains). The role of MMAR2337 is not 
yet known in LOS biosynthesis, but strains of M. marinum with loss of 
MMAR2333 or a disruption in MMAR2336 resulted in an inability to synthesise 
LOS-II to LOS-IV (Chapter 2 & 4).  
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The region between MKanA1_010100001140 and 
MKanA1_010100001190 show no matches with the M.marinum genome.  
Analysis of the protein sequences reveal presence of unique M. kansasii specific 
GTFs and methyltransfearses. The closest matches on a BLAST search with 
MKanA1_010100001140 are the plant pathogens Clavibacter michiganensis sp. 
michiganensis and sp. sependonicus. A characteristic GT-2 structural fold is 
detected with bacterial dolichol phosphate mannose (DPM)-like domains. 
Eukaryotic DPM synthases are members of the GTF-2 super family that catalyse 
the transfer of nucleotide sugars to dolichol phosphate.  In bacteria, homologues 
of DPM synthases use polyprenol phosphate, rather than dolichol phosphate. 
MKanA1_010100001150c and MKanA1_010100001155 encode a type-2 GTF 
with a bacterial DPM1-DPG synthase domain and a glucose-1-phosphate 
cytidyltransferase domain, respectively. The bacterial dolichol-phosphate 
glucosyltransferase (DPG) is involved in the transfer of the glucose from a UDP-
glucose to a polyprenol carrier. The nucleotide transferase enzymes transfer 
nucleotides onto phosphosugars. In M. marinum a caryophyllose sugar is present 
in LOS-II to LOS-IV and a type-2 GTF with a bacterial DPM1-DPG synthase 
domain MMAR2333 is likely involved in the transfer of the caryophyllose to a 
polyprenol carrier and by actions of other GTFs the sugar is added to the growing 
LOS chain (Sarkar et al., 2011). The protein product of MKanA1_010100001290 
is a rhamnosyltransferase which shares 89% identity to a type-2 GTF in M. 
marinum MMAR2349 (Wbbl2). MKanA1_010100001295 encodes a GTA type 
glycosyltransferase and the amino acid sequence has a significant match to a GTF 
in M. marinum, MMAR2351. Disruption of MMAR2351 did not affect LOS 
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biosynthesis in M. marinum (Chapter 4). MKanA1_010100001310c encodes a 
UDP-glycosyltransferase and the protein shares 83% identity to MMAR2353. A 
disruption in MMAR2353 did not seem to affect LOS biosynthesis as shown in 
Chapter 4. 
5.3.1.2 Other classes of enzymes  
MKanA1_010100001160 encodes a NAD-dependant epimerase/dehydratase. It 
shares 44% amino acid identity with the M. marinum MMAR2336 which encodes 
a UDP-glucose 4-epimerase and both the enzymes possess conserved NAD 
binding motifs. This family of proteins use NAD as a cofactor and catalyse 
various reactions using a nucleotide sugar substrate. Disruption in MMAR2336 
resulted in a mutant strain which failed to produce LOS-II to LOS-IV and 
accumulated an intermediate similar to LOS-II* (Chapter 4), which lacked the 
nucleotide sugar caryophyllose. MKanA1_010100001170 encodes a 
methyltransferase and the protein posess methyltransferase motifs at both N and C 
terminus. MKanA1_010100001175 encodes a perosamine which belongs to the 
WecE superfamily (3-amino, 5-hydroxy benzoic acid synthase / aspartate amino 
transferase family). These enzymes are pyridoxal phosphate dependant and are 
predicted to be involved in cell wall biosynthesis. A sugar transaminase present in 
the LOS cluster in M. marinum, MMAR2320 (WecE) was shown to be involved in 
the partial biosynthesis of the N-acylated dideoxy galactose found in LOS-IV of 
M. marinum (Rombouts et al., 2010). The higher LOSs in M. kansasii has a 
unique N-acyl-kanosamine (N-acyl propionamido hexose sugar) and the gene 
product MKanA1_010100001175 maybe unique to M. kansasii and involved in 
biosynthesis of the N-acyl kanosamine.  MKanA1_010100001195 encodes a S-
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adenosyl methionine dependant methyltransferase and shares 83% amino acid 
sequence identity with the M. marinum LOS cluster methyltransferase 
MMAR2339.  The genes between MKanA1_010100001205 and 
MKanA1_010100001250 are annotated as conserved hypothetical proteins and 
maybe unique to M. kansasii. Amongst this region, MKanA1_010100001245c    
encodes a transport family protein mmpl (mycobacterium membrane protein, 
large) which is identical to MMAR2342 (MmpL). These are large proteins 
involved in transport of various classes of molecules and further characterization 
is required to decipher if the protein is possibly involved in transport of the LOSs 
across the cell membrane.  
 
5.3.1.2.1 Polyketide synthases (Pks) and Pks associated genes 
MKanA1_010100001200 encodes polyketide synthase 5 and has considerable 
identity to the Pks5 from M. marinum MMAR2340. Loss of MMAR2340 resulted 
in a strain deficient in production of all the LOSs in M. marinum. The terminal 
glucose in the LOS is acylated. It is predicted that the Pks5 genes are involved in 
acylating the glucose core in LOSs. Two copies of Pks5 are present in both M. 
marinum and M. kansasii. MKanA1_010100001255c encodes the other Pks5 gene 
in M. kansasii, known as Pks5_1.  MKanA1_010100001205 encodes an acyl-CoA 
synthetase which is similar to MMAR2341 (FadD25). The protein product of 
MKanA1_010100001320c is a polyketide associated protein PapA3. M. kansasii 
PapA3 shares 90% identitiy to PapA3 from M. marinum and posesses a 
phosphopantetheine binding motif and is predicted to be involved in catalysing 
condensation reactions. Disruption in PapA3 (MMAR2355) resulted in a strain 
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lacking all the four LOSs in M. marinum. The conserved domains in this protein 
and phenotype predict that PapA3 is involved in condensing the fatty acyl chains 
generated by the Pks5. 
5.3.2 Generation of Tn-mutants in M. kansasii using phAE181 
A mariner-based transposon Tn5371 was used to generate a transposon library of 
M. kansasii using the recombinant phage phAE181 (Kriakov et al., 2003) and the 
data included in this chapter describe the isolation and identification of M. 
kansasii Tn-mutants with altered colony morphology. phAE181 has not been 
reported to be used earlier with M. kansasii, hence prior to transduction it was 
tested for ability to form plaques on a M. kansasii lawn (Figure 5.2)  
 
 
Figure 5.2. Plaque formation on a lawn of M. kansasii and M. smegmatis. A) 10l 
spot of phAE181 on overaly of M. kansasii on 7H10 + OADC soft agar, incubated at 
30°C for 5 days. B) 10l spot of phAE181 on overaly of M. smegmatis on overlay of 
7H10 + OADC soft agar, incubated at 30°C for 5 days. 
5.3.3  Isolation of M. kansasii Tn-mutants with altered colony morphology 
Variations in colony morphology of mycobacteria have been reported from very 
early literature (Steenken, 1950). Variations reported were usually smooth and 
rough colony morphology and have been associated with immunospecificity 
(Petroff and Steenken, 1930). Changes in LOS patterns in M. marinum often led 
to altered colony morphology (Chapter 2). M. kansasii strains showed distinct 
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variations in colony morphology (Fregnan and Smith, 1962) and the variations 
were attributed to the presence and absence of LOSs (Belisle and Brennan, 1989). 
This basis of variation was used to distinguish between hyg-resistant M. kansasii 
transductants obtained from the transposon mutagenesis. From the library of ~700 
Tn-mutants, 196 colonies were selected by visual determination of rough /smooth 
phenotype. These were inoculated into 96-well culture plates in 7H9 complete 
media with Hygromycin B and grown till mid-log phase. In order to view single 
colony morphology, the cultures of the bacterial strains were then used to generate 
serial dilutions of upto10
-8
. The neat culture and the dilutions were spotted 7H10 
agar and 7H10-T (0.05% Tween 80) agar plates. The plates were incubated for 2 
weeks at 37°C (5% CO2) and isolated single colonies were studied under a 
binocular microscope.  The same was done for the wild type strain. Some mutants 
showed altered colony morphology as compared to the wild type strain. Also 
under the same growth conditions and equal volume of inoculum, some had 
slower growth and smaller colonies whilst few had larger colonies as compared to 
the wild type strain. 
 
  
 
 
 
 
 
Figure 5.3. Colony morphology of M. kansasii wild type. 10μl spot of a mid-log phase 
culture and single colony. 7H10Tw; 7H10 agar containing 0.05% Tween 80. 
Chapter 5                                                                       LOS Tn-mutants in M. marinum 
 
164 
 
Chapter 5                                                                                  LOS biosynthesis in M. kansasii 
                           
165 
 
 
 
F
ig
u
re
 5
.4
. 
C
o
lo
n
y
 m
o
rp
h
o
lo
g
y
 o
f 
M
. 
k
a
n
sa
si
i 
T
n
-m
u
ta
n
t 
st
ra
in
s.
 A
) 
a
n
d
 C
) 
1
0
μ
l 
sp
o
t 
o
f 
a
 m
id
-l
o
g
 p
h
a
se
 c
u
lt
u
re
; 
 B
) 
a
n
d
 D
) 
S
in
g
le
 c
o
lo
n
y
 o
f 
ea
ch
 T
n
-m
u
ta
n
t.
 7
H
1
0
T
w
 -
 7
H
1
0
 a
g
a
r 
co
n
ta
in
in
g
 0
.0
5
%
 T
w
ee
n
 8
0
. 
S
ca
le
 b
a
r 
re
p
re
se
n
ts
 1
m
m
. 
S
in
g
le
 c
o
lo
n
y
 i
m
a
g
e 
o
f 
m
u
ta
n
t 
st
ra
in
 H
2
 w
a
s 
n
o
t 
a
v
a
il
a
b
le
. 
 
Chapter 5                                                                                  LOS biosynthesis in M. kansasii 
                           
166 
 
5.3.4   Isolation of transposon insertion sites and identification of disrupted genes in M. 
kansasii mutants with altered colony morphology. 
The restriction enzyme BssHII has no recognition sites in the transposon Tn-5371. This 
enzyme is hence used for digesting genomic DNA obtained from the Tn-mutant. When a 
fragment spanning the Tn-disrupted DNA circularizes by ligation, it can replicate as a plasmid 
as Tn-5371 has a R6K ori. The transposon insertion sites were rescued in E. coli cc118 pir in 
this way. The isolated plasmids were then sequenced using primers KMN1 5' 
AGTGCCACCTAAATTGTAAGC 3' and HOPS1 5' GCTTACAATTTAGGTGGCACT 3'. 
The sequence obtained was used as query for a BLAST (Altschul et al., 1990) search on the 
Xbase genome database http://www.xbase.ac.uk/mycodb/blast. 
The Table 5.3 shows the list of genes disrupted in the Tn-mutants isolated from the 
colony morphology screen. The aim of this research project was to generate mutants in the 
LOS biosynthesis pathway. Surprisingly, only one of the mutants isolated in this screen has a 
gene disruption in an ORF in the putative LOS cluster. The mutant strain F1 showed a 
disruption in the M. kansasii gene MKanA1_010100001215 which falls in the gene cluster 
homologous to the M. marinum LOS cluster. This mutant was further analysed to detect 
changes in LOS profiles. 
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Table 5.3 Genes disrupted by Transposon insertion in M. kansasii mutants  
Muta
nt no 
Gene no Gene name Function 
Homologue in 
M. marinum 
A3 MKanA1_010100012848 
hypothetical 
protein 
4-hydroxybenzoate 
3-monoxygenase 
MMAR4271 
A8 MKanA1_010100011352 
Acyl-CoA 
synthetase 
involved in fatty 
acid biosynthesis 
MMAR4476 
(pks16) 
C2 MKanA1_010100001510 
putative 
transmembrane 
protein 
unknown function MMAR2388 
C4 MKanA1_010100024653 
hypothetical 
protein 
translation 
incomplete on 
carboxyl end 
MMAR0482 
B4 MKanA1_010100025520 
hypothetical 
protein 
zinc peptidase like 
superfamily 
MMAR3123 
B9 MKanA1_010100011087 
hypothetical 
protein 
Acyl-ACP 
thioesterase , 
involved in lipid 
metabolism 
MMAR0791 
D12 MKanA1_010100011032 
putative 
peptidase 
amino acid 
transport and 
metabolism 
MMAR0779 
(peptidase) 
F1 MKanA1_010100001215 
hypothetical 
protein 
unknown function MMAR4618 
G4 MKanA1_010100003997 
integral 
membrane 
acyltransferase 
cellular metabolism MMAR0477 
H2 MKanA1_010100019271 
PPE family 
protein 
unknown function MMAR1849 
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5.3.5  LOS profile analysis of selected M. kansasii F1-mutant  
M. kansasii F1::hyg had a transposon insertion in the gene MKanA1_010100001215, which 
encodes a protein with no conserved domains. Bioinformatics analysis shows that the protein 
product shares 55% identity with M. marinum protein MMAR4618. MKanA1_010100001215 
lies downstream to the Pks5 ORF and also falls in the gene cluster homologous to the M. 
marinum LOS gene cluster as shown in Table 5.2. Since the M. kansasii LOS gene cluster 
involves more genes as compared to M. marinum and presence of mor LOS types in this 
strain, the mutant strain M. kansasii F1::hyg was selected for further biochemical analysis of 
the cell wall polar lipids to study the effect of deletion of MKanA1_010100001215 .  
Cultures of the wild type and mutant strains were grown upto an O.D. of 0.6 and 
pulsed with [
14
C]-acetate to label lipids. Polar and apolar lipids were extracted and analysed 
by 2D-TLC as described by Dobson et al. (1985).  This study was primarily focussed on 
detecting any alteration in the LOS profiles, hence the polar lipids were analysed using solvent 
system E- chloroform / methanol / water : 60/30/6 (v/v) in direction 1 and chloroform / acetic 
acid/ methanol / water : 40/25/3/6 (v/v) in direction 2. 
There were no detectable changes in the LOS profile between the wild type and mutant 
strain. The following figure shows the LOS pattern in the wild type strain and the mutant F1 
(Figure 5.5). 
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Figure 5.5. 2D-TLC autoradiograph showing labelled polar lipids from M. kansasii wild type and 
M. kansasii F1::hyg grown in Middlebrook 7H9 broth. Direction 1- chloroform: methanol: 
water, 60:40:6 (v/v/v), direction 2- chloroform: acetic acid: methanol: water, 40:25:3:6 (v/v/v/v). 
M. kansasii F1::hyg does not differ in LOS production as compared to the wildtype. 
  
5.4  Discussion  
Mycobacteria are characterised by the presence of species or type specific glycolipid antigens. 
M. kansasii is an opportunistic pathogen causing tuberculosis - like disease in humans. The 
cell wall of M. kansasii has been reported to be varied in terms of smooth and rough types. 
The smooth and rough morphologies have been reported to govern infection establishment in 
murine models (Collins and Cunningham, 1981). Later, it was shown that the smooth and 
rough forms are due to the presence or absence of the highly polar immunogenic LOS (Belisle 
and Brennan, 1989).  
Based on the amount of sugar residues in the LOSs of M. kansasii, the involvement of 
many glycosyltransferases is predicted in their biosynthesis. M. marinum LOS biosynthesis 
Chapter 5                                                                                  LOS biosynthesis in M. kansasii 
                           
170 
 
cluster has five glycosyltransferases (GTFs). In comparison, the LOS cluster (from in-silico 
analysis of the genome based on amino acid identity search) reveals the presence of nine GTFs 
in M. kansasii. Out of these five GTFs are unique to M. kansasii and the four others share high 
identity with GTFs in the M. marinum LOSs gene cluster. This relates to the diversity of the 
glucose core in M. kansasii LOSs.  
 The aim to this project was to identify the LOS gene cluster by bioinformatics analysis 
and alignment of M. kansasii genes with M. marinum genes. Due to unavailability of complete 
sequence information, generation of targeted knockouts in this species was a hindrance. We 
used mycobacteriophage mediated transposon mutagenesis for generation of mutants in M. 
kansasii. The transposon mutants were further screened based on their colony morphology and 
were sequenced. Unfortunately, this study failed to detect any mutant defective in the LOS 
biosynthesis cluster. A large library of mutants was generated but due to time constraints in 
this thesis project, the work could not be carried any further. Future plans would involve 
screening of the remaining transposon mutants and also generation of targeted knockout 
strains (using specialised transduction) of the GTFs in M. kansasii and studying the effects of 
loss of these genes on the LOS profiles. Availability of the complete genome information of 
M. kansasii will accelerate this process. 
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6.1 Introduction 
    Mycolic acids constitute a major group of cell wall lipids and are one of the defining 
features of M. tuberculosis. They are a vital component of the cell wall and essential to the 
survival of the organism. They also play a critical role in virulence (Glickman et al., 2000; 
Dubnau et al., 2000). These long chain -alkyl--hydroxy fatty acids are comprised of 60 – 90 
carbons and consist of a meromycolic acid chain (upto C56; which varies between types of 
mycolates and the species they originate from), and a saturated - branch consisting of 24 – 26 
carbons (Brennan and Nikaido, 1995). Mycolic acids are found in various families of the 
suborder Corynebacterineae, chiefly in Mycobacteriaceae, Corynebacteriaceae, 
Nocardiaceae and Gordoniaceae families which are closely related. The mycolic acids of the 
pathogenic mycobacteria differ from those of other related genera such as Corynebacterium, 
and Nocardia in that they are the longest (C70 to C90) (Watanabe et al., 2001; Watanabe et al., 
2002). Mycolic acids confer unique properties to mycobacteria, such as unusually low 
permeability and consequent resistance to common antibiotics (Glickman et al., 2001; Bhatt et 
al., 2007b; Daffé and Draper, 1998). As most genes involved in the mycolic acid biosynthesis 
are essential, pathways involved in mycolate biosynthesis can be exploited as potential drug 
targets. Existing front-line anti-tubercular drugs, such as INH and ethionamide, owe their 
therapeutic properties to the inhibition of enzymatic components of the mycolic acid 
biosynthesis pathway. Research in the past two decades has successfully deciphered the 
biosynthetic pathway for mycolic acids. However, the processing and transport of mycolic 
acids are not yet clearly understood. A review by Takayama et al. (2005) gave an insight into 
the possible pathways in which the mycolic acid processing and transport may take place. 
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These hypothesized pathways were based on findings from a mix of bioinformatics analysis 
and experimental data.  
 Mycobacteria contain two fatty acid synthases (FAS) systems - FAS-I and FAS-II. 
FAS-I is a multidomain peptide found both in eukaryotes and prokaryotes; mycobacterial 
FAS-I works in a bimodal fashion, catalysing the  formation of ‘housekeeping’ fatty acids 
(C18) as well as the -branch of mycolic acids (Bloch and Vance, 1977) thus contributing to 
(Zimhony et al., 2004). FAS-II on the other hand is a multienzyme complex similar to fatty 
acid synthases from other prokaryotes and plants, and consists of four discrete enzymatic 
components (Figure 6.1). 
6.1.1 Role of FAS-I and FAS-II in mycolic acid biosynthesis 
FAS-I catalyses de novo fatty acid biosynthesis using acetyl-CoA and malonyl-CoA primers. 
After transacylation of these substrates to the enzyme, elongation takes place by condensation 
of the two starter units to generate a -ketobutryl-S-Enzyme (covalently linked to the FAS-I 
enzymes via a thioester linkage). This intermediate product undergoes -ketoacyl reduction, 
dehydration and enoyl-reduction to give rise to a butryl-S-enzyme product. Continuous 
elongation of the C4-S-enzyme product fatty acids produces long-chain fatty acids. The C16 
and C18 fatty acids are used to the synthesis of membrane phospholipids and the C20 and C26-
CoA products are fed to the FAS-II cycle (Takayama et al., 2005).  
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Figure 6.1. Mycolic acid biosynthesis in M.tuberculosis adapted from Bhowruth et al. (2008). 
Malonyl-AcpM is generated from malonyl-CoA by mtFabD, which is then ligated to FAS-I 
synthesized C14-CoA by mtFabH. The product of this is a C16 acyl-AcpM which is further 
processed by the FASII to generate meromycolates (C56). These meromycolates are ligated to the 
C26 fatty acids synthesized by the FAS-I to form the -branch of mycolic acids. The final step is 
catalyzed by Pks13 which involves condensation of the meromycolates to the the -branch to 
produce mycolic acids. 
 
FAS-II is only able to elongate CoA derivatives of long chain fatty acids generated by 
the FAS-I cycle and employs an acyl carrier protein (ACP, termed AcpM in M. tuberculosis) 
to shuttle the substrates between each enzyme component (Kremer et al. 2001). The initial 
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elongation reaction requires the substrate malonyl-AcpM. This is generated by the 
transacylation reaction of holo-ACP with malonyl-CoA and is catalysed by the enzyme 
mtFabD (malonyl-CoA: ACP transacylase) (Kremer et al., 2001). The acyl-CoA primer from 
FAS-I is then condensed with malonyl-AcpM by the enzyme mtFabH (-ketoacyl ACP 
synthase) and is channelled into the FAS-II system. Within the FAS-II cycle, the acyl-AcpM 
undergoes keto-reduction by MabA (FabG1) (Marrakchi et al., 2002), dehydration by a -
hydroxyacyl-AcpM dehydratase and enoyl-reduction by an enoyl-AcpM-reductase, InhA 
(Quemard et al., 1995; Bhatt et al., 2007b). The product, a fatty acyl-AcpM with two more 
carbons added, is repeatedly fed back into the cycle to elongate the chain upto 56 carbons.  
During this chain elongation process, mtFabH activity is replaced by the -ketoacyl AcpM 
synthases KasA and KasB which catalyses the subsequent acyl extension steps (Bhatt et al., 
2007a;Bhatt et al., 2005; Slayden and Barry, 2002; Schaeffer et al., 2001). MtFabH is the 
initiator of mycolic acid elongation and structural studies reveal that it possesses the catalytic 
triad (Cys
112
, His
224
 and Asn
274
) which is conserved amongst -ketoacyl ACP synthase III. 
Recombinant mtFabH also showed sective preference for acyl-CoA as a substrate than acyl-
ACP primers (Choi et al., 2000). 
The penultimate step in the synthesis of mycolic acids is the Claisen-type condensation 
reaction catalysed by Pks13 (Rv3800), a polyketide synthase which links the -branch from 
FAS-I (C20 -26 acyl- CoA) with the meromycolate chain (C56 acyl-AcpM) from FAS-II to 
generate a -alkyl, -keto acid, reduction of which yields an oxo-mycolic acid product 
(Portevin et al., 2004), which is subsequently reduced by a reductase, Rv2509 (Lea-Smith et 
al., 2007; Bhatt et al., 2008) to yield a mature mycolic acid.  
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Pks13 is an essential gene in mycobacteria and is very attractive as a drug target. A C. 
glutamicum pks-13 deletion mutant strain was unable to synthesize corynomycolics acids and 
produced fatty acid precursors (Gande et al., 2004). The meromycolyl-S-AcpM derived from 
the the FAS-II is converted to meromycolyl-AMP by a specific fatty acid AMP-ligase FadD32 
(Trivedi et al., 2004). The C26-S-CoA generated by FAS-I is carboxylated by the actions of 
acyl-CoA carboxylases, AccD4 and AccD5 to produce 2-carboxyl- C26-S-CoA. These two 
products are substrates for the condensation reaction catalysed by pks13 to yield the -keto 
ester. This is then converted to a mature mycolate by the action of a reductase, proposed to be 
Rv2509.The majority of the mycolates are then esterified to arabinogalactan of the PG-AG 
layer, and some end up in the cell wall as  trehalose monomycolate (TMM), trehalose 6.6’-
dimycolate (TDM) and glucose monomycolate (GMM) (Minnikin et al., 2002). These 
mycolate derivates are thought to intercalate with the mycolates attached to the PG-AG layer.  
 
6.1.2 Processing and transport of mycolic acids  
Mycolic acid biosynthesis is well established but pathways undelying the processing of newly 
synthesized mycolic acids remain unknown. The mycolyltransferases activity of the Ag85 
complex (Belisle et al., 1997; Puech et al., 2002) and role of Myc-PL as a carrier bound 
intracellular intermediate (Besra et al., 1994) remain the only known components of these 
pathways. Based on experimental and in silico analysis, Takayama et al. (2005), proposed a 
series of reactions that could occur after the newly synthesised mycolic acid  is released from 
Pks13.These reactions are hypothesised to occur partly inside the cell and are completed 
outside the cell (Figure 6.2). The enzymes proposed to be involved in this pathway are 
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mycolyltransferase-I and mycolyltransferase-II. Takayama et al., (2005) reported the presence 
of 2 classes of mycolyltransferases in mycobacteria – a cytoplasmic mycolyltransferase I and 
membrane associated mycolyltransferase II. 
 
 
 
 
 
 
 
 
Figure 6.2. Schematic representation of processing of newly synthesized mycolic acids in M. 
tuberculosis (Takayama et al., 2005). Enzymes involved: 1 - mycolyltransferase I, 2-
mycolyltransferase II, 3 - TMM-P-phosphatase, 4 - TMM transporter, 5 and 6 - FbpA, FbpB and 
FbpC. 
 
Mycolic acids from mycolyl-S-Pks13 are transferred to D-mannopyranosyl-1-
phosphoheptaprenol (MPH) by a cytoplasmic mycolyltransferase-I, to produce MycPL. 
MycPL then migrates to the inner surface of the cell membrane is proposed to dock next to an 
ABC transporter. Inside the ABC transporter the mycolyl group is transferred to trehalose 6-
phosphate by mycolyltransferase-II which results in a TMM phosphate. The phosphate group 
is removed by trehalose 6-phosphate phosphatase and TMM is transported outside the cell by 
the ABC transporter (Takayama et al., 2005). After transport, TMM is then used as a substarte 
for mycolate transfer to the AG and to transferred to the arabinogalactan and to form TDMs by 
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the antigen-85 complex to produce arabinogalactan-mycolate and trehalose dimycolate, 
respectively (Takayama et al., 2005; Sathyamoorthy and Takayama, 1987). 
The final stages in the formation of the mycobacterial cell wall involve transport and 
attachment of the mycolic acids to the peptidoglycan-arabinogalactan and formation of the 
TDM. Trehalose is a disaccharide formed by a -1,1-glucosidic linkage of two -glucose 
units. The fibronectin binding proteins of the antigen-85 complex, Ag85A, Ag85B and Ag85C 
(known as FbpA, FbpB and FbpC respectively) are thought to be involved in this last step of 
cell wall assembly (Kremer et al., 2002).   These are major secretory proteins of M. 
tuberculosis and posess high affinity towards fibronectin, hence abbreviated fibronectin 
binding protein (Fbp) - FbpA (Rv3804c), FbpB (Rv1886c) and FbpC (Rv0129c). These 
proteins have a signal peptide at the N-terminus and a carboxylesterase at the C -terminus and 
have been shown to possess mycolyltransferases activities in vitro. They catalyze the transfer 
of mycolyl residues from ’- trehalose monomycolate to another resulting in ’ trehalose 
dimycolate (Belisle et al., 1997). 
It is quite likely that the mycolyltransferases might have an activity similar to the 
esterase activity of Ag85 on TMM. Based on the presence of the catalytic triad of serine, 
histidine and glutamic acid, esterase D domain, protein sequence identities to Ag85 and 
homology across many mycobacterial genomes, the involvement of Rv3802c 
(mycolyltransferase-I) and Rv1288, Rv0519c, Rv0774c (mycolyltransferases-II) as potential 
candidates for mycolyltransferases in mycolic acid processing was predicted (Takayama et al., 
2005). Rv3802c is located in the gene cluster responsible for mycolic acid biosynthesis, 
upstream of fadD32 (Rv3801) and pks13 (Rv3800), encodes a phospholipase/thioesterase 
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(Parker et al., 2009) and is an essential protein (Sassetti and Rubin, 2003; Meniche et al., 
2009) . However, these studies did not show the in vivo role of Rv3802c in Mycobacterium. 
This study focussed on the potential role of Rv1288 and Rv0519c as the mycolyltransferases-II 
gene and investigate their roles and essentiality in survival of the bacterium.  
Rv1288 encodes a 456 amino acid protein and shares ~26% sequence homology and 
~41% identity at amino acid levels with the FbpA of the Ag85 complex. The protein is 
characterized by the presence of 3 LysM (lysine domains) motifs at the N-terminus. LysM 
domains were identified in cell wall degrading enzymes and also have been shown to mediate 
peptidoglycan binding (Birkeland, 1994). The C-terminal amino acids match to an esterase D 
family protein. This family of proteins includes Ag85 mycolyltransferases from C. 
glutamicum. Further the active site residues forming the catalytic triad –serine, histidine and 
glutamic acid are conserved in this protein.  
Rv0519c encodes a conserved membrane protein and shares ~29% sequence homology 
and ~48% amino acid identity to Rv1288. It encodes a 300 amino acid membrane protein and 
also possesses the active site catalytic triad of serine, histidine and glutamic acid. Both Rv1288 
and Rv0519c have homologous genes in Mycobacterium bovis, Mycobacterium smegmatis, 
Mycobacterium marinum, Mycobacterium leprae and Mycobacterium avium.  
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Figure 6.3. Multiple sequence alignment of the M.  tuberculosis Fbp antigens with Rv1288 and its 
orthologue in M. smegmatis MSMEG3437. Numbers indicate the amino acid co-ordinates of 
MSMEG3437. Dots indicate gaps. Red boxes with white letters indicate identical amino acid 
sequences at the aligned position for all three proteins. White boxes indicate similar or identical 
residues for two of the three proteins at the aligned position; the bold sequence letters in these 
boxes indicate identical or similar residues at the aligned position. 
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Figure 6.4. Multiple sequence alignment of the M. tuberculosis Fbp antigens with Rv0519c and its 
orthologue in M. smegmatis MSMEG5851. Numbers indicate the amino acid co-ordinates of 
MSMEG5851. Dots indicate gaps. Red boxes with white letters indicate identical amino acid 
sequences at the aligned position for all three proteins. White boxes indicate similar or identical 
residues for two of the three proteins at the aligned position; the bold sequence letters in these 
boxes indicate identical or similar residues at the aligned position. 
 
Transport of mycolic acids and attachment to the cell wall remains unclear to date. 
Takayama et al.(2005),  proposed a hypothetical pathway involving the transfer of a mature 
mycolate to an isoprenoid carrier to form Myc-PL and consequent transfer to a trehalose to 
generate trehalose monomycolate. There are two different hypotheses post this event – the 
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TMM is transported outside the cell by an unknown mechanism followed by which it is used 
as a substrate by the mycolyltransferases enzymes of the Ag85 complex (Belisle et al., 1997; 
Puech et al., 2002) to transfer the mycolate residue to another TMM to form TDM or to the 
arabino-galactan to form the mAG-complex. The other theory suggests intracellular synthesis 
of TMM and flipping of Myc-PL to the outside for use as a substrate for extracellular TDM 
generation.   
The genome of M. tuberculosis has thirteen genes encoding a family of RND proteins 
(resistance, nodulation and cell division) proteins, (Cole et al., 1998; Domenech et al., 2005). 
These are a family of multidrug resistance pumps and mediate transport of various drugs, dyes 
and fatty acids across the cytoplasmic membrane and have been reportedly present in all 
kingdoms of life. However none of the thirteen MmpLs M. tuberculosis, MmpL1 – MmpL12, 
unlike their functions in other organisms have been reported in drug transport and resistance.  
Instead in mycobacteria, these proteins are predicted to have a role in transport of complex cell 
wall lipids and are known as MmpL (Mycobacterial membrane proteins Large). MmpLs are 
large proteins and are proposed to serve as a scaffold for localized synthesis of cell wall lipids, 
pairing with an ABC transporter (Sonden et al., 2005) or an MmpS protein (Deshayes et al., 
2010). MmpL8 has been shown to be involved in the synthesis of sulfolipid-I by transporting 
an intermediate of the molecule to extracytoplasmic enzymes (Converse et al., 2003; 
Domenech et al., 2004). Thus, if mycolates were transported as sugar-bound substrates the 
involvement of an MmpL protein in the translocation of a bound mycolate molecule outside 
the cell is possible. The mycolate-moiety transported outside maybe then used as a substrate 
for mycolylation of the cell wall.  
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Many of the MmpL genes occur in the same gene cluster involved in biosynthesis of the 
polyketide synthase genes, cell wall associated glycolipids like lipoologosaccharides, 
sulfolipids, glycopeptidolipids and complex lipids like phthiocerol dimycocerosate which 
indicate their involvement in the transport of complex lipids in M. tuberculosis (Domenech et 
al., 2004; Domenech et al., 2005; Cole et al., 1998; Converse et al., 2003; Sonden et al., 2005; 
Rombouts et al., 2011; Cox et al., 1999). Insertion mutations in MmpL7, involved in the final 
stages of biosynthesis of pthiocerol dimycolates (Jain and Cox, 2005), revealed the strains had 
impaired growth patterns and lethality. While a M. tuberculosis strains with mutation in 
MmpL8, which transports a sulfolipid precursor, and a MmpL11, reported to be involved in 
the transport of an unknown substrate was able to establish infection  but interestingly was 
attenuated in virulence in ‘time to death’ studies in murine models (Domenech et al., 2005).  
The genes MmpL3 and MmpL11 are closely related and occur in the gene cluster 
involved in mycolic acid transport. Further there is a synteny between the two genes across all 
mycobacterial species (Figure 6.5). Mycolic acids are essential for the survival of 
mycobacteria (Bhatt et al., 2005; Portevin et al., 2004; Vilcheze et al., 2000).  The synteny 
between mmpL3 and mmpL11 is conserved across all mycobacterial genomes. M. leprae, 
possess a minimal genome but makes mycolic acids. Hence it is an useful model to find out 
genes involved in mycolic acid biosynthesis. The synteny between the mmpL3 and mmpL11 is 
also also observed in the genome of M. leprae which has homologues of five M. tuberculosis 
MmpL genes which include MmpL 3 and MmpL11. Thus it was likely that these two genes 
are involved in mycolic acid transport in M. tuberculosis. MmpL3 has been shown to be 
essential while MmpL11 has been shown to be involved in virulence. Due to MmpL 3 being 
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essential and time constraints in generation of a conditional mutant, this study proceeded with 
characterisation of MmpL11.  
 
 
Figure 6.5 Genomic region comparison around MmpL11 and MmpL3 in A) M. tuberculosis 
H37Rv, B) M. bovis, C) M. avium, D) M. marinum, E) M. leprae and F) M. smegmatis , showing 
synteny between the two genes across all mycobacterial species. 
 
The primary aim of this project was to understand mycolic acid processing and transport 
pathways in mycobacteria. Based on the report by Takayama et al. (2005), mycolyltransferase 
Rv1288 and Rv0519c were selected as candidates to study their possible role in mycolic acid 
A) 
B) 
C) 
D) 
E) 
F) 
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processing. In this study we investigated the roles of the Mycobacterium smegmatis genes 
MSMEG3437 and MSMEG5851, homologues of Rv1288 and Rv0519c. The advantages of 
using M.smegmatis as a surrogate system for M. tuberculosis research are its non pathogenic 
nature and faster growth rates. In order to study the role of mycolyltransferases, I planned to 
first attempt the generation of knockout strains of MSMEG3437 and MSMEG5851.  If 
either/both were found to be essential, CESTET (Conditional expression-specialised 
transduction essentiality testing) would be used to generate conditional mutant strains. 
Additionally, this study probed the role of MSMEG0241, the M. smegmatis homologue 
of mmpL11, which shares 72% sequence identity with the M. tuberculosis gene. 
 
6.2 Materials and Methods 
6.2.1 In silico analysis of M. smegmatis MmpL11 (MSMEG0241) 
The MSMEG0241 (Ms-MmpL11) gene sequence was obtained from the Comprehensive 
Microbial Resource website (http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi). 
CLUSTALW and ESPript were used to produce multiple sequence alignments of MmpL11 
from different mycobacterial species. The Expasy server (http://expasy.ch/) and the Centre for 
Biological Services server (http://www.cbs.dtu.dk) were used to predict the transmembrane 
domains. 
6.2.2 Plasmids, strains and DNA manipulation 
Plasmids, bacterial strains and phages used in this study are listed in Table 6.1. Escherichia 
coli strains were routinely cultured in Luria-Bertani (LB) broth at 37⁰C. M. smegmatis strains 
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were grown at 37⁰C in tryptic soy broth (TSB) or 7H9 broth or on TSB agar or Middlebrook 
7H10 medium, supplemented with 0.02% Tween 80. Hygromycin B (Roche) and Kanamycin 
sulfate (Sigma) were used at concentrations of 100g/ml and 25g/ml respectively for M. 
smegmatis and Hygromycin B (Roche) at 150g/ml for E.coli. For experiments involving the 
usage of phages, Tween 80 was not used in media. Mycobacteriophages were routinely 
propagated on Middlebrook’s 7H9 with 0.2% glycerol. Phage high titres were generated using 
protocols described by Larsen et al. (2007). 
Table 6.1 Bacterial strains, plasmids and phages used in this study  
Plasmids, phages and  
strains 
Description Reference 
Plasmids 
 
p0004s 
 
 
pMSMEG3437 
 
 
 
pMSMEG5851 
 
 
 
pMSMEG0241 
 
 
 
pMV261 
 
 
Phages 
 
phAE159 
 
 
 
phAEMSMEG3437 
 
 
 
phAEMSMEG5851 
 
 
 
Cosmid containing the Hygr-SacB cassette 
 
 
Derivative of p0004S obtained by cloning the 
right and left PCR flanks of MSMEG3437 
 
 
Derivative of p0004S obtained by cloning the 
right and left PCR flanks of MSMEG5851 
 
 
Derivative of p0004S obtained by cloning the 
right and left PCR flanks of MSMEG0241 
 
 
KanR , E. coli-mycobacterial shuttle vector 
(ColE1 oriM Phsp60) 
 
 
 
Conditionally replicating shuttle phasmid 
derived from lytic mycobacteriophage TM4 
 
 
Derivative of phAE159 obtained by cloning 
pMSMEG3437into its PacI site 
 
 
Derivative of phAE159 obtained by cloning 
pMSMEG5851into its PacI site 
 
 
Larsen et. al., 2007 
 
 
This work 
 
 
 
This work 
 
 
 
This work 
 
 
 
Stover et al., 1991 
 
 
 
 
Larsen et  al., 2007 
 
 
 
This work 
 
 
 
This work 
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phAEMSMEG0241 
 
 
Bacterial strains 
 
E.coli TOP 10 
 
 
 
 
HB101 
 
 
 
 
M. smegmatis mc2155 
 
 
 
MSMEG3437 
 
 
 
MSMEG5851 
 
 
MSMEG0241 
 
 
MSMEG0241-C 
 
 
 
MSMEG0241-RvC 
 
 
Derivative of phAE159 obtained by cloning 
pMSMEG0241into its PacI site 
 
 
 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara 
leu) 7697 galU galK rpsL (StrR) endA1 nupG 
 
 
E. coli K-12 F__(gpt-proA)62 leuB1 glnV44 
ara-14 galK2 lacY1 hsdS20 rpsL20 xyl-5 mtl-1 
recA13 
 
 
Wild type strain, Ept mutant of M.smegmatis 
strain mc26 
 
 
M. smegmatis disrupted in gene MSMEG3437 
 
 
 
M. smegmatis disrupted in gene MSMEG5851 
 
 
 
M. smegmatis disrupted in gene MSMEG0241 
 

MSMEG0241, complemented with wild type 
copy of the gene MSMEG0241 
 
 
MSMEG0241, complemented with wild type 
copy of the gene Rv0202c 
 
This work 
 
 
 
 
 
Invitrogen 
 
 
 
Stratagene 
 
 
 
 
Snapper et al., 1990 
 
 
This work 
 
 
 
This work 
 
 
 
This work 
 
 
This work 
 
 
 
This work 
 
6.2.3 Generation of recombinant knockout phages 
Allelic exchange plasmids pMSMEG0241, pMSMEG3437,  pMSMEG5851 were 
generated using PCR amplified upstream and downstream flanks of MSMEG0241, 
MSMEG3437 and MSMEG5851 cloned on either sides of a hygromycin resistance cassette in 
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the vector p0004S. Left and right flank sequences of were PCR amplified using primers listed 
in Table 6.2.  
 
Table 6.2 Primers used for generation of knockout constructs in M. smegmatis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 5' -3' 
Region 
amplified 
Size 
MSMEG0241_LL 
 
TTTTTTTTCCATAAATTGGTGGTT
GGTCTGCGGGTTCTC 
 
left side flank 
sequence of 
MSMEG0241 
970 bp 
MSMEG0241_LR 
 
TTTTTTTTCCATTTCTTGGCTTCT
GGCGCAGCTGTTTGG 
 
 
MSMEG0241_RL 
 
TTTTTTTTCCATAGATTGGTTCTC
ATACGGCAGCTCTGG 
right side 
flank sequence 
of 
MSMEG0241 
925 bp 
 
MSMEG0241_RR 
 
TTTTTTTTCCATCTTTTGGGTTCG
GTCAGTCACGAGTAG 
 
MSMEG3437_LL 
 
TTTTTTTTCAGAAACTGACTAGG
CCCAGACACAAC left side flank 
sequence of 
MSMEG3437 
830 bp 
 
MSMEG3437_LR 
 
TTTTTTTTCAGTTCCTGCACGAAG
TCGGGAAAGATG 
 
MSMEG3437_RL 
 
TTTTTTTTCAGAGACTGCGAGAG
CTACCGGAACAAG 
right side 
flank sequence 
of 
MSMEG3437 
998 bp 
 
MSMEG3437_RR 
 
TTTTTTTTCAGCTTCTGTGGCGCA
CACCGATTAC 
 
MSMEG5851_LL 
 
TTTTTTTTCCATAAATTGGCTCGT
CCACCAGTGATG left side flank 
sequence of 
MSMEG5851 
855 bp 
 
MSMEG5851_LR 
 
TTTTTTTTCCATTTCTTGGAACGA
ACCCGTCACGTAGG 
 
MSMEG5851_RL 
 
TTTTTTTTCCATAGATTGGCACCA
GCGATCCCTTCTAC 
right side 
flank sequence 
of 
MSMEG5851 
864 bp 
 
MSMEG5851_RR 
 
TTTTTTTTCCATCTTTTGGTCCCG
AGGTCTCACTGTTC 
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The PCR products were gel purified (QIAGEN gel purification kit) and digested with Van91I 
(left and right flanks of MSMEG0241 and MSMEG3437) and AlwNI (MSMEG5851). The 
digested fragments were ligated with P0004S-Van91I digested fragments using T4 DNA 
ligase. The ligation mix was then transformed into chemically competent E. coli Top10 cells 
and transformants were selected on LB agar with Hygromycin at 37°C. Plasmids obtained by 
miniprep (Qiagen miniprep kit) were digested with Van91I and PacI and sequenced to confirm 
presence of the left and right flanks. The PacI digested knockout plasmids pMSMEG0241, 
pMSMEG3437 and pMSMEG5851 was then ligated with PacI digested phAE159 DNA. 
The ligation mix was then packaged in the temperature sensitive mycobacteriophage phAE159 
 phage heads and transduced into E.coli HB101 and selected on LB agar with Hygromycin at 
37°C.  
6.2.4 Generation of M. smegmatis deletion mutants. 
The cosmids recovered from E. coli HB101 were confirmed by digestion with PacI digestion. 
The positive cosmids were transformed by electroporation into M. smegmatis at 1800V and 
recovered at 30°C for ~4 hours in TSB. The recovered cells were then harvested and 
resuspended in 200µl of MP buffer. This was mixed with 200µl of freshly growing M. 
smegmatis and 5ml molten soft agar (50°C) and poured on 7H9 basal agar plates and 
incubated at 30°C for 2 -3 days and allowed to form plaques. The plates were soaked in 
minimum amount of MP buffer for 5-6 hours and the solution containing phages was filtered 
and stored at 4°C. This generated recombinant phages - phMSMEG0241, phMSMEG3437 
and phMSMEG5851 designed to replace the genes MSMEG0241, MSMEG3437 and 
MSMEG5851 respectively with hyg. 
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M. smegmatis cultures were grown in 50ml of TSB (0.05% Tween 80) to an OD600 of 
about 0.8 and harvested by centrifugation at 4500xg for 10 minutes. The cell pellet was 
washed twice with 50ml of MP buffer. Finally the pellet was resuspended in 2ml of MP buffer 
and 2ml of high titre (10
-10
 pfu /ml) phage lysate was mixed with the cells. A control was set 
up where 0.5 ml of resuspended cell was mixed with 0.5ml of MP buffer. The mix was 
incubated overnight at 37°C followed by harvesting and recovery with 10ml TSB with Tween-
80 for 12 -24 hours at 37°C. This was plated onto TSB agar plates with hygromycin B and 
plates were incubated at 37°C for 1 – 2 weeks. Hygromycin resistant colonies obtained after 
transduction of M. smegmatis mc
2
155 (wild type strain) were inoculated in 10ml TSB-Tween 
80 with hygromycin B for genomic DNA extraction and further characterization.  Once 
confirmed by Southern blot, one strain of each MSMEG0241, MSMEG3437  and 
MSMEG5851 were picked for further biochemical analysis.   
  
6.2.5 Southern blot to confirm knockouts 
Restriction enzymes were selected based on the sequence of the knockout plasmids. For 
MSMEG0241 and MSMEG5851 the restriction enzymes used was KpnI, and 
MSMEG3437 genomic DNA was digested with NcoI. The wildtype genomic DNA was also 
digested with respective enzymes listed above. Following digestion, the genomic DNA 
fragments were separated by gel electrophoresis.In the mutant strains the gene is replaced by a 
hyg-SacB gene, thus after digestion the pattern of fragment produced will differ from the 
wildtype in either size or number of fragments. PCR products of the left and right flanks of the 
respective genes were used as probes. 
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The procedure was performed as described in DIG High Prime DNA Labelling and 
Detection Starter Kit II (cat no – 11585614910, Roche). This kit uses digoxigenin, a steroid to 
label DNA probes by random priming. The hybridized probes are then immunodetected by 
anti-digoxigenin-AP (Fab fragments), which are visualised by chemiluminescence. 
6.2.6 Complementation of the MSMEG0241 mutant. 
Complemented strains were constructed by cloning a copy of MSMEG0241 in the 
mycobacterial replicative plasmid pMV261 (kanamycin resistant) and introduced in the 
mutant strain by electroporation. The M. tuberculosis MmpL11 gene Rv0202c was also cloned 
in pMV261 and introduced into the MSMEG0241 strain to generate an Rv–complemented 
strain. 
Table 6.3 Primers used for generation of complemented strains 
Name  Sequence (5' → 3') Product Size 
    MSM0241C_ F GATCGATCGAATTCCATGATGCGCTTGAGCAGCACT* 
MSMEG0241 
gene sequence 
2865 bp 
  MSM0241C_ R GATCGATCAAGCTTTCATTCGCCTCCTCCAGCATT# 
 
    Rv0202C_ F GATCGATCGAATTCCATGATGCGCTTGAGCCGCAA* Rv0202c 
(Mmpl11) gene 
sequence 
2901 bp 
  Rv0202C_ R GATCGATCAAGCTTTCACCTCGCCTCCAACA# 
 
 
      
*Underlined sequence shows EcoRI restriction site, # Underlined sequence shows HindIII restriction site 
 
6.2.7 Growth curve  
Growth of the wild type mc
2
155, mutant MSMEG0241 and MSMEG0241-C complemented 
strain was monitored at O.D. 600nm over a period of 0 to 48 hours at intervals of 6, 12, 24, 36 
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and 48 hours. All the strains were grown in Tryptic soy broth with 0.05% Tween 80 and 
appropriate antibiotics at 37° C. The starting O.D. for all the cultures was 0.2. 
 
6.2.8 Colony morphology and sliding motility  
Mid-log cultures of the bacterial strains were streaked on TSB agar plates with and without 
tween. The plates were incubated for 2-3 days at 37°C and isolated single colonies were 
studied under a microscope. The sliding motility assay was adapted from Mathew et al (2006). 
Middle-brook 7H9 was supplemented with 60ml /l glycerol and 10% OADC was solidified 
using 0.3% high grade agarose (Bioline). To check the effect of detergent on biofilm 
formation, 0.05% Tween 80 was added to a set of plates, and another set of plates were made 
with no glycerol. 
5µl culture (O.D600 = 0.5) was spotted at the centre of the plates and allowed to dry for 
1hour. Biofilm formation was evaluated after incubation at 37⁰ C for 3-5 days in a humidified 
incubator. 
6.2.9 Analysis of cell envelope lipids 
M. smegmatis cultures were grown to an OD600 nm of 0.4 in Tryptic soy broth and 7H9 
medium in the presence and absence of 0.05% Tween 80 at 37°C with appropriate antibiotics 
where required in a shaking incubator, following which 1 mCi/ml [1,2-
14
C]acetate (57 
mCi/mmol, GE Healthcare, Amersham Bioscience) was added to the culture and the 
incubation was continued for another for
 
12 hours.  The labelled bacterial cells were harvested, 
washed, and
 
dried. The dried cells were initially resuspended in 2 ml of petroleum ether (60–
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80°C), and mixed for 30 minutes. The upper layer was collected in a fresh tube and the 
remaining cell suspension re-extracted with 2ml of petroleum ether (60–80°C). The upper 
layers were pooled and dried. This petroleum ether extract contains surface exposed, non-
covalently bound lipids. Apolar and polar lipids from the remaining cell pellet were extracted 
as described in Chapter 8. 
The apolar lipid extract (50,000 cpm) was applied to the corners of 6.666 cm plates of 
silica gel 60 F254 (Merck 5554) TLC plates. The plates were then developed in solvent system 
C, using direction 1, chloroform/methanol /water (100:14:0.8, v/v/v) and direction 2, 
toluene/acetone (80:20, v/v) to separate 
14
C-labelled lipids (free fatty acids and mycolic acids). 
Lipids were visualized by autoradiography by overnight exposure of Kodak XOmat AR film 
to the TLC plates to reveal [
14
C]labelled lipids and compared to known standards.  
To study the effect of loss of genes MSMEG0241, MSMEG3437 and MSMEG5851 on 
the wall bound mycolates and fatty acids, delipidated cells were subjected to alkaline 
hydrolysis using 5% aqueous tetrabutylammonium hydroxide (TBAH) at 100°C overnight, 
followed by the addition of 4 ml of CH2Cl2, 500 l of CH3I, 2 ml of water, followed by 
mixing for 30 min. The upper aqueous phase was discarded following centrifugation and the 
lower organic phase washed thrice with water and evaporated to dryness. The resulting fatty 
acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs) were dissolved in 
diethyl ether (CH2Cl2) and insoluble residues removed by centrifugation. The clear supernatant 
was evaporated to dryness and re-dissolved in 200 l of CH2Cl2. Equivalent volumes of the 
resulting solution of FAMEs and MAMEs were subjected to TLC using silica gel plates (5735 
silica gel 60F254; Merck, Darmstadt, Germany), developed in petroleum ether-acetone (95:5). 
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Autoradiograms were produced by overnight exposure of Kodak X-Omat AR film to the 
plates to reveal [14C]-labelled FAMEs and MAMEs. Argentation (Ag
2+
) -TLC was performed 
by using Ag
2+
 -impregnated TLC plates developed twice in direction 1, hexane-ethyl acetate 
(19:1, v/v), and then thrice in direction 2, petroleum ether-acetone (17:3, v/v).    
6.3  Results  
6.3.1 In silico analysis of MmpL11 and its neighbouring genes  
Genome comparison shows that MSMEG0241 is homologous to mmpL11 (Rv0202c) in M. 
tuberculosis. The M. smegmatis protein has 69% identity with the M. tuberculosis protein in a 
969 amino acid overlap, and 70.9% genetic similarity and the genetic region is conserved 
between mycobacterial species. The M. smegmatis protein also has 67.8% similarity in a 1010 
amino acid overlap with Mycobacterium avium (MAP 3637) MmpL11 protein sequence with a 
72.4% genetic match; 65.8% identity in a 1015 amino acid overlap with 55% genetic identity 
in Mycobacterium leprae (ML 2617) and a 69% similarity in a 969 amino acid overlap with 
Mycobacterium bovis BCG (BCG 0239), and 70.9% gene identity. M. leprae has a high degree 
of gene deletions but still possess 5 of the MmpL proteins (Lamichhane et al., 2005), MmpL 
11 being one of them. This suggests that the MmpL 11 protein, although non-essential for 
survival, performs vital functions in cell wall related pathways in mycobacteria. As shown in 
Fig 6.5 the synteny between MmpL3 and MmpL11 is conserved across all mycobacterial 
genomes. 
The MmpL11 protein also has a high level of structural similarity to MmpL3, which is 
an essential gene and the both the proteins have similar transmembrane domains. The MmpL3 
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(MSMEG0250) gene has been shown to be involved in mycolate transfer (C.Varela, University 
of Birmingham, communicated). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Transmembrane domain predictions of MmpL 11 (MSMEG0241) and MmpL 3 
(MSMEG0250) from M. smegmatis, showing the transmembrane helices, extracellular and 
cytoplasmic domains, which is similar to the predicted topology of the M. tuberculosis proteins. 
A) 
B) 
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Figure 6.7. Multiple sequence alignment of the M. tuberculosis MmpL11 (Rv0202c) protein with 
MmpL 11 proteins in M. bovis, M. leprae, M. avium, and M. smegmatis (MSMEG0241). Numbers 
indicate the amino acid co-ordinates of MSMEG0241. Dots indicate gaps. Red boxes with white 
letters indicate identical amino acid sequences at the aligned position for all three proteins. 
White boxes indicate similar or identical residues for two of the three proteins at the aligned 
position; the bold sequence letters in these boxes indicate identical or similar residues at the 
aligned position. 
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6.3.2 Southern blot to confirm knockouts 
 Southern blot was done as described in Chapter 8 to confirm the replacement of the targeted 
genes by hyg-SacB. Digestion of the genomic DNA with restriction enzymes KpnI, the wild 
type would show a 15Kb band and the mutant strain MSMEG0241 would reveal 2 bands of 
5.137Kb and 6.827Kb. Whereas the mutant strain MSMEG5851 would produce 2 fragments, 
7Kb and 11.7Kb in size. Digestion of the wild type and mutant strain MSMEG3437 genomic 
DNA with NcoI revealed 2 fragments of 2Kb and 5.4Kb in the wild type strain and a 5Kb 
fragment in the mutant strain. The procedure was performed as suggested by manufacturer 
guidelines in (DIG High Prime DNA Labelling and Detection Starter Kit II cat no – 
11585614910, Roche). This kit uses digoxigenin, a steroid to label DNA probes by random 
priming. The hybridized probes are then detected uisng anti-digoxigenin-AP (Fab fragments), 
and subsequently visualised by chemiluminescence. 
None of the genes tested were essential for growth under laboratory media. This 
indicates that either the functions are redundant or they play a minor role in the organism’s 
metabolism. 
6.3.3 Characterization of the mutant strains MSMEG3437 and MSMEG5851 
6.3.3.1 Effects of deletion of MSMEG3437 and MSMEG5851 on colony morphology 
Changes in cell wall components, including mycolates affects colony morphology. Previously 
it has been shown that loss of gene encoding mycolic acid biosynthesis enzymes, e.g., KasB in 
M. smegmatis is responsible for alteration in colony patterns (Bhatt et al., 2007a). In order to 
study the possible consequences of deletion of the genes MSMEG3437 and MSMEG5851 on 
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M. smegmatis physiology, colony morpholgy was studied. Isolated single colonies of the wild 
type and mutant strains on TSB agar with and without the presence of tween-80 were 
compared. The mutants MSMEG3437 and MSMEG5851 did not show any variation from the 
usual crenulated colony morphology exhibited by the wild type M. smegmatis strain. colony 
morphology exhibited by the wild type M. smegmatis strain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. Colonies of wild type (mc
2
155), mutant strains MSMEG3437 and MSMEG5851 on 
TSB-agar and TSB-agar-0.05% Tween-80. Single isolated colonies are shown. Scale bar = 1mm. 
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6.3.3.2 Analysis of lipid profiles of mutant strains MSMEG3437 and MSMEG5851. 
Mutants strains MSMEG3437 and MSMEG5851, predicted mycolyltransferases, did not 
show any change in colony morphology. Presence or absence of tween did not appear to have 
any phenotypical  effect on the mutants MSMEG3437 and MSMEG5851. To further 
analyse the effects of deletion of these genes, cell wall lipid analysis was done to detect any 
alterations in the cell wall components- changes in the free fatty acids and mycolic acid levels 
/patterns. Bacterial strains were grown in TSB and 7H9 media in the presence and absence of 
0.05% Tween 80 for this study.  Presence of Tween in media or growth on different media 
TSB and 7H9 did not affect free fatty acids and free mycolate levels, but interestingly, a spot 
was observed in the 2D-TLCs of apolar lipids extracted from cultures grown in 7H9 media, 
both in presence and absence of Tween 80 (Figure 6.9). This accumulation has not been 
characterised yet but will be analysed in future. 
To check if the genes had any role in transferring Myc-PL to trehalose monomycolate 
(TMM) to synthesise trehalose dimycolate (TDM), the apolar lipids were separated on a 2D-
TLC system which separates TMMs and TDMs. This did not show any changes or altered 
pattern of migration suggesting that either the genes MSMEG3437 and MSMEG5851 are not 
involved in mycolates transfer in TDM biosynthetic pathway, or that these functions are 
redundant (Figure 6.10). 
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Figure 6.9. 2D TLC autoradiograph of apolar lipids extracted from wild type mc
2
155 and mutant 
strains MSMEG3437 and MSMEG5851. The strains were grown on TSB and 7H9 agar +/- 
0.05% Tween 80. Lipids were separated in solvent system ‘C’, direction 1 in 
chloroform/methanol 96:4, and in direction 2 in Toluene/acetone; 80:20. FFA- free fatty acids, 
FMA-free mycolic acids; ?, unknown. 
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Figure 6.10 2D TLC autoradiographs of apolar lipids extracted from mc
2
155 and mutant strains 
MSMEG3437 and MSMEG5851. Lipids were separated in solvent system ‘D’ direction 1 in 
chloroform: methanol: water; 100:14:0.8, and direction 2 in chloroform: acetone: methanol: 
water, 50:60:2.5:3. ?, unknown. 
Chapter 6                                                                          Mycolic acid transport and processing                           
203 
 
Further to detect any changes in the patterns of cell wall bound lipids in the mutant 
strains, the delipidated cells were subjected to alkaline hydrolysis and methylation to generate  
fatty acid methyl esters and mycolic acid methyl esters (FAME’s and MAME’s) (Chapter 8). 
M. smegmatis produces , ’ and epoxy mycolates. Analysis of the FAME’s and MAME’s 
were done by separating the FAME’s and MAME’s on 1 dimensional TLC (1D-TLC) using 
the solvents petroleum ether:acetone; 95:5 (v/v). The TLC plates were developed twice in this 
system and exposed to Kodak X-Omat AR film overnight. Analyses of FAME’s and MAME’s 
from the wild type and mutant strains revealed the presence of ’ and epoxy mycolates. 
The migration of FAMEs remained unaltered in all the mutant strains suggesting that fatty 
acid biosynthesis and transport have not been altered by loss of the genes. The profiles of the 
FAMES and MAMES are shown in Figure 6.11.  
 
Figure 6.11.   1D-TLC autoradiographs of cell wall bound mycolates (FAMEs and MAMEs) from 
M. smegmatis mc
2
155, mutant strains MSMEG3437 and MSMEG5851. All strains were grown 
in different media combinations – a) TSB, b) TSB –Tween 80 c) 7H9 and d) 7H9-Tween 80. Wall 
bounds fatty acids and mycolates were revealed after two developments in petroleum ether: 
acetone (95:5). 
 
 
A
) 
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6.3.4 Characterization of the mutant strains MSMEG0241 
6.3.4.1  Colony morphology changes due to loss of MSMEG0241 
In the MSMEG0241 mutant strain, the colonies were found to be slightly risen and showed 
reduction in the outer periphery as compared to the wild type. However on the Tween plates, 
the MSMEG0241 mutant showed a slower growth and rough, crinkled colony edges as 
compared to the wild type strain (Figure 6.12). 
 
 
 
 
 
 
 
 
 
 
Figure 6.12. Colonies of wild type (mc
2
155), mutant strains MSMEG0241 on TSB-agar and 
TSB-agar-0.05% Tween-80 plates . Single isolated colonies are shown. Scale bar = 1mm. 
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6.3.4.2 Growth curve of wild type and MSMEG0241 mutant and MSMEG0241-C 
complemented strain  
Growth of wild type mc
2
155, MSMEG0241 and MSMEG0241-C were compared in TSB 
medium. Growth of the wild type strain was completed after 48 hours and reached A600  of 
3.468, but the MSMEG0241 mutant strain reached to an O.D of 1.08 (Figure 6.13A ).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13. Growth analysis of MSMEG0241. A) Consequences of deletion of MSMEG0241 on 
the growth rate of M. smegmatis, measured at 6, 12, 24, 36 and 48 hours. B) Growth phenotype in 
tryptic soy broth medium supplemented with Tween 80 at 24 hours. 
B
) 
A
) 
B) 
A) 
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However, introduction of plasmid borne wild type copy of the gene MSMEG0241 to generate 
a complemented strain MSMEG0241-C appears to partially restore the growth rates to wild 
type phenotype. The complemented strain reached an O.D of 2.094. The mutant strain also 
showed ‘grainy’ apearence in liquid medium containing Tween-80, and formed clumps. The 
complemented strain appears to partially revert to wild type phenotype (Figure 6.13B). 
 
6.3.4.3 Cell wall lipid analysis of MSMEG0241  
In order to relate the phenotypic changes of the M. smegmatis MSMEG0241 mutant to 
alterations in the cell wall composition, the MSMEG0241 mutant strain, complemented strain 
MSMEG0241-C and wild type strain mc2155 were analysed for changes in cell wall lipids. 
Bacterial strains were grown in TSB and 7H9 media in the presence and absence of 0.05% 
Tween 80 for this study.  Presence of Tween in media or growth on different media TSB and 
7H9 did not affect apolar lipid profiles of free fatty acids and free mycolate. A mild 
accumulation of free mycolic acids was observed in MSMEG0241 (Figure 6.14). along with 
this accumulation, a spot was observed in the 2D-TLCs of apolar lipids extracted from 
cultures of both wild type and mutant strains grown in 7H9 media, both in presence and 
absence of Tween 80 (Figure 6.14). This spot has been denoted by ‘?’ in the Figure 6.14. This 
accumulations seems to disappear in the 2D-TLC profile of the mutant strain grown in 7H9 in 
presence of Tween 80. The ‘?’ species could possibly be an artefact or it is being actually 
made by the cells. This would need further characterisations and future work. 
To check if the genes had any role in transferring Myc-PL to TMM to synthesise TDM, the 
apolar lipids were separated on a 2D-TLC system which separates TMMs and TDMs. This did 
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not show any changes or altered pattern of migration suggesting that MSMEG0241 is not 
involved in transfer of mycolates in the TDM biosynthetic pathway (Fig 6.15). 
 
Figure 6.14. 2D TLC autoradiographs of apolar lipids extracted from M. smegmatis wild type 
mc
2
155 and mutant strains MSMEG0241. Lipids were separated in solvent system ‘C’, direction 
1 in chloroform/methanol 96:4, and in direction 2 in Toluene/acetone; 80:20. FFA-free fatty 
acids, FMA-free mycolic acids. 
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Figure 6.15. 2D TLC autoradiographs of apolar lipids extracted from M. smegmatis wild type 
mc
2
155 and MSMEG0241. Lipids were separated in solvent system ‘D’, direction 1 in 
chloroform: methanol: water; 100:14:0.8, and direction 2 in chloroform: acetone: methanol: 
water, 50:60:2.5:3. 
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 In the mutant MSMEG0241, an increased level of mycolic acids was observed when 
the apolar lipids were separated by 2D TLC as shown in Figure 6.12. To address the cause of 
the accumulation of mycolates in the mutant strain, first, the surface exposed, non-covalently 
bound lipids were extracted using petroleum ether, following which apolar and polar lipids 
were extracted from the remaining cell pellet. The fractions, petroleum ether extractable and 
apolar lipids from the remaining cell pellet were separated by 2D-TLC and the profiles are 
shown in Figure 6.16. 
The accumulation of free mycolates in and the difference in their migration pattern was 
consistent in the mutant strain under all four growth media. Majority of the free mycolic acids 
were found in the cell pellet after surface exposed petroleum fraction was removed indicated 
an inability of the mycolates in being translocated across the membrane. TLC’s analysis 
reveals the presence of free mycolates in the inside of the cell, which were released on 
disruption of the cell wall and further solvent extraction. The outer cell wall lipids were 
comparable between the wild type and mutant strains.  
Further to detect any changes in the patterns of cell wall bound lipids in the 
MSMEG0241 mutant, the delipidated cells were subjected to alkaline hydrolysis and 
methylation to FAME’s and MAME’s as detailed in Chapter 8. Analysis of the FAME’s and 
MAME’s from the wild type and mutant strains by 1D-TLC revealed the presence of  all the 3 
classes of mycolates produced by M. smegmatis, ’ and epoxy mycolates. The migration  
patterns of FAMEs remained unaltered in the mutant strain suggesting that fatty acid 
biosynthesis and transport have not been altered by loss of the MSMEG0241. The 1D - TLC 
profiles of the FAMES and MAMES are shown in Figure 6.17.   
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Figure 6.16 2D TLC autoradiographs of apolar lipids extracted from M. smegmatis wild type 
mc
2
155, MSMEG0241, MSMEG0241-C and MSMEG0241-CRv. Lipids were separated in 
solvent system ‘C’, direction 1 in chloroform/methanol 96:4, and in direction 2 in 
Toluene/acetone; 80:20. 
 
Figure 6.17 1D-TLC autoradiographs of cell wall bound mycolates (FAMEs and MAMEs) from 
M. smegmatis mc
2
155 and mutant strains MSMEG0241. All strains were grown in different 
media combinations – a) TSB, b) TSB –Tween 80 c) 7H9 and d) 7H9-Tween 80. Wall bounds 
fatty acids and mycolates were revealed after two developments in petroleum ether: acetone 
(95:5). 
A
) 
Chapter 6                                                                          Mycolic acid transport and processing                           
211 
 
6.3.4.4 Effect of deletion of MSMEG0241 on biofilm formation 
An alteration in colony morphology was observed for the mutant strain MSMEG0241 and to 
further study the role of the gene  MSMEG0241, ability to form biofilms was tested and 
compared with the wild type and complemented strains.  Previous studies have shown that M. 
smegmatis can translocate over the surface of solid growth medium by a sliding mechanism 
and can also form biofilm on polyvinyl chloride plates (Recht and Kolter, 2001; Recht et al., 
2000; Martinez et al., 1999). Mutants of M. smegmatis and Mycobacterium marinum defective 
in biosynthesis of glycopeptidolipids, mycolyldiacylglycerol and lipooligosaccharides are 
defective in biofilm formation (Recht and Kolter, 2001; Chen et al., 2006; Ren et al., 2007). 
Extracellular non-covalently bound mycolic acids have been reported to be abundant in 
biofilms in M. tuberculosis and M. smegmatis (Ojha et al., 2008; Ojha et al., 2005). 
Involvement of FAS-II enzymes in biofilm maturation and defective biofilm formation by 
strains mutated in the genes KasA and inhA (Ojha et al., 2005) indicate a role of mycolic acids 
in biofilm formation.  
MmpL11 is reported to be involved in transport of an unknown substrate possibly in the 
mycolic acid transport pathways (Domenech et al., 2005). To determine the effect of loss of 
MSMEG0241 on biofilm formation, the wild type mc
2
155, mutant MSMEG0241 and 
complemented strain MSMEG0241-C strains were allowed to grown on different biofilm 
media. 
The mutant strain displayed less ability to swarm over the media as compared to the wild 
type strain. The complemented strain appears to have reverted to wild type phenotypes. This 
data along with the involvement of mycolates in biofilm formation and predicted function of 
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MSMEG0241 suggest a role of the MmpL11 gene in translocation of the mycolates to the 
outer cell wall in Mycobacterium.    
 
Figure 6.18. Biofilm formations on different media combinations. Comparisons of growth 
between strain mc
2
155, MSMEG0241 and MSMEG0241-C, after 5 days of incubation at 37°C 
under humidified conditions. Actual images of colonies.     
 
6.3.4.5 Analysis of biofilm matrix lipids  
Free mycolates have been reported to be involved in biofilm formation in mycobacteria 
(Ojha et al., 2008). The mutant strain MSMEG0241 displayed a reduced ability to form 
biofilms as compared to the wild type strain. Given the involvement of mycolates in the 
extracellular matrix, lipids extracted from bacteria grown on solid biofilm media were 
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separated on 2D TLC to relate to change in free mycolate profiles. The wild type, mutant and 
complemented strains were grown on solid biofilm media (Recht and Kolter, 2001), 
containing 
14
C-acetate and incubated at 37°C in a humidified chamber for 5- 7 days. The 
colony material was scraped and used for extractions of the extracellular non-covalently bound 
and inner cell wall lipids.  The mutant strain shows higher amounts of free fatty acids and 
reduced levels of mycolic acids in the petroleum ether outer cell wall extract as compared to 
the apolar lipids (Figure 6.19).  
 
Figure 6.19. 2D TLC of petroleum ether extracts and apolar lipids, extracted from biofilms 
formed by the wild type strain mc
2
155, MSMEG0241 and MSMEG0241-C. Lipids were 
separated in direction 1 in chloroform/methanol 96:4, direction 2 in toluene/acetone 80:20. 
 
MSMEG0241 encodes MmpL11, a putative membrane protein belonging to a family of 
RND proteins known to be involved in drug resistance and mediates transport of complex 
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molecules across the membrane. The predicted topology of the MmpL 11 is quite similar to 
the topology of MmpL 3, which is an essential gene and is involved in transport of mycolates 
in the final biosynthesis of TDMs (C.Varela communicated, University of Birmingham). 
These 2 MmpL genes occur in the same gene cluster and the synteny is conserved across all 
sequenced mycobacterial genomes. Domenech et al. (2005) had observed that an mmpL11 
mutant of M. tuberculosis was attenuated in the mouse model of infection, but were unable to 
identify the exported metabolite. We now have preliminary data that suggests a role for 
MmpL11 in mycolic acid metabolism: a mutant of M. smegmatis MSMEG0241, the 
homologue of mmpL11 had reduced levels of cell envelope-associated free mycolic acids, 
indicating that while the gene was not essential, its function was related to mycolic acid 
metabolism. Ojha et al., have suggested that extracellular free mycolic acids are derived from 
newly-synthesised TDM via the action of exported esterases; our results indicate that 
MmpL11 may play a role in this process. Free mycolates are required for biofilm formation 
and interestingly the MSMEG0241 mutant was defective in biofilm formation.  From the 
phenotype of the MmpL11 deletion mutant in M. smegmatis, MSMEG0241 and its probable 
function, we suggest that MSMEG0241 maybe involved in shuttling the free mycolic acids to 
the outer cell wall.   
6.4 Discussion 
Mycolic acids are key components of the mycobacterial cell wall and enzymes involved in 
their biosynthesis are the targets of many antituberculosis drugs like INH, ethionamide and 
thiolactomycin. Mycolic acid biosynthesis has been studied extensively but post biosynthesis 
processing and transport is not clearly understood, thus obstructing identification of novel 
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drug targets in the transport of this vital cell wall component. Belisle et al. (1997) 
demonstrated that the 3 members of the antigen-85 complex, Ag85A (FbpA), Ag85B (FbpB) 
and Ag85C (FbpC) in M. tuberculosis are involved in mediating mycolyltransferase reactions 
which finally results in forming the mycolyl-arabinogalactan-peptidoglycan of the cell wall 
(Belisle et al., 1997). Based on these findings and identification of proposed class II 
mycolyltransferases by Takayama et al. (2005), the homologues of potential 
mycolyltransferases Rv1288 and Rv0519c in M. smegmatis, MSMEG3437 and MSMEG5851 
were characterised in an attempt to elucidate mycolic acid processing in M. tuberculosis.  
A group of transport pumps have also been reported to be involved in transport of lipids 
across the cell wall. The genomes of many mycobacteria including the highly pathogenic M. 
tuberculosis H37Rv contain a number of genes encoding proteins belonging to a family of 
multidrug resistant pumps known as RND proteins (Domenech et al., 2005). Many of these 
genes have been reported to be associated with gene cluster involved in biosynthesis of 
various sulfolipids, glycopeptidolipids, and acylated trehalose and phthiocerol 
dimycocerosates (Camacho et al., 2001; Domenech et al., 2004). Phylogenetic analysis of the 
MmpL genes from M. tuberculosis, M. avium, M. leprae, M. marinum, M. smegmatis (Figure 
6.6) show that some of these genes occur in a closely related cluster, e.g. – MmpL3 and 
MmpL11, and some are interestingly associated with the pks genes, e.g. –MmpL8, MmpL10 
and MmpL12. Out of all the MmpL’s in mycobacteria only MmpL 3 was reported to be 
essential and is involved in mycolate transport  and MmpL 11 and MmpL 8 have been reported 
to play a role in virulence in murine models (Domenech et al., 2005; Converse et al., 2003). 
MmpL11 has also been identified to be involved in transport of an ‘unknown substrate’ and in 
another study, involved in heme transport (Tullius et al., 2011). Tullius et al. (2011) suggested 
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a role of MmpL3-MmpL11 gene cluster in heme acquisition. The authors report generation of a 
strain with deletion in the region MSMEG0250 in M. smegmatis. This strain was deficient in 
heme uptake. However, we noticed no difference in heme uptake by the MSMEG0241 strain 
as compared to the wild type mc
2
155.  Earlier studies by Domenech et al.(2005) also reported 
the homologue of MSMEG0250 in M. tuberculosis, MmpL3 to be essential for survival and a 
deletion mutant failed to survive (Domenech et al., 2005). In M. smegmatis, the MmpL11 
protein is encoded by the gene MSMEG0241 and shares a very high sequence identity and 
similar predicted transmembrane topology with MmpL3. Hence, MSMEG0241 was further 
characterised to identify if its ‘unknown substrate’ is a mycolate. 
This work was aimed at studying the roles of mycolyltransferases MSMEG3437, 
MSMEG5851 and MSMEG0241 in mycolic acid processing and transport pathway. Mutant 
strains were generated in M. smegmatis mc
2
155 using mycobacteriophage mediated 
specialised transduction (Bardarov et al., 2002). Cell envelope lipid analysis revealed no 
changes in lipid patterns in the mutant strains MSMEG3437, MSMEG5851. The strains did 
not show any difference in growth rates or colony morphology. This indicates that deletion of 
MSMEG3437 or MSMEG5851 does not affect any pathways required for survival of the 
bacterium and possibly other genes restore the functions/ roles of these genes in vivo.  
The mutant strain MSMEG0241 was retarded in growth and had a tendency to form 
clumps in liquid growth media. The mutant also displayed an inability to form biofilms as 
compared to the wild type strain. This defect was compensated on introducing a plasmid borne 
copy of the wild type gene into the mutant strain. The mutant strain also displayed comparable 
growth phenotypes as the wild type strain with and without the presence of Fe
2+
 and hemin 
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(heme) in minimal media. Intercellular uptake and availability of heme was determined by 
spectrophotometric assays for heme, which showed no difference in heme uptake abilities 
between the wild type and mutant strains, suggesting that the role of MSMEG0241 in heme 
transport is superfluous in vivo. 
Mycolates are readily stripped off from the cells during solvent extractions. In the 
mutant strain MSMEG0241 it was observed that the mycolic acids are still contained in the 
inside of the cell, post petroleum ether extraction of surface exposed lipids which is revealed 
on methanolic saline disruption of the cell wall and further solvent extractions.  This is an 
indication that the loss of the gene is responsible for blocking a part of the mycolate transport 
across the cell wall. From our experiments we conclude that the gene MmpL11 is involved in 
shuttling the free mycolic acids to the outer cell wall. Since there is no complete shutdown of 
mycolate transport, it is quite possible that the essential gene MmpL3, which is present in the 
same gene cluster and has similar conserved domain is the primary free mycolic acid 
transporter in the mycobacterial cell wall. 
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This chapter summarises the findings from the two different research themes covered in this 
thesis; LOS biosynthesis, and mycolic acid processing and transport in mycobacteria. Areas of 
future work are also addressed. 
At the outset, I used a two pronged approach to identify and characterize genes involved in 
LOS biosynthesis in Mycobacterium marinum: (1) the generation and use of transposon 
libraries to screen for LOS defective mutant strains, and (2) the generation of targeted mutants 
of genes with a putative role in LOS biosynthesis The later approach was applied to the 
glycosyltransferase MMAR2333 and polyketide synthase MMAR2340 in M. marinum using the 
mycobacteriophage-based Specialised Transduction technique. Although phage mediated 
transposon mutagenesis has been reported in M. marinum this is the first report of delivery of 
allelic exchange substrates for targeted gene knockouts in this species. The MMAR2333 
mutant strain was able to produce LOS-I and an intermediate between LOS-I and LOS-II, 
LOS-II*. Similarity of MMAR2333 to other bacterial DPM-like synthases, 2D-TLC and mass 
spectrometry analysis suggests that is likely to be involved in the transfer of a nucleotide 
bound caryophyllose residue to a poyprenol unit to generate the substrate for other GTFs 
involved in synthesis of the higher LOSs.  
The tetraglucose core of LOSs in M. marinum possess two different acyl chains. 
MMAR2340 encodes a polyketide synthase and is present in the gene cluster identified to be 
involved in LOS biosynthesis. A second polyketide synthase gene is also present in this cluster 
–MMAR2344 (pks5_1). This relates to the presence of two different methyl branched 
acylations in the LOS structure. Biochemical characterization of a MMAR2340 null mutant 
revealed that the mutant strain is deficient in production of all the four LOS subtypes 
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indicating the involvement of pks5 in synthesis of either one of the methyl branched acyl 
chains which is further attached to the tetraglucose core by the acyl transferases present in the 
cluster. Following the synthesis and addition of the first acyl chain, the second acyl chain, 
possibly synthesised by pks5_1 is added to acylated core by the acyltransferases. 
The frequency of obtaining mutants by Specialised Transduction in M. marinum is very 
low, hence the second approach was focussed on generating a transposon library and screening 
mutants based on colony morphology changes to further analyse defects in LOS biosynthesis 
pathway. Additionally we had access to another transposon library of LOS defective strains 
from an ongoing collaboration with Dr. A. Van der Woude and Prof. W. Bitter, VUMC, 
Amsterdam, the Netherlands. This library was generated using the wild type strain E11. The 
strains selected in this study were disrupted in the genes MMAR2307, MMA2319, MMAR2320, 
MMAR2327, MMAR2336, MMAR2340, MMAR2341, MMAR2353, MMAR2355, MMAR2356 
and MMAR5170. From the transposon library created in-house, we were able to isolate a 
mutant strain disrupted in the gene MMAR2351, a glycosyltransferase. 2D-TLC analysis of the 
above mutant strains revealed various defects in LOS production. Disruptions in MMAR2307 
resulted in a strain which accumulated LOS-I, MMAR2327::aph and MMAR2336::aph strains 
accumulated an intermediate between LOS-I and LOS-II* and LOS-II respectively, 
MMAR2319 and MMAR2320 disrupted strains accumulated LOS-III and a transposon 
insertion in the genes MMAR2340, MMAR2341, MMAR2355 and MMAR2356  was 
responsible for strains with complete loss of LOSs. Surprisingly, no defect in LOS 
biosynthesis was observed when the putative GTF genes MMAR2351 and MMAR2353 were 
disrupted.  
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The mutant strains MMAR2333, MMAR2340, MMAR2327::aph, MMAR2336::aph, and 
MMAR2340::aph were also assessed for changes in virulence by infecting murine bone 
marrow derived macrophages. None of the strains were found to be altered in their abilities to 
survive within macrophages, but strains with total absence of LOS’s (deletion/disruption in 
pks5) and a strain accumulating a precursor of LOS-II, LOS-II*(MMAR2333) elicited a 
strong TNF- release much higher compared to TNF- levels released on infection with M. 
marinum wild type strains. Interestingly, a LOS-II’ accumulating strain MMAR2336::aph and 
LOS-II accumulating strain MMAR2327::aph seemed to lower the TNF- release levels. This 
relates with reports of inhibition of TNF- response by LOS-III (Rombouts et al., 2009) and 
LOS-IV (Rombouts et al., 2010). Our findings suggested that while LOSs did not affect 
intracellular survival, alterations caused changes in the cytokine response. The cytokine 
responses also relate with the hypothesis that LOSs act as avirulence factors in the 
mycobacterial cell wall. 
In silico analysis was done to locate the LOS gene cluster in the LOS producing 
opportunistic pathogen M. kansasii and a number of M. kansasii-specific GTFs were identified 
in the cluster reflecting the larger number of LOS species found in M. kansasii.  A transposon 
library was generated to screen for strains deficient in LOS biosynthesis. Unfortunately mutant 
strains obtained from the screen were not in the genetic region involved in LOS biosynthesis 
in M. kansasiii and no further studies were conducted. 
Generation of null mutants of the other GTF MMAR2311, second polyketide synthase gene 
MMAR2344 and transporter MMAR2342 (mmpl12) is currently ongoing and will shed more 
light on the glycosylation and acylations of the LOS core. With the availability of the whole 
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genome sequences of M. kansasii and “M. canettii” phages will be generated for delivery of 
allelic exchange substrates by specialised transduction to generate null mutants of targeted 
genes in M.kansasii and M. canettii. 
The other theme of this thesis was the study of the processing and transport of mycolic 
acids in Mycobacterium smegmatis.  Mycolic acid biosynthesis has been studied in great 
detail but their processing and transport still remains unknown. I investigated the role of 
two genes MSMEG3437 (homologue of Rv1288) and MSMEG5851 (homologue of 
Rv0519c) as the Mycolyl Transferase-II involved in generating an intermediate of mycolic 
acid processing. The ability to generate null mutants of these genes in M. smegmatis 
showed that the genes were not essential for growth; this was uncharacteristic of genes that 
play a role in mycolate metabolism which are largely essential genes. Characterisation of 
the mutant strains revealed no changes in growth, colony morphology or lipid profiles, and 
together these findings suggested that either the two genes were not Mycolyl Transferase-
II candidates, or that the roles they played were redundant.   
In contrast to the above genes, I obtained a phenotype for the M. smegmatis mmpl11 
gene (MSMEG0241) which also identified as a probable candidate involved in transport of 
mature mycolates. Whilst the gene was non-essential, the mutant strain exhibited retarded 
growth, and was unable to form biofilms.  Furthermore, 2D-TLC of cell envelope lipids 
reveals that the gene MSMEG0241 is involved in shuttling the free mycolic acids to the 
outer cell wall. Ongoing work in our laboratory has now established that the neigbouring 
essential gene mmpl3, which is present in the same cluster as mmpl11 is the primary 
transporter of mycolates in the mycobacterial cell wall, and together these data suggest a 
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co-ordination of the two processes. Protein-protein interaction studies will potentially shed 
more light on the complexes involved in the transport of mycolic acid intermediates. 
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8.1 Media preparations 
8.1.1 Luria-Bertani (LB) broth 
25g of LB (Tryptone-Yeast extract-NaCl 2:1:2 w/w/w) is dissolved in 1 litre of distilled water 
and sterilised by autoclaving. 
8.1.2 LB agar 
37g of LB-agar mix (Tryptone-Yeast extract: NaCl: Agar 2:1:2:3 w/w/w/w) was dissolved in 1 
litre of distilled water and autoclaved. Antibiotics were added to molten agar after the cooling 
it down to approximately 55°C, mixed thoroughly before pouring into petri dishes (25ml) 
aseptically. .  
8.1.3 Tryptic Soy Broth (TSB) 
30g of TSB mix (Pancreatic casein digest-Papaic soybean digest-dextrose-NaCl-K2HPO4 
34:6:5:10:5 w/w/w/w) is dissolved in 1 litre of distilled water and sterilised by autoclaving. 
8.1.4 Tryptic Soy Agar (TSA) 
TSA is prepared by mixing 30g of TSB powder and 15 grams of agar in 1 litre of distilled 
water and autoclaved. Antibiotics were added to molten agar after the cooling it down to 
approximately 55
0
C, mixed thoroughly before pouring into petri dishes (25ml) aseptically.  
8.1.5 Middlebrooks 7H9 broth 
4.7g of the 7H9 broth mix was dissolved in 900ml distilled water. To this 2.5ml of glycerol 
was added and filter sterilised. 100ml ADC (BD) was added aseptically and the solution stored 
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at 4
°
C. 10% OADC (BD) was used when growing M. marinum and M. kansasii as it was 
observed that these two species thrived better when supplemented with OADC. M. smegmatis 
was grown with the usual 10% ADC supplementation. 
8.1.6 Middlebrooks 7H10 broth 
7H10 broth was made up according to media composition of Middlebrook’s 7H10 agar, 
without the addition of agar and filter sterilised. The broth was supplemented with 10% 
OADC (BD).  
8.1.7 Middlebrooks 7H10 agar 
19g of the 7H10 broth mix was dissolved in 900ml distilled water. To this 2.5ml of glycerol 
was added and filter sterilised. 100ml OADC (BD) was added aseptically and the solution 
stored at 4
0
C. 
8.1.8 Middlebrooks 7H11 agar 
4.7g of the 7H11 broth mix was dissolved in 900ml distilled water. To this 2.5ml of glycerol 
was added and filter sterilised. 100ml OADC (BD) was added aseptically and the solution 
stored at 4
0
C. 
 
8.1.9 7H9 Basal agar 
2.35g of 7H9 broth mix was dissolved in 500ml distilled water and 1.25 ml glycerol was 
added. 7.5g of agar (Bacto Agar – BD) was added and the solution was autoclaved. Once the 
temperature was ~ 55
0
C, 20 ml plates are poured aseptically. 
Chapter 8  General materials and methods 
227 
 
8.1.10 7H9 Soft agar  
2.35g of 7H9 broth mix was dissolved in 500ml distilled water and 1.25 ml glycerol was 
added. 3.75 grams of agar (Bacto Agar – BD) was added and the solution was autoclaved. 
Once the temperature was ~ 55
0
C. the tubes were ready for overlay. 
8.1.11 Antibiotic and Supplements 
Table 8.1 List of antibiotics and supplements 
Additives      Stock 
Concentration 
Storage 
 
Hygromycin B 
 
50mg/ml 
4 
0
C, protected from light 
Kanamycin 25mg/ml -20
0
C , filter sterilised 
Chloramphenicol 30mg/ml -20
0
C , filter sterilised 
Gentamicin 50mg/ml 4 
0
C, protected from light 
Oleic acid-albumin-
dextrose-catalase(OADC) 
and ADC 
 
10% 
 
4 
0
C 
Tween 80 10% Room temperature, protect 
from light 
 
8.2 Molecular biology techniques  
8.2.1 DNA electrophoresis 
DNA fragments are usually separated by electrophoretic means. Agarose gel electrophoresis 
have been used in this work for separation of DNA. Different percentage of agarose gels 
(0.6% - 1%) were prepared by dissolving / melting Molecular biology grade agarose (Bioline) 
in Tris acetate EDTA (TAE) buffer. DNA samples loaded onto the agarose gel in wells were 
separated under a horizontal electric field ( 110 – 140 V, 400mA) and DNA was visualised by 
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staining the gel with ethidium bromide and viewing under UV light (Bio-Rad Gel Doc 
systems). 
8.2.2 Polymerase Chain Reaction (PCR) 
PCR mix using Phusion polymerase  
Components Condition A Condition B Condition C Condition D 
Forward primer 
 
1l 
  Reverse primer 
 
1l 
  Template  DNA 
 
l 
  dNTP 
 
1l 
  Polymerase 
 
1l 
  GC/HF buffer 
 
l 
  Milli Q water 13.5l 9.5l 11.5l 8.5l 
DMSO - l - l 
Magnesium sulfate - - 1l 1l 
 
8.2.3 Digestion of DNA 
20 l single or double digestion reactions were set up depending on experimental 
requirements. 5l of purified DNA (plasmid / genomic DNA/ PCR product) was mixed with 
2l of digest buffer , 1l of restriction enzyme, 2l of 10X BSA (wherever required) and the 
solution id made upto 20l with distilled water. This is incubated for 30 -120 minutes at 37°C, 
unless special temperatures are required for activity of ceratin enzymes, e.g. BssHII, 55°C. 
. 
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8.2.4 Ligation 
Digested DNA fragments with compatible ends can be ligated using T4 DNA ligase. A 20l 
ligation reaction is set up using 1l of T4 DNA ligase enzyme, 2l of 10X T4 ligase buffer, 
required concentrations of DNA fragments and distilled water. This is incubated at 16
0
C for 
12-16 hours and transformed into competent E.coli cells to amplify and purify plasmids. 
8.3 Preparation of chemically competent E. coli cells 
A single colony of E. coli (TOP-10 strain) was inoculated into 2.5 ml LB medium and 
incubated at 37°C overnight. The overnight culture was then used to inoculate 250 ml LB 
medium with 20 mM MgSO4. Cells were grown to an O.D 600 of 0.4-0.6 and then harvested 
by centrifugation at 4500g for 10 min at 4°C. Cell pellets were gently resuspended in 1/4th 
volume of ice-cold TFB1 (30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM 
RbCl2, 15% glycerol, filter-sterilised and stored at 4°C) and resuspended cells were incubated 
on ice for 5 min. Cells were harvested by centrifugation as described previously and were then 
gently resuspended in 1/25 of the volume of ice-cold TFB2 (10 mM MOPS or PIPES, pH 6.5, 
75 mM CaCl2, 10 mM RbCl2, 15% glycerol, filter-sterilised and stored at 4°C). Cells were 
incubated on ice for 15-60 min and then stored as 100μl aliquots at -70°C. 
8.3.1 Transformation of E. coli competent cells 
E. coli competent cells were thawed on ice and then the ligation reaction (5μl) was added to 
the cells. Cells and the ligation reaction were mixed gently and then incubated on ice for 30 
min. Cells were transformed by heat shock at 42°C for 90 seconds followed by which the cells 
were placed on ice to cool. LB medium (1ml) was added into the tube and incubated at 37°C 
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for about 45 min with shaking. The transformed cells were then plated onto appropriate 
selection plates. 
8.3.2 Plasmid extraction 
Plasmid DNA purification kits by QIAGEN were used for all of this work. Bacteria containing 
the gene of interest borne on a plasmid are grown with appropriate selection markers in a 
shaking incubator. The cells are harvested and lysed with buffers P1& P2 which contains 
RNase and sodium dodecyl sulfate respectively. This allows precipitation of DNA and 
proteins from the cells. Neutralization was done using buffer N3 (acetate and guanidine 
hydrochloride). This precipitates large DNA and facilitates binding of plasmid DNA to the 
spin column.The mix is centrifuged and the supernatant is loaded onto the provided spin 
columns, which retains the plasmid DNA. The spin column was washed with PE buffer 
(containing ethanol) and plasmid DNA is eluted with distilled water or 10 mM Tris-HCl 
pH8.0. 
8.4 Generation of knockout phage for null mutant creation using Specialised 
Transduction. 
Approximately 1 kb sequences of the upstream and downstream regions of the ‘target gene 
(geneX)’ were PCR-amplified from M. marinum 1218R or M. smegmatis mc2155 genomic 
DNA using appropriate primer pairs. The figure 8.1 shows the sequential procedures involved 
in generation of the knockout phage. The PCR products were purified and the primer 
incorporated Van91I sites were digested with Van91I, following which the digested PCR 
fragments were cloned into Van91I-digested p0004S to generate the allelic exchange plasmid 
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pΔgeneX. One positive plasmid was PacI digested and ligated to PacI digested phAE159 
DNA. The ligation mix was then packaged into empty -phage heads and transduced into E. 
coli HB101. Cells containing phasmid DNA were selected for on LB agar containing 
hygromycin at 37°C. Packaging of pΔgeneX into phAE159 was confirmed by PacI digestion.  
The positive phasmids were transformed by electroporation into M. smegmatis at 1800V and 
recovered at 30°C for ~4 hours in TSB. The recovered cells were then harvested and 
resuspended in 200 µl of MP buffer. This was mixed with 200 µl of freshly growing M. 
smegmatis and 5 ml molten soft agar (50°C) and poured on 7H9 basal agar plates and 
incubated at 30°C for 2 -3 days and allowed to form plaques. The plates were soaked in 
minimum amount of MP buffer for 5-6 hours and the solution containing phages was filtered 
and stored at 4°C. This generated the recombinant phage - phgeneX designed to replace the 
‘targeted gene’ with hyg.  
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Figure 8.1 Schematic representations of the events during generation of the knockout plasmid 
leading to the recombinant phage which is used to replace the targeted gene by specialised 
transduction, adapted from (Bhatt and Jacobs, 2009). 
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Specialised transduction of M. marinum 1218R was performed as described previously 
for other mycobacteria (Bardarov et al., 2002). M. marinum or M. smegmatis cultures were 
grown in 50ml of 7H9+10% OADC  or TSB respectively with 0.05% Tween 80 to an OD600 of 
about 0.8 and harvested by centrifugation at 4500xg for 10 minutes. The cell pellet was 
washed twice with 50ml of MP buffer and resuspended in 2ml of MP buffer and 2ml of high 
titre (10
-10
 pfu /ml) phage lysate was mixed with the cells. A control was set up where 0.5 ml 
of resuspended cells was mixed with 0.5ml of MP buffer. The mix was incubated overnight at 
37°C followed by harvesting and recovered with 10ml 7H9+10% OADC with Tween-80 at 
37°C for 4-5 hours incase of M. smegmatis and overnight for M. marinum and M. kansasii. 
This was plated onto 7H10+10% OADC-agar plates with hygromycin B and plates were 
incubated at 37°C for 1-4 weeks depending on the strain of Mycobacteria. Hygromycin 
resistant colonies obtained after transduction were inoculated in 10ml 7H9+10% OADC -
Tween 80 with hygromycin B for genomic DNA extraction and further characterization.  
Allelic exchange of geneX with a hygromycin resistance cassette in hygromycin resistant 
transductants was confirmed Southern blot.  One such transductant was chosen for subsequent 
experiments.   
8.5 Genomic DNA extraction  
Bacterial cells were harvested from a 10 ml culture by centrifugation at 4500g for 10 minutes. 
The cell pellet were resuspended in 450 μl glucose Tris-EDTA (GTE) solution (25 mM Tris-
HCl pH 8.0, 10 mM EDTA, 50 mM glucose) with 10 mg/ml lysozyme and incubated at 37°C 
overnight. To this 10% sodium dodecyl sulfate (100 μl) and 50 μl of 10 mg/ml Proteinase K 
(Sigma, cat. P4914) were added, and the mixture was incubated at 55°C for 3 – 4 hrs. 5M 
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NaCl (200 μl) and preheated CTAB solution (160 μl) were added and the mixture incubated at 
65°C for 10 min. 
Chloroform: isoamyl alcohol (24:1) extraction was performed twice to exclude protein 
before DNA was precipitated with 560μl of isopropanol (0.7 volume of total mixture). The 
DNA pellet was washed with 70% ethanol and air-dried before dissolving in Tris buffer (10 
mM Tris-Cl, pH 8.5) or water. 
8.6 Southern blotting 
The agarose gel was depurinated in 0.25M HCl for 10minutes, followed by denaturation (1.5 
M NaCl, 0.5 M NaOH) for 10 -15 minutes and finally neutralised for 15 – 20 minutes ( 0.5 M 
Tris-HCl pH 7.2, 1 M NaCl ). The DNA on the gel was then transferred onto a nylon 
membrane (Nylon Membrane, positively charged, No-11209299001, Roche) by capillary 
transfer with 20X SSC (3 M NaCl, 0.3 M sodium citrate, pH 7.0 ), overnight. DNA was fixed 
to the membrane by UV cross-linking. After cross-linking, the membrane was rinsed with 
distilled water and used for hybridization, labelling and detection. The procedure was 
performed as described in DIG High Prime DNA Labelling and Detection Starter Kit II (cat no 
– 11585614910, Roche). This kit uses digoxigenin, a steroid to label DNA probes by random 
priming. The hybridized probes are then immunodetected by anti-digoxigenin-AP (Fab 
fragments), which are visualised by chemiluminescence. 
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8.7 Preparation of mycobacterial electrocompetent cells 
Mid-log phase mycobacterial cells were washed with 1 volume (original volume of culture) of 
10% glycerol (filter-sterilized, pre-cooled to 4°C) twice and harvested by centrifugation at 4°C 
at 4500g. Cells were resuspended in 1/10 volume of 10% glycerol and aliquoted (200 μl) for 
immediate use or can be stored at -70°C. 
8.7.1 Electroporation of mycobacteria 
200 l electrocompetent cells were thawed on ice and 3μl - 5μl of plasmid dissolved in water 
was added to the cells. The mix was left on ice for 15 minutes and then placed into a chilled 1 
mm electroporation cuvette. Electroporation was done using an Eppendorf Electroporator 
(model no - 2510) at 1800V. TSB (1ml) (for M. marinum, 7H9 was used) was added and cells 
were allowed to recover at 37°C (for M. marinum at 30°C) for at least one generation time 
before plating on TSB agar (M. smegmatis) or 7H10 agar (M. marinum) agar with appropriate 
antibiotics. 
8.8  Radioactive labeling of lipids 
Mid-log phase mycobacterial cultures (10ml) were labelled with 1μCi/ml of [14C] acetic acid-
sodium salt (50mCi/ml, Amersham Pharmacia Biotech) and incubated for 12 hours in case of 
M. smegmatis and 24 hours for M. marinum. The [
14
C]-labelled cells were harvested by 
centrifugation and washed with PBS before freeze-drying. 
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8.9 Lipid extraction 
[
14
C]-labeled polar and non-polar lipids were extracted using the methods described by 
Dobson et al., (1985). The dried [
14
C]-labelled cells were mixed with 2 ml of CH3OH/0.3% 
NaCl (100:10, v/v) and 2 ml of petroleum ether (b.p.60-80°C) for 30 min. The mixture was 
centrifuged at 4000g for 5 minutes and the upper layer removed and stored in a different tube. 
Petroleum ether (2 ml) was added to the lower fraction and allowed to mix on a rotator for 
another 30 minutes. This was centrifuged and the upper layer was removed .The combined 
upper layers containing the non-polar lipids were dried under liquid nitrogen and were further 
analysed. 
Polar lipids were further extracted by adding 2.3 ml of CHCl3/CH3OH/0.3 % NaCl 
(90:100:30, v/v/v) to the lower aqueous layer. The solution was mixed for 1 hour and 
centrifuged and the supernatant removed and stored in a fresh tube. The remaining pellet was 
extracted twice by the addition of 0.75 ml of CHCl3/CH3OH/0·3% NaCl (50: 100: 40, v/v/v) 
and mixing for 30 min each time before centrifugation and removal of supernatant. The 
defatted cells were stored for further analysis. To the pooled supernatants, 1.3 ml of CHCl3 
and 1.3 ml of 0.3 % NaCl was added and mixed for 10 min, centrifuged and the lower layer 
recovered and dried. The dried apolar and polar lipids were dissolved in 200 μl of 
CHCl3/CH3OH (2:1, v/v); and 5 μl was dried in a scintillation vial and then mixed with 5 ml 
scintillation fluid and radioactivity incorporated was measured in terms of counts per minutes. 
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8.9.1 Fatty acid methyl esters (FAMEs) and Mycolic acid methyl esters (MAMEs) 
extraction from defatted cells and whole cells 
The [
14
C]-labeled cells or de-fatted cells were subjected to alkaline hydrolysis using 5% 
aqueous tetrabutylammonium hydroxide at 100°C overnight. CH2Cl2 (4 ml), CH3I (300 μl) 
and water (2 ml) was added to the reaction mixture followed by mixing for 30 min. The upper 
aqueous phase was discarded, and the lower organic phase was washed twice with water and 
evaporated to dryness. MAMEs were redissolved in diethyl-ether, and the solution was 
evaporated to dryness. The final residue was either weighed in case of cold samples or 
dissolved in CH2Cl2 (200 μl) and 5 μl of the resulting solution was used for liquid scintillation 
counting. 
8.9.2 Large scale lipid extraction and analysis 
Polar and apolar lipids were extracted as described by Dobson et al.,(1985). Briefly, 6 g of dry 
M. marinum cells were treated in 220 ml of methanolic saline (20 ml 0.3% NaCl and 200 ml 
CH3OH) and 220 ml of petroleum ether for 2 h (Dobson et al., 1985). The suspension was 
centrifuged and the upper layer containing apolar lipids was separated. The step was repeated 
twice. The two upper petroleum ether fractions were combined and dried. For polar lipids, 260 
ml CHCl3/CH3OH/0.3% NaCl (9:10:3, v/v/v) was added to the lower aqueous phase and 
stirred for 4 h. The mixture was filtered and the filter cake re-extracted twice with 85 ml of 
CHCl3/CH3OH/0.3% NaCl (5:10:4, v/v/v). Equal amounts of CHCl3 and 0.3% NaCl (145 ml 
each) were added to the combined filtrates and stirred for 1 h. The mixture was allowed to 
settle, and the lower layer containing the polar lipids recovered and dried. The polar lipid 
extract was examined by two dimensional thin-layer chromatography (2D-TLC) on aluminum 
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backed plates of silica gel 60 F254 (Merck 5554), using CHCl3/CH3OH/H2O (65:25:4, v/v/v) in 
the first direction and CHCl3/CH3COOH/CH3OH/H2O (40:25:3:6, v/v/v/v) in the second 
direction. The thin-layer chromatographic plates sprayed with the appropriate staining solution 
to detect the presence of lipids, glycolipids or phospholipids as described earlier. 
8.9.3  Thin layer chromatography (TLC) analysis for lipids 
Equivalent amounts (25,000 to 50,000 cpm) of each sample were spotted on TLC plates (5554 
silica gel 60F524; Merck) for further 1D- or 2D-TLC analysis using following solvent 
systems. Incase of cold samples, 50 -100ug of apolar or polar lipids were spotted on TLC 
plates for 1D /2D separation and analysis. Cold samples were stained with MPA , alpha-
naphthol or phosphate stains and charred where required to reveal the positions of the lipids on 
the TLC plates. [
14
C]-labelled lipids were revealed by 24-72hrs exposure to Kodak X-Omat 
AR film. 
8.9.3.1  Solvent systems for 2D TLC  analysis. 
Apolar lipids are separated by systems A,B,C,D. Polar lipids are separated using systems D 
and E. TLC plates should be air dried well before every solvent run. 
System A 
Direction 1 
Thrice with petroleum ether (b.p. 60-80°C)/ ethyl acetate - 98:2 (v/v) 
Direction 2 
Once with petroleum ether (b.p. 60-80°C)/acetone - 92:8 (v/v) 
 
System B 
Direction 1 
Thrice with petroleum ether (b.p. 60-80°C)/acetone - 92:8 (v/v) 
Direction 2 
Once with toluene/acetone - 95:5 (v/v) 
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System C 
Direction 1 
Once with chloroform/methanol - 96: 4 (v/v) 
Direction 2 
Once with toluene/acetone - 80:20(v/v) 
 
System D 
Direction 1 
Once with chloroform/ methanol /water - 100:14:0.8 (v/v/v) 
Direction 2 
Once with chloroform/acetone/ ethanol /water - 50:60:2.5:3 (v/vv/v) 
 
System E 
Direction 1 
Once in chloroform/ methanol /water - 60:30:6 (v/v/v) 
Direction 2 
Once in chloroform/acetic acid/ methanol /water - 40:25:3:6 (v/vv/v) 
 
Note : TLC plates are activated by baking at 100
0
C for one hour before application of samples for 
running in system E. One hour drying between runs is also required for system E. 
 
8.9.3.2 TLC analysis for Fatty Acid Methyl Esters (FAMEs) and Mycolic Acid Methyl 
Esters (MAMEs) 
The FAMEs/MAMEs mixture (25,000 cpm) was subjected to 1-D TLC (5554 silica gel 
60F524; Merck), developed in petroleum ether (b.p. 60°C-80°C):acetone (95:5, v/v).[
14
C]-
labeled FAMEs/MAMEs were revealed by overnight exposure to Kodak X-Omat AR film. 
8.9.3.3  Argentation TLC 
Silica gel TLC plates were coated with 10% silver nitrate solution. Coating is done in a way 
that only the run in direction 2 will encounter silver coating. The plates were air-dried 
followed by heating for about 2 hours in an oven. The plates are then used immediately or can 
be stored away from light and under airtight conditions for a few days. These plates are 
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developed twice in hexane: ethyl acetate /95:5; (direction 1), followed by thrice in petroleum 
ether: diethyl ether / 85:15; (direction Ag 2). 
 
8.9.4 Derivatization of sugar residues in LOS-U and analysis by MALDI-MS 
Per-O-methylation of LOS-U was done by adding 0.5ml of anhydrous dimethyl sulfoxide to 
2mg of the purified LOS-U, followed 100-200l of 4.8M dimethyl sulfinyl carbanion (dimsyl 
ion). The reaction was incubated at room temperature with stirring for 1 h in a reducing 
environment. 100l methyl iodide was then added to the reaction mix and the incubation was 
continued for another hour. The above step was repeated and the final reaction mixture was 
quenched with ~1ml of water. The sample was then dried and the resulting per-O-methylated 
sample was diluted in DMSO/H2O (1:1 v/v) and applied to a Sep-PakC18 cartridge (Alltech) 
and eluted with 100% acetonitrile followed by 100% ethanol. The eluate was dried and the 
per-O-methylated sample was dissolved in chloroform.   
8.10 MALDI-TOF-MS analysis  
 
MALDI-MS analysis was performed by Dr. P. Ashton and Mr N.G. May, School of 
Chemistry, University of Birmingham.The matrix used was 2,5-dihydroxybenzoic acid at a 
concentration of 10 µg/µl, in a mixture of water/ethanol (1:1, v/v), 0.1% trifluoroacetic acid. 
Analyses were performed on Voyager DE-STR MALDI-TOF instrument (PerSeptive 
Biosystems, Framingham, MA) using linear mode detection. The mass spectra were mass 
assigned using external calibration. 
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8.11 NMR spectroscopy  
NMR spectroscopy was performed by Dr. N. Spencer, School of Chemistry, University of 
Birmingham. NMR spectra of purified LOS-III, isolated from MMAR2320::aph were recorded 
on a Bruker DMX-500 equipped, with a double resonance (1H/X)-BBi z-gradient probe head.  
8.12  Chemicals, reagents and enzymes 
All chemicals and solvents were purchased from BD, Sigma-Aldrich (Dorset, UK), Bio- Rad 
(Ca, USA) and Fisher Chemicals (UK) unless otherwise stated, and were of AnalR grade, 
Molecular Biology or equivalent. Enzymes were obtained from New England Biolabs (NEB), 
Fermentas, Invitrogen, and Finzymes. 
8.13 Extraction and infection of bone marrow derived macrophages  
Lower body parts of Balb/c mice were obtained from Dr. D. A. Lammas (Institute of 
Biomedical Research, University of Birmingham).Tissue was removed and legs were 
dissected away from the body. The pelvic and femoral bones were cleaned and separated at the 
knee joint. The bone was cut off at each end and bone marrow was expelled with 5 ml bone 
marrow medium (Dulbecco’s modified Eagle’s medium (DMEM- Invitrogen) , supplemented 
with 4.5 g/L glucose, L-glutamine, pyruvate and 10% heat-inactivated fetal bovine serum 
(FBS), from both ends by using syringe. Cells were collected in to a 30ml screw top universal 
tube and harvested by centrifuging at 1500 rpm, 5 minutes. Cells were resuspended gently in 
10 ml fresh DMEM and gently aspirated to break down the cell aggregates. Cell suspension 
was adjusted to 10
6
cells/ml and seeded into 12 well plates with 10
6
cells/well. Cells were 
incubated 5-7 days at 37
0
C under 10% (v/v) CO2 and were fed every 2-3 days. The medium 
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was changed on day 6. The bone marrow derived macrophages were activated, using 
recombinant mouse INF- (Invitrogen) at a concentration of 100 units/ml. 
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